O
f
f
i
c
i
a
l
T
i
t
l
e
:
A
P
h
a
s
e
I
R
a
n
d
o
m
i
z
e
d
,
O
p
e
n
-
L
a
b
e
l
C
l
i
n
i
c
a
l
T
r
i
a
l
t
o
E
v
a
l
u
a
t
e
D
o
s
e
,
S
a
f
e
t
y
,
T
o
l
e
r
a
b
i
l
i
t
y
a
n
d
I
m
m
u
n
o
g
e
n
i
c
i
t
y
o
f
a
S
t
a
b
i
l
i
z
e
d
P
r
e
f
u
s
i
o
n
R
S
V
F
S
u
b
u
n
i
t
P
r
o
t
e
i
n
V
a
c
c
i
n
e
,
V
R
C
-
RSVRGP084
-
00
-
V
P
(
D
S
-
C
a
v
1
)
,
A
l
o
n
e
o
r
w
i
t
h
A
l
u
m
A
d
j
u
v
a
n
t
i
n
H
e
a
l
t
h
y
Adults
C
l
i
n
i
c
a
l
T
r
i
a
l
s
.
g
o
v
I
d
e
n
t
i
f
i
e
r
:
[STUDY_ID_REMOVED]
D
o
c
u
m
e
n
t
T
y
p
e
:
•
 
R
e
d
a
c
t
e
d
F
i
n
a
l
V
e
r
s
i
o
n
o
f
t
h
e
S
t
u
d
y
P
r
o
t
o
c
o
l
(
S
t
a
t
i
s
t
i
c
a
l
A
n
a
l
y
s
i
s
C
o
n
s
i
d
e
r
a
t
i
o
n
s
l
o
c
a
t
e
d
i
n
S
e
c
t
i
o
n
6
o
f
t
h
e
P
r
o
t
o
c
o
l
)
•
 
Redacted
F
i
n
a
l
V
e
r
s
i
o
n
o
f
IRB
-
a
p
p
r
o
v
e
d
I
n
f
o
r
m
e
d
C
o
n
s
e
n
t
Document/Da
te
:
•
 
P
r
o
t
o
c
o
l
V
e
r
s
i
o
n
7
.
0
:
A
u
g
u
s
t
2
3
,
2
0
1
9
•
 
V
e
r
s
i
o
n
7
.
0
I
R
B
-
a
p
p
r
o
v
e
d
I
n
f
o
r
m
e
d
C
o
n
s
e
n
t
:
S
e
p
t
e
m
b
e
r
9
,
2
0
1
9
 
 
 
 
VACCINE
 
RESEARCH
 
CENTER
 
 
Protocol VRC 
317
 
(NIH 1
7
-
I
-
0058
)
 
 
A
 
P
HASE 
I
 
R
ANDOMIZED
,
 
O
PEN
-
L
ABEL 
C
LINICAL 
T
RIAL TO 
E
VALUATE 
D
OSE
,
 
S
AFETY
,
 
T
OLERABILITY AND 
I
MMUNOGENICITY OF A 
S
TABILIZED 
P
REFUSION 
RSV
 
F
 
S
UBUNIT 
P
ROTEIN 
V
ACCINE
,
 
VRC
-
RSVRGP084
-
00
-
VP
 
(DS
-
C
AV
1),
 
A
LONE OR WITH 
A
LUM 
A
DJUVANT
,
 
IN 
H
EALTHY 
A
DULTS 
 
 
Vaccine Provi
ded by:
 
National Institute of Allergy and Infectious Diseases 
 
Vaccine Research Center 
 
Bethesda, Maryland
 
Clinical Trial Sponsored by:
 
National Institute of Allergy and Infectious Diseases 
 
Vaccine Research Center 
 
Bethesda, Maryland
 
IND Sponsored by:
 
Nat
ional Institute of Allergy and Infectious Diseases 
 
Vaccine Research Center 
 
Bethesda, Maryland
 
 
IND 
17256
 
-
 
held by 
VRC
 
 
 
 
Principal Investigator:
 
Grace Chen
, 
MD
, 
MPH
 
Vaccine Research Center, National Institute of Allergy and Infectious Diseases 
(NIAID)
 
National Institutes of Health (NIH)
 
Bethesda, MD 20892
 
IRB Initial Review Date:  
December 5, 2016
 
 
Version 
7.0
 
August 2
3
, 2019
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 
2019
 
 
TABLE OF CONTENTS
 
 
ABBREVIATIONS
 
................................
................................
................................
.........................
6
PRÉCIS
 
 
................................
................................
................................
................................
......
8
1.
INTRODUCTION
 
................................
................................
................................
........
9
1.1.
Rationale for
 
Evaluation of DS
-
Cav1
 
................................
................................
.........
10
1.2.
Rationale for Use of Aluminum
–
Based Adjuvant
 
................................
......................
11
1.3.
Previous Human Experience
 
................................
................................
.......................
11
1.
4.
Assessment of Immunogenicity
 
................................
................................
..................
12
2.
STUDY PRODUCTS
 
................................
................................
................................
.
12
2.1.
VRC
-
RSVRGP084
-
00
-
VP
 
................................
................................
.........................
13
2.2.
Alu
minum Hydroxide Suspension 
-
 
Adjuvant
 
................................
...........................
13
2.3.
Preclinical Toxicology Studies of VRC
-
RSVRGP084
-
00
-
VP
 
................................
...
13
3.
STUDY OBJECTIVES
 
................................
................................
..............................
13
3.1.
Primary Objectives
 
................................
................................
................................
.....
13
3.2.
Secondary Objectives
 
................................
................................
................................
.
13
3.3.
Exploratory Objectives
 
................................
................................
...............................
13
4.
STUDY DESIGN AND CLI
NICAL PROCEDURES
 
................................
...............
14
4.1.
Eligibility Criteria
 
................................
................................
................................
.......
15
4.1.1.
Inclusion Criteria
 
................................
................................
................................
........
15
4.1.2.
Exclusion Criteria
 
................................
................................
................................
.......
15
4.2.
Clinical Procedures and Evaluations
 
................................
................................
..........
16
4.2.1.
Screening
 
................................
................................
................................
....................
17
4.2.2.
Enrollmen
t
 
................................
................................
................................
..................
17
4.2.3.
Product Administration
 
................................
................................
...............................
17
4.2.4.
Post
-
Injection Follow
-
Up and Diary Card
 
................................
................................
..
18
4.2.5.
Follow
-
Up through End of Study
 
................................
................................
...............
18
4.2.6.
Concomitant Medications
 
................................
................................
...........................
19
4.3.
Dose Continuation and Dose Escalation Plans
 
................................
...........................
19
4.4.
Criteria for Discontinuing Subject Participation
 
................................
........................
20
4.4.1.
Discontinuation from Study Injections
 
................................
................................
.......
20
4.4.2.
Discontinuation from Protocol Participation
 
................................
..............................
21
4.5.
Criteria for Pausing and Resuming the Study
 
................................
.............................
21
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
3
 
of 
56
 
4.5.1.
Criteria for Pausing the Study
................................
................................
.....................
21
4.5.2.
Plan for Review of Pauses and Resuming Rules
 
................................
........................
21
5.
SAFETY AND ADVERSE E
VENTS
 
................................
................................
........
21
5.1.
Adverse Events
 
................................
................................
................................
...........
21
5.2.
Serious Adverse Events
 
................................
................................
..............................
22
5.2.1.
Serious Adverse Event Definition
 
................................
................................
..............
22
5.2.2.
Reporting Serious Adverse Events to the IND Sponsor
 
................................
.............
22
5.2.3.
IND Sponsor Reporting to the FDA
 
................................
................................
...........
23
5.3.
Reporting to the Institutional Review Board
 
................................
..............................
23
5.3.1.
Unanticipated Problem
 
................................
................................
...............................
23
5.3.2.
Non
-
Compliance
 
................................
................................
................................
.........
24
5.3.3.
Protocol Deviation
 
................................
................................
................................
......
24
5.3.4.
D
eath
 
................................
................................
................................
...........................
25
5.3.5.
New Information
 
................................
................................
................................
.........
25
5.3.6.
Suspension or Termination of Research Activities
 
................................
....................
25
5.3.7.
Expedited Reporting to the IRB
 
................................
................................
.................
25
5.3.8.
Annual Reporting to the NIAID IRB
 
................................
................................
..........
26
6.
STATISTICAL CONSIDER
ATIONS AND SAMPLE AN
ALYSIS
 
........................
26
6.1.
Overview
 
................................
................................
................................
.....................
26
6.2.
Endpoints
 
................................
................................
................................
....................
26
6.2.1.
Primary Endpoints: Safety
 
................................
................................
..........................
26
6.2.2.
Secondary Endpoints: Immunogenicity
 
................................
................................
......
27
6.2.3.
Exploratory Endpoints
 
................................
................................
................................
27
6.3.
Sample Size and Accrual
 
................................
................................
............................
27
6.3.1.
Power Calculations for Evaluation of Safety
 
................................
..............................
27
6.3.2.
Power Calculations for Evaluation of Immunogenicity
 
................................
.............
28
6.4.
Statistical Analysis
 
................................
................................
................................
......
28
6.4.1.
Baseline Demographics
 
................................
................................
..............................
28
6.4.2.
Safety Analysis
 
................................
................................
................................
...........
28
6.4.3.
Analysis of Immune Responses
 
................................
................................
..................
28
6.4.4.
Missing Data
 
................................
................................
................................
...............
29
6.4.5.
Interim Analyses
 
................................
................................
................................
.........
29
6.4.6.
Randomization of Treatment Assignments
 
................................
................................
29
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
4
 
of 
56
 
7.
PHARMACY PROCEDURES
 
................................
................................
...................
29
7.1.
Study Products
 
................................
................................
................................
............
29
7.2.
Study Product Presentation and Storage
 
................................
................................
.....
30
7.2.1.
Labels
 
................................
................................
................................
..........................
30
7.2.2.
Storage
 
................................
................................
................................
........................
30
7.3.
Preparation of Study Products for Administration
 
................................
.....................
31
7.3.1.
Preparation of VRC
-
RSVRGP084
-
00
-
VP (non
-
adjuvanted)
 
................................
.....
31
7.3.2.
Preparation of VRC
-
RSVRGP084
-
00
-
VP with Adjuvant
 
................................
..........
32
7.4.
Study Product Administration
 
................................
................................
....................
33
7.5.
Study Product Accountability
 
................................
................................
.....................
33
7.5.1.
Documentation
 
................................
................................
................................
............
33
7.5.2.
Dispo
sition
 
................................
................................
................................
..................
33
8.
HUMAN SUBJECTS PROTE
CTION
 
................................
................................
.......
33
8.1.
Institutional Review Board
 
................................
................................
.........................
33
8.
2.
Subject Recruitment and Enrollment
 
................................
................................
..........
34
8.2.1.
Participation of Children
 
................................
................................
.............................
34
8.2.2.
Participation of Site Employees
 
................................
................................
..................
34
8.3.
Informed Consent
 
................................
................................
................................
.......
34
8.4.
Subject Confidentiality
 
................................
................................
...............................
35
8.5.
Risks and Benefits
 
................................
................................
................................
......
35
8.5.1.
Ris
ks
 
................................
................................
................................
...........................
35
8.6.
Plan for Use and Storage of Biological Samples
 
................................
........................
36
8.6.1.
Use of Samples, Specimens and Data
 
................................
................................
.........
36
8.6.2.
Storage and Tracking of Blood Samples and Other Specimens
 
................................
.
36
8.6.3.
Disposition of Samples, Specimens and Data at Completion of the Protocol
 
............
36
8.6.4.
Loss or Destruction of Samples, Specimens or Data
 
................................
..................
37
8.7.
Compensation
 
................................
................................
................................
.............
37
8.8.
Safety Monitoring
 
................................
................................
................................
.......
37
8.8.1.
Protocol Safety Review Team
 
................................
................................
....................
37
9.
ADMINISTRATION AND L
EGAL OBLIGATIONS
 
................................
..............
38
9.1.
Protocol Amendments and Termination
 
................................
................................
.....
38
9.2.
Study Documentation and Study Records Retention
 
................................
..................
38
9.3.
Data Collection, Data Sharing, an
d Protocol Monitoring
 
................................
...........
38
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
5
 
of 
56
 
9.3.1.
Data Collection
 
................................
................................
................................
...........
38
9.3.2.
Dat
a Sharing Plan
 
................................
................................
................................
.......
39
9.3.3.
Source Documents
 
................................
................................
................................
......
39
9.3.4.
Protocol Monitoring
 
................................
................................
................................
....
39
9.4.
Language
 
................................
................................
................................
.....................
39
9.5.
Policy Regardin
g Research
-
Related Injuries
 
................................
..............................
39
10.
REFERENCES
 
................................
................................
................................
...........
40
APPENDIX I:
INFORMED CONSENT FOR
M
 
................................
................................
........
44
APPENDIX II:
CONTACT INFORMATION
 
................................
................................
...........
45
APPENDIX III:
SCHEDULE OF EVALUATI
ONS
 
................................
................................
..
48
APPENDIX IV:
ASSESSMENT OF RELATI
ONSHIP TO VACCINE AN
D 
ADVERSE EVENT SEVERI
TY GRADING
 
................................
............................
50
 
LIST OF TABLES
 
Table 1:  
VRC 317 Study Schema
 
................................
................................
.............................
14
Table 2:  
Probability of Observing Adverse Events
 
................................
................................
..
27
 
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
6
 
of 
56
 
ABBREVIATIONS
 
Abbreviation
 
Term
 
AE
 
adverse event
 
ALP
 
alkaline phosphatase
 
ALT
 
a
lanine aminotransferase
 
AoU
 
assessment of understanding
 
AST
 
aspartate
 
aminotransferase
 
β
-
HCG
 
human chorionic gonadotropin
 
Cav
 
Cavity 
Fill
ing Variant of RSV F protein
 
CBC
 
complete blood count
 
CDC
 
Center
s
 
for Disease Control
 
and Prevention
 
CFR
 
Code of Federal Regulations
 
cGMP
 
Current Good Manufacturing Practices 
 
CHIKV
 
chikungunya virus
 
CI
 
confidence interval
 
CMV
 
cytomegalovirus
 
CRO
 
c
ontract 
r
esearch 
o
rganization
 
DENV
 
dengue virus
 
DNA
 
deoxyribonucleic acid
 
DS
-
Cav1
 
Disulfide Bond, Cavity
-
Fill
ing (Variant 
Molecule) 1 of RSV F 
protein
 
EDTA
 
e
thylenediaminetetraacetat
e
 
ELISA
 
enzyme
-
linked immunosorbent assay
 
ELISpot assay
 
enzyme
-
linked immunospot assay
 
F
 
fusion protein
 
FDA
 
Food and Drug Administration
 
G
 
glycoprotein
 
GCP
 
Good Clinical Practices
 
GLP
 
Good Laboratory Practices
 
HIV
 
human immunodeficiency virus
 
HLA
 
human leukocyte antigen
 
HRPP
 
Human Research Protections Progra
m
 
IB
 
Investigator’s Brochure 
 
ICF
 
informed consent form
 
ICH
 
International Conference on Harmoni
s
ation
 
ICS
 
intracellular cytokine staining
 
IM
 
intramuscular
 
IND
 
Investigational New Drug
 
IRB
 
Institutional Review Board
 
m
Ab
 
monoclonal antibody
 
mcg
 
microgram
 
MedDRA®
 
Medical Dictionary for Regulatory Activities
 
mL
 
milliliter
 
N
 
nucleoprotein
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
7
 
of 
56
 
Abbreviation
 
Term
 
NHP
 
non
human 
primate
 
 
NIAID
 
National Institute of Allergy and Infectious Diseases
 
NIH
 
National Institutes of Health
 
NIH CC
 
National Institutes of Health Clinical Center
 
NVITAL
 
NIAID Vaccine Immune T
-
Cell and Antibody Laboratory
 
PBMC
 
peripheral blood 
mononuclear cells
 
PCR
 
polymerase chain reaction
 
PI
 
Principal Investigator
 
PSRT
 
Protocol Safety Review Team
 
RSV
 
Respiratory s
yncytial 
v
irus
 
SAE
 
serious adverse event
 
SARS
 
Severe acute respiratory syndrome
 
SH
 
small hydrophobic
 
protein
 
SST
 
serum 
separator tube
 
TCR
 
tissue cross reactivity
 
ULN
 
upper limit of normal
 
UP
 
unanticipated problem
 
VE
 
vaccine efficacy
 
VIP
 
Vaccine Immunology Program
 
VITL
 
 
Vaccine Immunology Testing Lab
oratory
 
VLP
 
v
irus
-
l
ike 
p
article
 
VRC
 
Vaccine Research Center
 
WBC
 
white blood cell
 
WHO
 
World Health Organization
 
 
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
8
 
of 
56
 
PRÉCIS
 
Study Title:
 
A Phase I Randomized, Open
-
Label Clinical Trial to Evaluate Dose, Safety, 
Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein 
Vaccine, VRC
-
RSVRGP084
-
00
-
VP (DS
-
Cav1), Alone or with Alum Adjuvant in 
Healthy Adults 
 
Study Design:
 
T
his is a Phase I, open
-
label, dose escalation study to evaluate the dose, safety, 
tolerability, and immunogenicity of VRC
-
RSVRGP084
-
00
-
VP alone 
or
 
with alum 
adjuvant
 
in a 2
-
injection regimen.  The hypotheses are
 
that the vaccine will be safe and 
tolerable
 
for human administration
,
 
and 
will induce detectable immune response
.  The 
primary objective is to evaluate the safety and tolerability of the investigational vaccine
 
at 3 dose
 
level
s administered alone or with alum adjuvant 
as a homologous boost in 
health
y adults.  Secondary objectives 
relate to humoral and cellular 
immunogenicity of 
the investigational vaccine
 
regimen
.
 
Product 
 
Description:
 
VRC
-
RSVRGP084
-
00
-
VP (DS
-
Cav1) was developed by VRC, NIAID and is 
composed of the respiratory syncytial virus (RSV) fusion (F) glycoprotein ectodomain 
assembled as a trimer stabilized in its prefusion native conformation with a foldon 
trimerization domain a
t the C
-
terminus and 4 internal mutations designated DS
-
Cav1 
(4.1DHFR_RSVAF). 
 
The sequence is based on the RSV A2 strain from subtype A. 
 
The product is provided at a concentration of 0.5 mg/mL in 3 mL glass vials filled to 
1.2 mL. 
 
Adjuvant is an aluminu
m hydroxide suspension 
(alum) 
provided in a sterile, pyrogen
-
free 
suspension
 
at a concentration of 5 mg/mL in 3 mL glass vials filled to 0.7 ± 0.10 
mL. 
 
The alum dose is 500 mcg and will be field mixed. 
 
Subjects:
 
Healthy adult subjects ages 18
-
50.
 
Study P
lan:
 
S
ubject
 
will be
 
randomiz
ed
 
into 
DS
-
Cav1 or DS
-
Cav1 plus alum in each dose during 
the study
.
  
D
ose continuation
 
and dose escalation evaluations will occur to ensure the 
safety data support proceeding to the higher doses.  
Subjects will be evaluated for 
safety and immune responses
 
through blood 
and mucosal 
sample collection 
at specified 
timepoints throughout
 
the stu
dy.
  
The study schema is below:
 
VRC 317 Study Schema
 
Group
 
Subjects
 
Dose
 
Day 0
 
Week 12
[1]
 
1
 
15
 
50 mcg
 
DS
-
Cav1
 
DS
-
Cav1
 
2
 
15
 
DS
-
Cav1
 
+ 
a
lum
 
DS
-
Cav1
 
+ 
a
lum
 
3
 
15
 
150 mcg
 
DS
-
Cav1
 
DS
-
Cav1
 
4
 
15
 
DS
-
Cav1
 
+ 
a
lum
 
DS
-
Cav1
 
+ 
a
lum
 
5
 
15
 
500 mcg
 
DS
-
Cav1
 
DS
-
Cav1
 
6
 
15
 
DS
-
Cav1
 
+ 
a
lum
 
DS
-
Cav1
 
+ 
a
lum
 
Total
 
90*
 
All DS
-
Cav1 vaccinations are administered with needle and syringe 
into the deltoid muscle. *Up to 
100
 
subjects may be enrolled if 
needed to evaluate safety
 
or immunogenicity
.
 
[1] This dose is 
optional
 
for the last 5 subjects enrolled in each group
 
that receive the Day 0 injection
 
and any additional subjects 
needed to 
evaluate 
safety
 
or 
immunogenicity
.
 
Duration:
 
The study schedule requires 
13
 
clinic visits and a telephone contact after each injection.  
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
9
 
of 
56
 
1.
 
INTRODUCTION 
 
Respiratory 
s
yncytial virus (RSV)
 
causes upper and lower respiratory infections
 
in child
ren
 
and 
adults of all ages, and leads to significant morbidity and mortality in pediatric, 
i
mmunocompromised, and geriatric populations 
[1]
. 
 
Worldwide, 
RSV is
 
the leading cause of 
respiratory
 
tract infections in children
, 
infecting 
50
-
70% of all children 
by age one and
 
nearly all 
children
 
by age two 
[2, 3]
.  
About 2%
 
of  
all children will require hospitalization for RSV.  
Infants born prematurely or those with congenital heart 
disease
 
 
hav
e a particularly high risk for 
severe disease, but more than half of hospitalized
 
infants,
 
have no identified risk factors.  The 
peak age of hospitalization is between 2
 
and 
3 months of age,
 
but more than half of all 
hospitalization
s
 
in children under 
5 ye
ars of age 
occur after
 
6 months
 
[4
-
7]
. 
 
 
Other risk factors include a family history or genetic predisposition to allergic inflammation and 
increase in IL
-
13 and IL
-
4 responses or a low level of maternally
-
transferred RSV
-
specific 
neutralizi
ng activity
 
[8]
. 
 
Additionally
, infants hospitalized for RSV are at 
greater 
risk for 
childhood wheezing and asthma
. 
 
Adults with compromised immune systems and those 
age
s 
65 
and older are also at increased risk of severe disease
 
[9, 10]
.  
 
Nearly all h
umans con
tract RSV 
by the age of three
 
and then
 
repeatedly throughout 
their lifetime
 
[11, 12]
. 
 
T
he 
economic impact 
of RSV 
in the United States 
(US) 
alone exceeds $400 million per 
year
 
[13, 14]
 
and worldwide, annual RSV hospitalizations are estimated to number more than 3
.4
 
million
 
[15]
.
 
Currently, there is 
no licensed RSV vaccine
.  A single 
licensed antiviral therapy
, 
Palivizumab
 
(
Syn
agis™
)
, is currently available for prevention of RSV.  Palivizumab
 
is an anti
-
RSV fusion 
protein
-
specific monoclonal antibo
dy
 
(
m
Ab)
 
used 
as passive prophylaxis 
to reduce the frequency 
of severe RSV disease in premature infants
,
 
but is only recommended for infants born at 28 
weeks of gestational age or less
 
[16
-
20]
.
  
Target populations for an RSV vaccine include 
pregnant women, infants, young children, and the elderly.  It is anticipated that 
a
ge
-
specific 
vaccine 
strategies
 
will be needed to generate effective immunity 
across a ra
nge of age groups 
[21]
. 
 
Vaccine
s
 
to prevent
 
RSV
 
mediated disease are both
 
urgently needed and uniquely challenging.  
In the late 1960s, a
 
formalin
-
inactivated RSV vaccine (FI
-
RSV) was associated with enhanced 
disease following subsequent RSV infection
 
[22]
.  Among 
FI
-
RSV
 
vac
cine
-
immunized infant 
subjects (n=31)
, 80% required hospitalization
 
following infection and
 
two d
eaths were reported.  
This is 
compared
 
to 5% 
requir
ing
 
hospitalization
 
following infection and no deaths among the
 
parainfluenza vaccine
-
immunized control infants
 
(n=40).  S
evere RSV disease was 
found to be 
more
 
frequent in vaccinees than in the same
-
age general population not enrolled in the vaccine 
study
 
[23
-
25]
.  
Because infants and small children 
are a
 
primary target population for an
 
effective
 
RSV vaccine, the legacy from that trial represents a substanti
ve obstacle for 
development of an RSV vaccine 
for 
antigen
-
naïve infants. 
 
 
Unique properties of RSV have provided 
challenges
 
to the development of a successful vaccine
. 
RSV encode
s
 
three envelope proteins, a small hydrophobic (SH) protein of unknown function, 
an attachment glycoprotein (G), and a fusion (F) protein.
  
Of these proteins, 
only the F protein is 
essential for infecting cells 
in vitro
; although, 
in vivo
, G protein express
ion provides an 
advantage for infection of human airway epithelia
 
[26]
.  The G protein is more variable than any 
other RSV protein
 
and
 
a
 
high proportion of G is secreted through an alternative translation 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
10
 
of 
56
 
initiation site, and acts as an immunomodulatory decoy for adaptive immune responses
 
[27]
. 
 
Non
-
structural RSV g
ene products
,
 
NS1 and NS2
,
 
both interfere with innate immune responses 
through coo
perative inhibition of interferon induction and effector functions
 
[28, 29]
.
 
RSV lacks an optimal animal model.
 
 
Rodent models such as mice and cotton rats are 
only 
semi
-
permissive for RSV infection, 
although
 
they are 
useful for 
defining 
immune response patterns
 
and rank
-
ordering candidate vaccines for neutra
lizing potency and protective capacity. 
 
Nonhuman primates (NHP) 
are useful 
for immunogenicity and challenge
 
studies
, but 
possess
 
variable levels of susceptibility to infection
 
and generally require large inocula intranasally and 
intratracheally to consist
ently establish infection
.  
 
S
ubstantive advances in understanding both RSV biology and immune system development and 
function have 
resulted in a number of
 
RSV vaccine 
development approaches using 
a variety of 
platforms
, many of which have advanced to clin
ical evaluation, including live
-
attenuated 
vaccines, 
chimeric virus vaccines and viral
-
vectored vaccines, usually expressing F, sometimes 
in combination with other viral genes
 
[30
-
33]
.
  
However, none of these designs based on F have 
yet demonstrated vaccine efficacy in clinical trials, despite showing protection in animal models, 
emphasizing the need to use an antigen that induces immune response
s relevant to human 
protection.
 
Several trials with RSV subunit vaccines have been conducted in pre
-
immune children and 
adults. 
 
A series of adjuvanted RSV F 
protein 
candidate vaccines administered alo
ne or in 
combination with G and/
or
 
N
 
(nucleoprotein)
 
were deemed safe in seropositive subjects, but did 
not generate immune responses of sufficient breadth or potency to advance into antigen
-
naïve 
infants 
[3
4
-
38]
.  Another subunit vaccine composed of a fusion of a protein G fragment to the 
albumin
-
binding domain of streptoco
ccal protein G elicited robust immune responses in 
seropositive humans, but subjects reported an unacceptable rate of erythema 
purpura
 
[39, 40]
.  A 
version of RSV F 
protein 
in the post
-
fusion conformation formulated without adjuvant has 
advanced to Phase 2 trials
.  Among 
1600 subjects
 
age 
60 years or older
,
 
44% effectiveness in 
preventing all RSV symptoms, 64% effectiveness in preventing lower respiratory tract 
symptoms, and 
a 
4.8
-
fold increase in anti
-
F IgG response among vaccinees
 
was observed 
[41]
.
 
1.1.
 
Rationale for 
Evaluation of
 
DS
-
Cav1
 
B
ased on the reduction of severe disease by 
palivizumab
,
 
which is 
specific for the RSV F 
glycoprotein and studies of maternal cord serum
, there is evidence
 
that neutralizing activity in 
serum is a correlat
e
 
of protection against RSV
.  P
alivizumab 
is recommended for 
prophylactic
 
administration 
to high
-
risk neonates 
during 
their first winter season, 
at 
the height of RSV 
infection risk
 
[42]
.  The
 
RSV F protein
,
 
l
ike multiple other 
Class
 
I viral fusion proteins, 
undergoes a dramatic structural rearrangement as it mediates the membrane fusion process 
required for viral entry.  During this process, it transitions from a
 
metast
able prefusion 
to 
stable 
postfusion conformation. 
 
By
 
protein adsorption and competition 
studies, the prefusion 
conformation of RSV 
F (pre
-
F) 
has been demonstrated to elicit the maj
ority of neutralizing 
activity 
in human serum 
[43, 44]
. 
 
Knowledge of these key facts led the Vaccine Research Center 
(VRC) to
 
pursue a structure
-
guided design approach to preserve 
neutralization
-
sensitive site
s on 
pre
-
F surfaces and produce a stabilized pre
-
F subunit candidate vaccine.  
 
The co
-
crystal structure
 
of the RSV F protein and the D25 mAb
 
revealed a previously
-
unidenti
fied, prefusion
-
specific 
quaternary 
antigenic site, designated 
antigenic 
site zero (Ø) that 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
11
 
of 
56
 
is abolished in the shift to the 
stable 
postfusion conformation
. 
 
C
omputational modelling studies 
undertaken on the basis of this crystal structure
 
led to
 
experiments that evaluated more than 100 
combinations of those sequence changes projected to stabilize F in the prefusion conformation.  
A variant comprising S155C, S290C, S190F, and V207L within the context of wild type F 
protein sequence
,
 
including nati
ve C
-
terminus
,
 
met criteria for expression of the F protein 
stabilized in the prefusion conformation.
  
The two cysteines
 
(S155C, S290C)
 
form a disulfide 
bond, the two bulky side chain mutations
 
(S190F, V207L)
 
occlude 
a 
hydrophobic 
cavity
 
and 
promote hydrop
hobic packing interactions, and 
 
together
 
these changes enable expression of 
an 
unprecedented
 
conformation
ally
-
stable F 
prefusion 
protein
, 
DS
-
Cav1
 
(
D
i
-
S
ulfide; 
Cav
ity
, first
 
variant
)
 
[45, 46]
.  T
he protein assumed a 
quaternary
 
structure closely approximating the 
previously
-
solved D25
-
bound RSV F, bound prefusion
-
specific antibodies with nanomolar 
to 
subnanomolar 
affinities, and in 
both 
mouse and NHP 
vaccine 
studies, elicited 
neutralizing titers 
between 70
-
 
and 80
-
fold greater than those elicited by
 
postfusion F.  
The majority of antibodies 
induced by DS
-
Cav1 are specific for the unique surfaces on prefusion F and the rest target 
surfaces shared between pre
-
F and post
-
F conform
ations.  Because the large majority of RSV 
neutralizing antibodies in human sera recognize surface
s
 
unique to 
pre
-
F, it is anticipated that 
boosting adults with DS
-
Cav1 will elicit a greater boost in neutralization activity than prior RSV 
candidate vaccine
s that have utilized F antigens in the postfusion conformation. 
 
Based on its safety, immunogenicity and efficacy profiles in preclinical studies
 
[45]
, 
the
 
candidate 
DS
-
Cav1 
vaccine
 
is being evaluated for the first time in healthy adults in this Phase 1 
clinical trial.
 
Because 
preliminary data suggest immune responses after the first
 
dose
 
alone may 
provide valuable data 
regarding the duration of the va
ccine
-
induced immune response, 
the last 5 
subjects enrolled into each group will have the option 
to receiv
ing (
or 
not receiving) 
the second 
vaccine dose
.
 
1.2.
 
Rationale for Use of
 
Aluminum
–
Based Adjuvant 
 
Adjuvants improve the immune response to many vaccines 
[47, 48]
.  The most common 
aluminum
-
based adjuvants includes aluminum hydroxide, aluminum phosphate, potassium 
aluminum sulfate, or mixed aluminum salts 
[49, 50]
.  Several phenomena contribute to the effect 
of aluminum hydroxide based adjuvants
 
including
: a ‘repository effect’ 
that
 
occurs when the 
antigens aggregate on the adjuvant particle and are de
posited to the immune cell for long 
duration to induce immune responses, a pro
-
phagocytic effect, and possibly the activation of the 
pro
-
inflammatory nucleotide like receptor protein 3 dependent pathways 
[50]
.  Aluminum
-
based 
adjuvants often improve humoral and innate responses and may lead to increased antibody titers, 
rapid induction of responses, reduction in size or frequency of doses, increased breadth of 
responses to overcome pathogen diversity, induction of long
-
lasting immune memory responses, 
and induction of response to overcome poor immune systems in elderly and young children 
[51
-
54]
.  
Based on over six decades of use, a
luminum is 
broadly
 
accepted to be safe, well
-
tolerated 
and effective
 
[51, 52]
.
 
1.3.
 
Previous Human Experience 
 
The
 
only 
human experience with 
VRC
-
RSVRGP084
-
00
-
VP
 
alone or with adjuvant
 
is from the 
current trial that is ongo
ing
.
 
 
As of 
Augus
t 08
,
 
2019
 
a total of 
9
5
 
subjects have enrolled
 
and 
received one or two injections of a 
50, 150, or 500 mcg 
DS
-
Cav1 vaccine
, alone or with alum
. 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
12
 
of 
56
 
All dose
 
escalation steps have been completed as per protocol; and no stopping or pausing rules 
have been met at any time during the study.Overall, 
all formulations of 
the DS
-
Cav1 vaccine
 
h
ave been well
-
tolerated and assessed as safe by the Protocol Safety Review T
eam (PSRT).
 
I
mmunogenicity data reveal a more than 10
-
fold boost in neutralizing activity in serum from 
antibodies targeting prefusion
-
specific surfaces of RSV F
 
[55]
. 
 
Aluminum adjuvants have been used in vaccines for many decades with a demonstrated safety 
profile 
[56]
.  Aluminum is the most common adjuvant used in human vaccines licensed by the 
Food and Drug
 
Administration (FDA) 
[57, 58]
.  Aluminum
-
containing v
accines have been 
associated with erythema, subcutaneous nodules, contact hypersensitivity, granulomatous 
inflammation 
[56, 59]
.  A specific limitation is neurotoxicity in patients with decreased renal 
function 
[57]
. 
 
Aluminum
-
based adjuvants promote strong humoral immune responses, and therefore, are 
in
corporated in vaccines against diseases where neutralizing antibodies are required for 
protection such as diphtheria, tetanus and hepatitis B 
[
54]
.  The licensed HPV VLP vaccines, 
Gardasil (Merck & Co, Inc.) and Cervarix (GlaxoSmithKline) have alu
minum in the 
formulations at 0.5 mg of aluminum hydroxyphosphate sulphate per dose and 0.5 mg of 
aluminum hydroxide per dose, respectively 
[60]
. 
 
As per 
21 
Code of Federal Regula
tions
 
(
CFR
)
 
part 610.15, the amount of alum
inum
 
in biological 
products cannot exceed 0.85 mg/dose. 
 
The amount of alum
inum
 
in vaccines currently licensed 
in the US ranges from 0.125
-
0.85 mg/dose
 
[58]
.  Based on FDA regulations, experience with 
HPV VLP vaccines and VRC pre
-
clinical data
, VRC plans to use 0.5 mg/dose of aluminum 
hydroxide adjuvant in this phase 1 study.
 
1.4.
 
Assessment of Immunogenicity
 
Specimens to evaluate immunogenicity will be collected at baseline and at specified time points 
throughout the study.  The primary immunogenic
ity time
 
point
s
 
are 
2 and/or 
4 weeks after the 
first dose
. 
 
Measurements of 
RSV
-
specific humoral immune responses will be assessed by 
neutralization antibody assays.
 
 
ELISA and other exploratory assays to assess humoral and 
cellular immune responses may be performed with stored samples. 
 
Human leukocyte antigen 
(HLA) type may be obtained from stored samples if needed to assess HLA
-
class restricted 
cellular responses
.  
Additional measurements of antibody, B cell and T cell responses may also 
be assessed from stored samples for timepoints throughout the study as exploratory evaluations.
 
This includes tests using
 
a number of high
-
throughput functional assays and high
-
throu
ghput 
biophysical profiling tools to comprehensively profile the humoral immune response elicited by 
DS
-
Cav1 vaccination
. 
 
The immunogenicity testing 
will be performed
 
at 
t
he NIAID 
Vaccine Immunology Program 
(VIP) laboratory
 
(formerly 
NVITAL
 
and VITL
)
, in 
research laboratories at the V
RC
, or by other 
approved 
scientific 
collaborators.
 
 
2.
 
STUDY 
PRODUCTS
 
Study 
products
 
are 
manufactured under
 
c
urrent
 
Good Manufacturing Practice
s (
c
GMP)
 
by
 
VRC/NIAID/NIH
 
at the VRC Pilot Plant operated 
under contract 
by
 
the
 
Vaccine
 
Clinical 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
13
 
of 
56
 
Materials Program
,
 
Leidos Biomedical Research, Inc
., Frederick, MD.  Specific manufacturing 
information is included on the product vial label and in the IB.  Quality Assurance lot release 
testing by the manufacturer a
nd ongoing stability programs verify conformance to product 
specifications throughout use in clinical trials.
 
2.1.
 
VRC
-
RSVRGP084
-
00
-
VP
 
VRC
-
RSVRGP084
-
00
-
VP (DS
-
Cav1
) 
vaccine 
is a sterile, aqueous, buffered solution filled into 
single dose vials
.
  
D
etails on 
VRC
-
RSVRGP084
-
00
-
VP
 
composition and manufacturing are 
found in the IB. 
 
2.2.
 
Aluminum Hydroxide Suspension 
-
 
A
djuvant
 
Aluminum Hydroxide 
Suspension
 
(adjuvant) is a sterile, pyrogen
-
free, suspension filled into 
glass vials at a nominal fill volume of 0.7 mL ± 0.10 m
L to allow withdrawal of 0.5 mL.  
Aluminum concentration is 5 ± 1 mg/mL.  Adjuvant is stored at 2
-
8°C, 
do not freeze.
 
2.3.
 
Preclinical Toxicology Studies
 
of 
VRC
-
RSVRGP084
-
00
-
VP
 
D
etails on preclinical studies conducted with 
VRC
-
RSVRGP084
-
00
-
VP
 
along or with adjuvant
 
can be found in the IB
.
 
3.
 
STUDY OBJECTIVES 
 
3.1.
 
Primary 
O
bjective
s
 
•
 
To evaluate the safety and tolerability of DS
-
Cav1 
alone or with adjuvant 
when 
administered IM at a 
dose of 50 mcg to healthy adults.
 
•
 
To evaluate the safety and tolerability of DS
-
Cav1 
alone or with adjuvant 
when 
administered IM at a dose of 150 mcg to healthy adults.
 
•
 
To evaluate the safety and tolerability of DS
-
Cav1 
alone or with adjuvant 
when 
administ
ered IM at a dose of 500 mcg to healthy adults.
 
3.2.
 
Secondary 
O
bjective
s
 
•
 
To evaluate the antibody response as measured by neutralization assay of DS
-
Cav1
 
alone or with adjuvant
 
at 
2 and/or 
4 weeks post 
first 
injection for each group.
 
•
 
To evaluate the antibody r
esponse as measured by neutralization assay of DS
-
Cav1
 
alone or with adjuvant
 
at 
2 and/or 
4 weeks post 
second 
injection for each group.
 
3.3.
 
Exploratory 
O
bjectives
 
•
 
To evaluate the frequency and magnitude of RSV
-
specific T cell
, 
antibody
 
and other 
immune
 
respons
es at specified timepoints throughout the study.
 
•
 
To determine if measurable levels of RSV
-
specific neutralizing antibodies can be 
found in salivary and nasal secretions at specified timepoints throughout the study.
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
14
 
of 
56
 
•
 
To evaluate epitope
-
specific neutralizati
on and monoclonal antibody binding (using 
the Octet System, (Bio
-
Layer Interferometry (BLI)) by competition assays at 
specified timepoints throughout the study.
 
4.
 
STUDY DESIGN
 
AND CLINICAL PROCED
URES
 
This
 
is
 
an open
-
label, 
dose
-
escalation study to examine 
the safety, 
tolerability
 
and dose of the 
DS
-
Cav1 vaccine alone or with adjuvant in healthy adults.  A vaccine regimen of DS
-
Cav1 as a 
prime followed 12 weeks later with a DS
-
Cav1 boost will be compared to a vaccine regimen 
of 
an adjuvanted DS
-
Cav1 prime followed 12 weeks later with an adjuvanted DS
-
Cav1 boost for 
each dose level.  
The last 
5 subjects
 
enrolled
 
in each group will be offered the option not to 
receive the boost at Week 12, such that immunogenicity of a single va
ccine dose can be 
evaluated. 
The hypothes
e
s 
are
 
that 
the vaccine 
will be
 
safe and tolerable 
for
 
human 
administration
 
and will induce detectable immune response
s
. 
 
The primary objective is to 
evaluate the safety and tolerability in healthy adults of the inv
estigational vaccine
 
alone and with 
adjuvant
.
 
 
Secondary objectives are related to the i
mmunogenicity of the vaccine alone and with 
adjuvant
.
  
The study 
schema is shown in
 
Table 
1
. 
 
Table 
1
:  
 
VRC 317 Stu
d
y Schema
 
VRC 317 Study Schema
 
Group
 
Subjects
 
Dose
 
Day 0
 
Week 12
[1]
 
1
 
15
 
50 mcg
 
DS
-
Cav1
 
DS
-
Cav1
 
2
 
15
 
DS
-
Cav1
 
+ 
a
lum
 
DS
-
Cav1
 
+ 
a
lum
 
3
 
15
 
150 mcg
 
DS
-
Cav1
 
DS
-
Cav1
 
4
 
15
 
DS
-
Cav1
 
+ 
a
lum
 
DS
-
Cav1
 
+ 
a
lum
 
5
 
15
 
500 mcg
 
DS
-
Cav1
 
DS
-
Cav1
 
6
 
15
 
DS
-
Cav1
 
+ 
a
lum
 
DS
-
Cav1
 
+ 
a
lum
 
Total
 
90*
 
All DS
-
Cav1 vaccinations are administered with needle and syringe 
into the deltoid muscle. *Up to 
100
 
subjects may be enrolled if 
needed to evaluate safety
 
or immunogenicity
.
 
 
[1] This 
dose is optional
 
for the last 5 subjects enrolled in each group
 
that re
ceive the Day 0 injection
 
and any additional subjects
 
enrolled 
to evaluate safety or immunogenicity
.
 
The study will be conducted at the VRC Vaccine Evaluation Clinic (VEC)
 
in the
 
NIH Clinical 
Center (NIH CC).  The visit schedule is shown in
 
Appendix 
III
.  
The expected duration of time 
on study per subject 
is 
approximately 
44
 
weeks
.
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
15
 
of 
56
 
4.1.
 
Eligibility 
Criteria
 
All inclusion and exclusion criteria must be met for eligibility.
 
4.1.1.
 
Inclusion Criteria
 
A subje
ct must meet all of the following criteria:
 
1.
 
1
8
 
to 
5
0
 
years 
of age
.
 
2.
 
Willing 
and 
able 
to comple
te the informed consent 
process
.
 
3.
 
Available for clinic 
visits through 
44
 
weeks after enrollment
.
 
4.
 
Able to provide proof of identity to the satisfaction of the 
study clinician completing the 
enrollment process.
 
5.
 
Willing to donate blood
 
and mucosal samples
 
to be
 
stored and
 
used for future research
.
 
6.
 
In good general health without clinically significant medical history.
 
7.
 
Physical examination and laboratory results without clinically significant findings and a 
Body Mass Index (BMI) ≤40 within the 
56
 
days prior to enrollment. 
 
Laboratory 
c
riteria 
within 
56
 
days prior to 
enrollment:
 
8.
 
WBC and
 
differential either within institut
ional
 
normal range or accompanied by
 
Principal Investigator (PI) 
or designee approval.
 
9.
 
Platelets = 125,000 
–
 
5
00,000/mm3.
 
10.
 
Hemoglobin within institutional normal range.
 
11.
 
Creatinine ≤ 1.1 x ULN.
 
12.
 
ALT ≤1.25 x ULN.
 
13.
 
Negative for HIV infection by 
an
 
FDA approved m
ethod of detection. 
 
Criteria applicable to 
women
 
of childbearing potential:
 
14.
 
Negative 
result on a 
human chorionic gonadotropin
 
pregnancy test on day of 
enrollment 
before receiving study
 
product
.
 
15.
 
Agree to use effective means of birth control from 
at least 
21 days 
before 
enrollment
 
through 
4
 
weeks after the 
last
 
injection
.
 
4.1.2.
 
Exclusion Criteria
 
A subject will be excluded if one or more of the following conditions apply:
 
Criteria applicable to 
women of 
childbearing potential:
 
1.
 
Breast
-
feeding
 
or p
lanning to become pregnant 
through 
4
 
weeks after the 
last injection
.
 
Subject has received any of the following:
 
2.
 
More than 10 days of systemic immunosuppressive medications or cytotoxic medications 
within the 4 wee
ks prior to enrollment or any within 
the 14 days prior to enrollment.
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
16
 
of 
56
 
3.
 
Blood products within 16 weeks prior to enrollment
.
 
4.
 
Live attenuated vaccines within 4 weeks prior to 
enrollment
.
 
5.
 
Inactivated vaccines within 2 weeks prior to enrollment
.
 
6.
 
Investigational research agents within 4 weeks prior to enrollment or planning to receive 
investigational products while on the study
.
 
7.
 
Current allergen immunotherapy with antigen injections, unless on maintenance 
schedule
.
 
8.
 
Current anti
-
TB 
prophylaxis or therapy
.
 
Subject has
 
any of the following:
 
9.
 
Serious reactions to vaccines that preclude receipt of study 
injections
 
as determined by
 
the investigator
.
 
10.
 
Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema
.
 
11.
 
Asthma that 
is 
not well controlled
.
 
12.
 
Diabetes mellitus (type I or II), with the exception of gestational diabetes
.
 
13.
 
Thyroid disease that is not well controlled
.
 
14.
 
Hypertension that is not well controlled.
 
15.
 
Evidence of autoimmune disease or immunodeficiency
.
 
16.
 
Idiopathic urti
caria within the past year
.
 
17.
 
Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet 
disorder requiring special precautions) or significant bruising or bleeding difficulties with 
IM injections or blood draws
.
 
18.
 
Malignancy th
at is active or 
history of
 
malignancy 
that is likely to recur during the study
.
 
19.
 
Seizure disorder other than: 1) febrile seizures, 2) seizures secondary to alcohol 
withdrawal more than 3 years ago, or 3) seizures that have not required treatment within 
the 
last 3 years
.
 
20.
 
Asplenia, functional asplenia or any condition resulting in the absence or removal of the 
spleen.
 
21.
 
Psychiatric condition that precludes compliance with the protocol; past or present 
psychoses; or within 5 years prior to enrollment, a history o
f suicide plan or attempt
.
 
22.
 
Any medical
, psychiatric, or social
 
condition that, in the judgment of the investigator, is a 
contraindication to protocol participation or impairs a 
subject’s 
ability to give informed 
consent
.
 
4.2.
 
Clinical Procedures and Evaluations
 
 
Evaluation of t
his 
investigational 
vaccine will include labo
ratory tests, medical history, 
physical
 
assessment by clinicians 
and
 
subject self
-
assessment.  
The schedule 
of study visits is shown
 
in 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
17
 
of 
56
 
the Schedule of Evaluations 
(
Appendix
 
III
)
.
 
 
Total blood volume drawn from each subject will 
not exceed 
550 mL in any 8 week period
.
 
4.2.1.
 
Screening
 
Screening for this study will be completed through the VRC’s screening protocol, VRC 500 
(NIH 11
-
I
-
0164).  Subjects will be recruite
d through Institutional Review Board (IRB)
-
approved 
advertising.  Evaluations and sample collections for screening processes include a medical 
history review, physical exam, any laboratory tests needed to confirm eligibility, and pregnancy 
test for women o
f reproductive potential.  If screening evaluations suggest a concerning health 
condition, appropriate evaluations should be conducted based on clinical judgment.  Screening 
evaluations for specific eligibility criteria must be completed within the time in
terval specified 
prior to enrollment for the given parameter and may be repeated, as needed, to confirm 
eligibility.  
Blood samples for research 
must
 
be collected during
 
screening
; 
although generally 
collected in the 56 days prior to enrollment, a 
particular interval of time prior to enrollment for 
collection of these samples is not specified
.
  
 
The informed consent form (ICF) will be reviewed and counseling related to pregnancy 
prevention will be provided. 
 
Subjects who are not up to date on standa
rd vaccinations may 
receive these, if available, during screening or at a later date during study participation.  As part 
of the informed consent process, an Assessment of Understanding (AoU) is completed on the 
day the subject is scheduled to enroll
, prio
r to signing the
 
VRC 317 ICF.  Incorrect 
answers will 
be explained by the study clinician
,
 
and the VRC 317
 
ICF
 
may be signed once the 
clinician is 
satisfied with the
 
subject’s
 
understanding of the study.
 
 
4.2.2.
 
Enrollment
 
Day 0 is defined as the day of protocol enrollment and first study injection. 
 
Protocol
-
specific 
eligibility is reviewed on Day 0 as part of the enrollment process, but eligibility evaluations 
conducted during a screening visit are routinely used for eligi
bility if the screening occurred 
within the specified window prior to the Day 0 visit. 
 
However, if clinical assessment on Day 0 
suggests significant changes may have occurred since the screening visit, then evaluations done 
on Day 0 are used for eligibili
ty.
 
 
Day 0 evaluations 
and medical history 
prior to the first 
injection are the baseline for subsequent safety assessments.
 
4.2.3.
 
Product Administration
 
On each injection day (prior to injection), laboratory
 
and research
 
samples will be collected and 
subjects wi
ll be clinically evaluated. 
 
A subject who arrives at the clinic with fever or evidence of 
an acute illness, which precludes administration of the vaccine, may be rescheduled within the 
allowed visit window
.  
Pregnancy test results for females of reproduct
ive potential must be 
confirmed as negative within 24 hours 
before 
each injection. 
 
When choosing a site for injection, clinicians should consider whether there is an arm injury, 
local skin problem or significant tattoo that precludes administering the inj
ection or will interfere 
with evaluating the arm after injection. 
 
It is recommended, but not required, that the first 
injection be administered into the non
-
dominant arm. 
 
It is preferred, but not required, to 
alternate arms for study injections. 
 
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
18
 
of 
56
 
All in
jections will be administered IM into upper arm deltoid muscle by needle and syringe.
  
For 
groups receiving adjuvant, the adjuvant will be field mixed by the site pharmacist prior to 
administration. 
 
4.2.4.
 
Post
-
Injection 
Follow
-
Up
 
and
 
Diary Card
 
Post
-
Injection 
F
ollow
-
Up
:  
Following 
each
 
study injection, subject
s
 
will be observed for a 
minimum of 
60
 
minutes.
 
 
Vital signs (temperature, blood pressure and pulse) will be taken 
at 
least
 
6
0
 
minutes post
-
injection. 
 
The injection site will be inspected for 
evidence of local 
reaction.
 
 
In keeping with the 
institution’s 
policy and good medical practice, acute medical care 
will be provided to subjects for any immediate allergic reactions or other injury resulting from 
participation in this research study.
 
Study
 
clinicians must inform subjects to 
contact the clinic 
at any time after each stud
y
 
injection 
if the
 
subject
 
ha
s
 
any concerning signs or symptoms.  
Follow
-
up on subject well
-
being will be 
performed by telephone on the first or second day following all inje
ctions and by clinic visits as 
shown in the Schedule of Evaluations (
Appendix 
III
).
 
Events following any study injection that may require clinical evaluation include rash,
 
urticaria, 
fever of 38.5˚C (Grade 2) or higher lasting greater than 24 hours, or significant impairment in the 
activities of daily living.  O
ther clinical concerns may prompt a study visit based on 
clinical 
judgment. 
 
Oral and nasal mucosal samples will b
e collected at specified study visits according to the 
Schedule of Evaluations in 
Appendix 
III
.  
A 
small ophthalmic sponge designed for clinical use
 
will be used to 
collect oral mucosal samples.  Flocked swabs will be used to collect the nasal 
mucosal samples
.  
These s
amples are for research purposes only and are not used for evaluating 
subject health. 
 
Diary Card
: 
 
Subjects will be given a “Diary Card” to use as a me
mory aid, on which to record 
temperature and symptoms daily for 7 days after each injection.  Subjects will be trained and 
encouraged to use the secure electronic database, but will also have the option to complete a 
paper diary card.  When the diary card 
parameters are recorded directly by the subject in the 
electronic database, the subject’s electronic record will be the source for these data.  
When 
collected, t
he paper diary card 
will 
be used as a source document.  When neither a paper nor 
electronic dia
ry is available from the subject, the clinician will document the source of 
reactogenicity information recorded in the study database.  
 
The solicited signs and symptoms on the diary card will include the following parameters: 
unusually tired/feeling unwel
l, muscles aches (other than at injection site), headache, chills, 
nausea, and pain/tenderness at injection site. 
 
Subjects will also record the day’s highest 
measured temperature and measurement of largest diameter for redness and swelling at injection 
si
te.
 
 
 
4.2.5.
 
Follow
-
Up
 
through 
End of Study
 
Study follow
-
up will continue via clinical visits through 
44
 
weeks after the first 
study injection
.  
The visit schedule is based on intervals of time after each 
study injection
 
administration
.  
Any 
subject who receives 
at least one study injection 
(including those subjects who elect not to 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
19
 
of 
56
 
receive the optional second dose) 
will be expected to continue with follow
-
up
 
for 
safety and 
immunogenicity through study Week 44 as per Schedule of Evaluations (
Appendix 
III
).
 
Throughout the study, any subject who 
is suspected of having an upper respiratory infection 
based on 
the 
presence of
 
r
hinorrhea
 
in conjunction with at least one additional 
sign and/or 
symptom
 
should be evaluated by nasal 
flock swab 
for PCR diagnostic purposes.  
 
The schedule of visits, 
allowable
 
windows for completing the visits, and evaluations performed 
at each visit 
are
 
shown in the 
Schedule of Evaluations 
in
 
Appendix 
III
.  
After 
Day
 
0
, deviations 
from the visit windows in completing study visits are discouraged and will be recorded as 
protoc
ol deviations, but are permitted
 
at the discretion of the 
PI
.
 
4.2.6.
 
Concomitant Medications 
 
Only routine prescription 
medications at the time of enrollment are recorded in the study 
d
atabase. 
 
Subsequently, c
oncomitant medications are 
only 
updated 
or recorded 
in the study 
database if there is
 
an occurrence of an adverse event 
(AE) 
that requires expedited reporting
 
or if 
the subject 
develop
s
 
a new chronic condition 
that 
requir
es
 
ongoing medical management
. 
Receipt of a FDA
-
approved vaccine at any time during the study will be recorded in the da
tabase 
(clinicians should work with subjects regarding the timing of licensed vaccines relative to study 
injection).  
Otherwise, the concomitant medication changes throughout the study will be 
recorded in the subject’s chart as needed for general medical r
ecords, but will not be 
recorded in 
the study database.
 
4.3.
 
Dose 
Continuation and
 
Dose
 
Escalation
 
Plans
 
Dose groups will be enrolled sequentially, with no more than one subject per day for the first 2 
study injections
 
of the study
. 
 
Dose
 
continuation and 
escal
ation will occur
 
after subjects have 
completed the first injection and
 
following interim safety data review
s
.
 
A
pproval
 
to proceed 
will 
be obtained 
from
 
the Protocol Safety Review Team (PSRT). 
 
•
 
The dose 
continuation
 
review (
for 50 mcg
) will occur 
when
 
at least 
5
 
subjects
 
who 
received 50 mcg in either 
Group 1 
or
 
Group 2
 
have completed post
-
injection follow
-
u
p through 
completion of the 7 day diary card
.
  
If assessed as safe to continue, 
enrollment of 
additional
 
subjects in Group 1 and Gr
oup 2 
may proceed.
 
•
 
The first dose escalation review (50 mcg to 150 mcg) will occur when 
at least 10 
subjects 
who received 50 mcg in either
 
Group 1 or Group 2 
have completed post
-
injection
 
follow
-
up through at least the “Study Week 2” visit. 
 
If 
assessed as
 
safe
, 
enrollment of additional subjects may proceed until at least 10 subjects have enrolled 
in each Group 1 and Group 2.  After that,
 
enrollment
s
 
may begin
 
in Group 3 and 
Group 4
. 
 
•
 
The second dose 
escalation
 
review (
150 mcg to 500 mcg
) will occur when at
 
least 
10 
subjects 
who received 150 mcg 
in
 
either 
Group 3 
or 
Group 4
 
have completed 
post 
injection
 
follow
-
up through at least the “Study Week 2” visit. 
 
If 
assessed as safe
, 
enrollment of additional subjects may proceed until at least 10 subjects have enro
lled 
in each Group 3 and Group 4.  After that
 
enrollment
s
 
may begin
 
in Group 5 and 
Group 6
.
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
20
 
of 
56
 
•
 
The
 
final
 
dose continuation review (for 50
0
 
mcg) will occur
 
when at least 
10 
subjects 
who received 500 mcg in either Group 5 or Group 6
 
have completed post 
injection
 
follow
-
up through at least the “Study Week 2” visit. 
 
If 
assessed as safe, enrollment 
of additional subjects may proceed until at least 10 subjects have enrolled in each 
Group 5 and Group 6
.
 
•
 
The second injection for all group
s may occur once the first dose of 
that dose 
level
 
has been assessed as safe
 
at the 
“Study Week 2” visit
.
 
If the first study injection is not completed
 
or there are discontinuations from the study before 
there are sufficient data to conduct the dose escalation review for a group, then extra subjects 
may be enrolled into that group in order to have the requisite data on at least 
10
 
subjects.  
Additionally
, AEs assessed as related to the study 
product
 
at the time of a dose escalation review 
may be judged by the PSRT to warrant adding additional subjects at a given dose level.
 
The IRB will be provided with documentation of the safety review process and notif
ication of 
the dose escalation.  Consultation with the IRB and FDA, if needed, as per study pause criteria 
(
Section 4.4
) will occur if indicated by the review.  One outcome of a dose escalation review 
may be to
 
re
commend evaluation of additional subjects at the current dose level and reassess for 
safety before proceeding to a higher dose level.
 
4.4.
 
Criteria for Discontinuing Subject Participation  
 
Decisions 
to
 
discontinu
e
 
study
 
injection
s
 
or protocol participation for a subject will be made by 
the 
PI
. 
 
4.4.1.
 
Discontinuation 
from
 
Study 
Injections
 
A subject may be 
discontinued
 
from 
study 
injections 
for the following reasons: 
 
•
 
Pregnancy
;
 
•
 
Grade 3 
AE
 
assessed as related
 
to study 
product
 
(
except that s
elf
-
limited Grade 3 
solicited reactogenicity does not require
 
discontinuation of injections)
;
 
•
 
Grade 4 
AE
 
assessed a
s related to study 
product
;
 
•
 
Immediate hypersensitivity reaction associated with study 
product
;
 
•
 
I
ntercurrent illness that is not expected to r
esolve 
before
 
the
 
next
 
scheduled 
injection
;
 
•
 
Treatment with systemic glucocorticoids (e.g., prednisone or other glucocorticoid) or 
other immunomodulators (other than nonsteroidal anti
-
inflammatory drugs 
[NSAIDs]), with the exception that study injection may
 
continue per 
PI
 
discretion if 
the next one occurs at least 2 weeks following complet
ion of glucocorticoid 
treatment
; or,
 
•
 
The 
PI 
assesses that it is not in the best interest of the subject to continue 
receiving 
study
 
product
.  
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
21
 
of 
56
 
4.4.2.
 
Discontinuation from Protoco
l Participation
 
A subject may be discontinued from protocol participation for the following reasons: 
 
•
 
Subject voluntarily withdraws;
 
•
 
The IND 
S
ponsor or regulatory 
authorit
ies 
stop the 
study
; 
or,
 
•
 
The PI assesses that it is not in the best interest of the subject to continue participation 
in the study or that the subject’s compliance with the study is not sufficient. 
 
4.5.
 
Criteria for Pausing 
and Resuming 
the Study 
 
4.5.1.
 
Criteria for Pausing the Study 
 
The 
P
I
 
and
 
PSRT
 
will closely monitor and analyze study data as they become available and will 
make determinations regarding the presence and severity of AEs.  
E
nrollments 
and 
a
dministration of
 
study 
product 
will be paused 
by the PI
,
 
and the IND Sponsor will be 
promptly 
notified
,
 
according to the following 
criteria
:
 
•
 
One
 
(or more) subject experience
s
 
a 
Serious A
dverse 
E
vent
 
(
SAE
)
 
assessed as related 
to study 
product
.
 
•
 
Two
 
(or more) subjects experience the same 
Grade 
3
 
or higher 
unsolicited AE
 
assessed 
as 
related to the study 
product
.
 
4.5.2.
 
Plan for Revi
ew of Pauses and Resuming Rules
 
The IND Sponsor
 
with participation by the
 
PSRT
, will
 
conduct the review and 
make the decision 
to resume
, amend
 
or close the study.
 
 
As part of the pause review, the reviewers will also advise 
on whether the study needs to be paused again for any subsequent 
AEs
 
of the same type.
 
E
nrollments 
and study product a
dministration 
would resume only if review of the 
AEs
 
that 
caused the pause result
 
in a recommendation to permit further study 
injections
 
and 
enrollments
.  
When indicated, safety data reports and changes in study status will be submitted to 
relevant 
regulatory authorities including 
the IRB in accordance with
 
Section 
5.3
 
and
 
institutional policy. 
 
5.
 
SAFETY AND ADVERSE E
VENTS
 
5.1.
 
Adverse Events
 
An 
adverse event (
AE
)
 
is any untoward or unfavorable medical occurr
ence in a human subject, 
including any abnormal sign (e.g., abnormal physical exam or laboratory finding), symptom, or 
disease temporally associated with the use of study treatment, whether or not considered related 
to the study treatment. 
 
 
AE
s
 
w
ill be gr
aded according to the T
able for 
G
rading 
S
everity of 
AEs
 
(
Appendix 
IV
).  
The 
following guidelines will be used to determine 
if
 
an 
AE
 
should be
 
recorded in the database:
 
•
 
Solicited 
AEs
 
(i.e. reactogenicity parameters) 
will be recorded in the study
 
database for 7 
days after 
each
 
study injection 
without the collection of
 
product
 
at
tribution assessments. 
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
22
 
of 
56
 
Clinicians will follow and collect resolution information for any reactogenicity symptoms 
that are not resolved within 7 days.
 
•
 
U
nsolicited AEs will be recorded in the study database 
from
 
the date of 
receipt of 
each
 
study injection
 
t
hrough the visit scheduled 
at 28 days 
after 
each
 
injection
 
with the 
collection of product attribution assessments.  
At other time periods between injections 
and when greater than 28 days after the last injection, only SAEs (as detailed in 
Section
 
5.2
)
 
and
 
new chronic medical conditions
 
will be recorded 
as an AE 
through the 
last study visit.
 
 
 
5.2.
 
Serious Adverse Events
 
5.2.1.
 
Serious Adverse Event Definition
 
The
 
term “
s
erious 
adverse e
vent” (SAE) a
s
 
defined in 21
 
Code of Federal Regulations
 
(
CFR
)
 
312.32
 
a
s
 
follows:
 
“
an 
adverse event
 
or suspected adverse reaction is considered "serious" if, in 
the view 
o
f either the investigator or sponsor, it results in any of th
e following outcomes: 
 
Death, 
a life
-
threatening adverse event, inpatient hospitalization or prolongation of existing 
hospitalization, a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions, or a co
ngenital anomaly/birth defect. 
 
Important medical events 
that may not result in death, be life
-
threatening, or require hospitalization may be considered 
serious when, based upon appropriate medical judgment, they may jeopardize the patient or 
subject and m
ay require medical or surgical intervention to prevent one of the outcomes listed in 
this definition. 
 
Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency room or at home, blood dyscrasias or convulsi
ons that do 
not result in inpatient hospitalization, or the development of drug dependency or drug abuse.
”
  
 
“Life threatening” refers to an AE that at occurrence represented an immediate risk of death to 
the subject.  An event that hypothetically 
may caus
e death if it occurs in a more severe form is 
not considered life
-
threatening
.  Similarly, a hospital admission for an elective procedure is not 
considered a SAE
.
 
 
5.2.2.
 
Reporting Serious Adverse Events to the IND Sponsor 
 
AE
s that meet 
SAE
 
Reporting Requirement
s 
must be reported 
by the clinical site 
and submitted 
on an expedited basis to the IND 
Sponsor
, according to 
s
ponsor guidelines as follows
: 
 
•
 
results in 
death
;
 
•
 
is 
life
-
threatening
;
 
•
 
results in persistent or significant disability/incapacity
;
 
•
 
requires 
unplanned inpatient hospitalization or prolongation of existing 
hospitalization
;
 
•
 
is a congenital anomaly/birth defect in the offspring of a study subject
; or,
 
•
 
is an important medical event that may jeopardize the 
subject
 
or may require 
intervention to prev
ent one of 
the other outcomes listed above
.
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
23
 
of 
56
 
Additionally
, any event, 
regardless of severity
, which in the judgment of a 
PI
 
represents a S
AE
, 
may be reported on an expedited basis.
 
An investigator will communicate an initial SAE report within 24 hours of si
te awareness of
 
occurrence to the IND 
S
ponsor by email to the VRC Protocol Operations Office (
Appendix 
II
). 
 
A written report by
 
the
 
investigator should be submitted to the
 
IND Sponsor within 3 working 
days. 
 
In order for the IND Sponsor to comply with regulations mandating sponsor notification of 
specified SAEs to the FDA within 7 or 15 calendar days, the investigator must submit additional 
information as soon as it is avai
lable.
 
 
5.2.3.
 
IND 
Sponsor
 
Reporting to the FDA
 
It is the responsibility of the IND Sponsor to make the determination of which SAEs are “serious 
and unexpected suspected adverse reactions” (SUSARs) as defined in 21 CFR 312.32.
 
•
 
Suspected adverse reaction
 
means any 
AE
 
for which there is a reasonable possibility 
that the drug caused the 
AE
.
 
•
 
Unexpected 
a
dverse 
e
vent
 
means an AE that is not listed in the IB
 
or is not listed at 
the specificity or severity that has been observed.  
 
All SUSARs, as determined by the IND Sponsor, will be reported to 
the
 
FDA a
s IND Safety 
Reports.  All 
IND Safety Reports will be provided 
to the IRB
. 
 
The IND Sponsor will also submi
t an IND Annual Report of the progress of the investigation to 
the FDA as defined in 21 CFR 312.33.
 
5.3.
 
Reporting to the Institutional Review Board
 
The following information is consistent with NIH IRB Policy 801: Reporting Research Events, 
Version 1, effective
 
July 1, 2019. 
 
Reportable Event 
-
 
An event that occurs during the course of human subject research that 
requires notification to the IRB.
 
For the purposes of this policy, reportable events include the following:
 
•
 
Unanticipated 
P
roblems 
(UPs) 
involving risk
s to subjects or others
,
 
•
 
Non
-
compliance (including major protocol deviations and noncompliance that is not 
related to a protocol deviation)
,
 
•
 
Deaths related or possibly related to research activities
, and
 
•
 
New information that might affect the willingness of
 
subjects to enroll or continue 
participation in the study
.
 
5.3.1.
 
Unanticipated Problem
 
A
n
 
unanticipated problem (UP) is defined as any incident, experience, or outcome that meets 
all
 
of the following criteria:
 
•
 
U
nexpected 
(
in 
terms of 
nature, severity, or freque
ncy
) given (a) 
the research 
procedures 
that are described in the protocol
-
related 
documents
,
 
such as the IRB 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
24
 
of 
56
 
approved research protocol and informed consent document; and (b) 
the 
characteristics of the subject population being studied; 
and
 
 
•
 
R
elated 
or poss
ibly 
related 
to participation in the research
 
(possibly related means 
there is a reasonable possibility that the incident, experience, or outcome may have 
been caused by the procedures involved in the research)
; 
and
 
 
•
 
S
uggests that the research places subjects or others 
(which may include research staff, 
family members or other individuals not directly participating in the research) 
at a 
greater risk of harm (including physical, psychological, economic, or social harm) 
r
elated to the research 
than was previously known or 
expected
. 
 
A UP must be reported within 7 calendar days of an investigator becoming aware of the actual or 
suspected UP
.
 
5.3.2.
 
Non
-
Compliance 
 
Non
-
compliance is the failure 
of investigator(s) to follow the appl
icable laws, regulations, or 
institutional policies governing 
the protection of human subjects
 
in research, or the requirements 
or determinations of the IRB, whether intentional or not
. 
 
 
Non
-
compliance may be unintentional (e.g. due to lack of understandi
ng, knowledge, or 
commitment), or intentional (e.g. due to deliberate choice to ignore or compromise the 
requirements of any applicable regulation, organizational policy, or determination of the IRB).
 
Non
-
compliance is further characterized as serious
 
or 
c
ontinuing 
as follows: 
 
•
 
Serious non
-
compliance 
-
 
Non
-
compliance, hether intentional or not, that results in 
harm or otherwise materially compromises the rights, welfare and/or safety of the 
subject. Non
-
compliance that materially effects the scientific inte
grity or validity of 
the research may be considered serious non
-
compliance, even if it does not result in 
direct harm to research subjects. 
 
•
 
Continuing non
-
compliance 
–
 
A pattern of recurring non
-
compliance that either has 
resulted, or, if continued, may r
esult in harm to subjects or otherwise materially 
compromise the rights, welfare and/or safety of subjects, affect the scientific integrity 
of the study or validity of the results.  The pattern may comprise repetition of the 
same non
-
compliant action(s), o
r different noncompliant events.  
 
Any actual or suspected non
-
compliance by any investigator or entity associated with the 
protocol must be reported to the IRB by the PI/designee within 7 calendar days of any 
investigator or individual associated with the
 
protocol first becoming aware.
 
5.3.3.
 
Protocol Deviation
 
A 
p
rotocol 
d
eviation is defined as a
ny change
,
 
divergence, or departure from 
the IRB
-
approved 
research protocol
 
and is further
 
characterized as major and minor as follows
:
 
 
•
 
Major Deviations 
–
 
Deviations fr
om the IRB approved protocol that have, or may 
have the potential to, negatively impact, the rights, welfare or safety of the subject, or 
to substantially negatively impact the scientific integrity or validity of the study. 
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
25
 
of 
56
 
•
 
Minor Deviations 
–
 
Deviations t
hat do not have the potential to negatively impact the 
rights, safety, or welfare of subjects or others, or the scientific integrity or validity of 
the study.  
 
For the reporting purposes, failure of subjects to comply with the research protocol does not 
r
epresent non
-
compliance unless that failure is due to an action or omission of a member of the 
research team, for example, the failure to give adequate instruction to the subject.
 
A major deviation must be reported within 7 calendar days of an investigator
 
becoming aware of 
an actual or suspected deviation.  Although PDs are also non
-
compliance, these should only be 
reported once as deviations.  Major deviations resulting in death must be reported within 24 
hours of the occurrence of the event or of any mem
ber of the study team becoming aware of the 
death.  
 
Researchers are responsible for monitoring their studies throughout the year for adherence to the 
IRB
-
approved protocol.  The purpose of this monitoring is to identify major deviations and to 
look for tr
ends in minor deviations that may indicate a systemic issue in how the study is being 
conducted that could potentially negatively impact the rights, safety, or welfare of participants or 
the study’s ability to produce scientifically valid results.  A serie
s of minor deviations pointing 
toward a more global issue that could affect the rights, safety or welfare of the participant or 
affect the validity of the study should be reported as a major deviation.  In all other instances, a 
summary of minor deviations
 
should be provided to the IRB at the time of continuing review
.
 
5.3.4.
 
Death
 
Any death of a research subject that is possibly, probably or definitely related to the research 
must be reported within 24 hours of an investigator becoming aware of the death.
 
5.3.5.
 
New Inf
ormation 
 
New information that might affect the willingness of a subject to enroll or remain in the study 
should be reported within 7 calendar days of an investigator first becoming aware. 
 
5.3.6.
 
Suspension or Termination of Research Activities
 
Any 
suspension or termination of research activities, including holds on new enrollment, placed 
upon the research by the study sponsor, NIH or IC leadership, or any regulatory agency must be 
reported within 7 calendar days of an investigator becoming aware.
 
5.3.7.
 
Ex
pedited Reporting to the IRB
 
Death related to research must be reported within 
24 hours
.
 
The following will be reported within 
7 calendar days
 
of investigator awareness: 
 
•
 
Actual or suspected UPs;
 
•
 
Actual or suspected non
-
compliance;
 
•
 
Actual or 
suspected Major PDs;
 
•
 
SAEs that are actual or suspected UPs;
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
26
 
of 
56
 
•
 
New information that might affect the willingness of a subject to enroll or remain in 
the study;
 
•
 
Suspension or termination of research activities, including holds on new enrollment, 
placed upon th
e research by the study sponsor, NIH or IC leadership, or any 
regulatory agency.
.
 
5.3.8.
 
Annual Reporting to the NIAID IRB
 
The following will be reported to the IRB in summary at the time of Continuing Review
:
 
•
 
Summary of UPs and non
-
compliance;
 
•
 
AEs, including SAE
s, that are not UPs, as a narrative summary statement indicating 
whether these events were within the expected range;
 
•
 
Minor PDs (aggregate summary);
 
•
 
Any trends or events which in the opinion of the investigator should be reported
.
 
6.
 
STATISTICAL CONSIDER
ATION
S AND SAMPLE ANALYSI
S
 
6.1.
 
Overview
 
This is a 
dose
-
escalation
 
study to evaluate the safety and immunogenicity of a 2
-
dose
 
regimen 
with 
the 
DS
-
Cav1 
vaccine
 
given alone or 
with adjuvant
. 
As available, the effect of a 
1
-
dose 
regimen will also be evaluated in up to
 
5 subjects in each group who will be offered 
the 
option to 
receive only a single administration of the study product.  
 
The primary objectives 
relate to 
safety
 
and 
tolerability
;
 
the s
econdary and exploratory objectives relate to 
immunogenicity
 
and 
durabil
ity of immune responses.
 
 
6.2.
 
Endpoints
 
6.2.1.
 
Primary Endpoints: 
Safety
 
Assessment of product safety will include clinical observation and monitoring of hematological 
and chemical parameters.  Reactogenicity will be closely monitored for 7 days after 
each product 
administration
 
and safety evaluated by clinical visits through t
he study duration.
 
The following parameters will be assessed:
 
•
 
Local reactogenicity signs and symptoms
 
 
•
 
Systemic reactogenicity signs and symptoms
 
 
•
 
Laboratory measures of safety 
 
•
 
Adverse 
events 
 
•
 
S
erious adverse 
events 
 
•
 
N
ew chronic medical conditions 
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
27
 
of 
56
 
6.2.2.
 
Secondary Endpoints: 
Immunogenicity
 
The princip
a
l immunogenicity endpoints are 
antigen
-
specific antibody responses as evaluated by
 
neutralization assays. 
 
The primary timepoint
s
 
for immunogenicity evaluation 
are
 
2 and/or 
4 
we
eks after the 
first
 
injection
 
for each 
group
.
  
Immunogenicity after the second injection will 
also be evaluated
 
when applicable
.
  
 
6.2.3.
 
Exploratory Endpoints
 
ELISA, neutralization assay, and T cell assays performed with research samples collected at 
study timep
oints as well as other immunogenicity assays throughout the study may be completed 
as exploratory evaluations
.
 
6.3.
 
Sample Size and Accrual
 
The study design is to 
have 90 healthy adult subjects divided equally among 6 groups. 
 
 
6.3.1.
 
Power Calculations for Evaluation
 
of Safety
 
The goal of the safety evaluation for this study is to identify 
safety concerns associated with 
injections of the investigational vaccine. 
 
Primary sample size calculations for safety are 
expressed in terms of the ability to detect serious adverse experiences
.
  
 
Table 
2
 
describes the proba
bility of observing 0 and 2 or more adverse events among 10, 15, 30, 
and 90 subjects, based on a range of true underlying probabilities. For example, if an adverse 
event of interest has a true incidence rate of 1%, there is an 86% chance that we won’t see 
any 
events in a group of 15 participants.  However, if this same 1% incidence applies to all 90 
participants in the study, there is a 60% (100
-
40%) chance of observing at least one occurrence 
and a 23% chance of observing 2 or more.
 
 
Table 
2
:  
 
Probability of Observing Adverse Events
 
 
Probability 
of Adverse 
Event
 
Prob
.
 
0/1
0
 
Prob
.
 
2+/10
 
Prob
.
 
0/15
 
Prob
.
 
2+/15
 
Prob
.
 
0/30
 
Prob
.
 
2+/30
 
Prob
.
 
0/90
 
Prob
.
 
2+/90
 
0
.01
 
0
.90
 
<
0
.01
 
0
.86
 
0
.01
 
0
.74
 
0
.04
 
0
.40
 
0
.23
 
0
.05
 
0
.60
 
0
.09
 
0
.46
 
0
.17
 
0
.21
 
0
.45
 
0
.01
 
0
.94
 
0
.1
0
 
0
.35
 
0
.26
 
0
.21
 
0
.45
 
0
.04
 
0
.82
 
<
0
.01
 
>
0
.99
 
If we do not observe any AEs in a group of 10 (for example, at the dose escalation review), the 
upper 95% confidence interval for the true incidence rate at that dose is 31%; that is, we can be 
reasonably confident that the true rate is no more than 31%. I
f we do not observe any of a 
specific type of adverse events in a specific arm (n=15), the upper bound of a 95% confidence 
interval for the true incidence is 21.8%. Similarly, if we do not observe any of a specific type of 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
28
 
of 
56
 
adverse events in a pair of arms 
(such as 1 & 2; n=30), the upper bound of a 95% confidence 
interval for the true incidence is 12%.
 
6.3.2.
 
Power Calculations for Evaluation of Immun
ogenic
ity
 
Although immunogenicity is a secondary endpoint, it is of sufficient interest that we briefly 
present the
 
power to detect a difference between immune responses before and after the first 
dose, and between two dose cohor
ts.  Based on previous research
[44]
, we expect the ELISA and 
n
eutralization results to be approximately normally distributed on the log
10
 
scale,
 
with standard 
deviation approximately 0.2
-
0.5 log
10
.  Using the conservative value of 0.5log
10
 
for the true 
standard deviation, we will have good power (90% or better) to detect a difference in the 
magnitude of the immune response of approximately .45 log
10
 
with 15 per group. With 30 per 
group, we will be able to detect a difference in the average 
magnitude of approximately 0.3 log
10
. 
 
6.4.
 
Statistical Analysis 
 
Since enrollment is concurrent with receiving the first study vaccination, the expectation is that 
all participants will receive at least one vaccination and therefore will provide some safety da
ta. 
 
All statistical analyses will be performed using statistical software
 
R
. 
 
No formal multiple 
comparison adjustments will be employed for safety endpoints or 
immunogenicity 
endpoints. 
 
6.4.1.
 
Baseline Demographics
 
Baseline characteristics including demographi
cs and laboratory mea
surements will be 
summarized using descriptive statistics.
 
6.4.2.
 
Safety Analysis
 
Reactogenicity:  
The number and percentage of subjects experiencing each type of 
reactogenicity sign or symptom will be tabulated by severity.  For a given sign
 
or symptom, each 
subject’s reactogenicity will be counted once under the maximum severity for all assessments.
 
Adverse Events:  
AE
s will be coded into Medical Dictionary for Regulatory Activities 
(MedDRA) preferred terms. 
 
The number and percentage of sub
jects experiencing each specific 
AE
 
will be tabulated by severity and relationship to 
study product
. 
 
For the calculations in these 
tables, each subject’s 
AE
 
will be counted once under the maximum severity or strongest 
recorded causal relationship to treat
ment.
 
A complete listing of AEs for each subject will provide details including severity, relationship to 
treatment, onset, duration and outcome.
 
Safety Laboratory Values: 
 
Boxplots of local laboratory values will be generated for baseline 
values and for v
alues measured during the course of the study.
 
 
Each boxplot will show the 1st 
quartile, the median, and the 3
rd
 
quartile.  Outliers, or values outside the boxplot, will also be 
plotted.
 
 
If appropriate, horizontal lines representing boundaries for abnorma
l values will be 
plotted.
 
6.4.3.
 
Analysis of Immune Responses
 
The primary immunogenicity time point
s
 
are 
2 and/or 
4 weeks after the first dose, although 
immunogenicity data at other time points will be examined as well.  The magnitude of the 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
29
 
of 
56
 
responses will be compared within subjects (before and after first dose; before and after second 
dose) and between subjects (bet
ween dose cohorts and between those who receive Alum and 
those who do not). 
 
The primary comparisons at 
2 and/or 
4 weeks p
o
st first dose will be 
compared using Wilcoxon Rank Sum tests, but regression models will also be explored that 
model post
-
dose immune
 
response as a function of pre
-
dose immune response, dose, Alum 
(yes/no), and possibly demographic variables such as age and gender. 
 
I
mmunogenicity will 
be 
analyzed for a variety of cohorts defined based on vaccination status, and specified in the 
Statist
ical Analysis Plan (SAP).  At minimum these may include ITT, PP, and mITT cohorts. 
 
6.4.4.
 
Missing Data
 
M
issing responses will be assumed to be missing completely at random.  
Analyses will include 
all samples available at each study time
 
point
.
 
6.4.5.
 
Interim 
Analyses
 
An interim analysis of immunogenicity data may be performed
 
when 
at least 10 subjects from 
Groups 1
-
4 reach 4 weeks post first dose.  Reports will be provided to the PI and other key VRC 
investigators for the purpose of informing future trial
-
rela
ted decisions in a timely manner and 
may be published as preliminary data.  Results should in no way influence the conduct of the 
trial in terms of early termination or later safety or immunogenicity endpoint assessments.
 
6.4.6.
 
Randomization of Treatment Assignm
ents 
 
At the start of the study, subjects will be randomized 1:1 to Groups 1 and 2. 
 
If the criteria for the 
first Dose Escalation 
are 
met, 
procedures for the interim safety review are completed,
 
and
 
there 
are at least 10 people enrolled in each of Groups 
1 and 2, subjects will be randomized 1:1 in 
Groups 3 and 4. 
 
If the criteria for the second Dose Escalation 
are 
met, 
procedures for the interim 
safety review are completed, 
and there are at least 10 people enrolled in each of Groups 3 and 4, 
subjects will 
be randomized 1:1 in Groups 5 and 6. 
 
Once all groups have
 
at least
 
10 
subjects 
per 
group, or if the dose escalation criteria are not met, subjects will be randomized in equal 
proportions to all groups that are open. 
 
The subject and the study clinicians will be informed 
of 
the subject’s group assignment upon 
completing 
the 
enrollment in 
the data
base
.
To decrease the potential for participant dropouts during the period between randomization and 
initial vaccination, rand
omization will occur on Day 0 after the study consent is signed and 
eligibility is confirmed.  If subjects accrued to a study group do not complete the number of 
injections
 
and
/or a
 
follow
-
up duration specified, then additional subjects may be accrued in t
hat 
group. 
 
7.
 
PHARMACY 
PROCEDURES
 
7.1.
 
Study 
Products
 
The 
study 
products
 
are
 
prepared under 
c
GMP
 
by the VRC 
Pilot 
P
lant
 
and must meet lot release 
specifications prior to clinical 
use
. 
 
T
his study includes one investigational vaccine
, 
one 
adjuvant
, and one diluent
 
as follows:
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
30
 
of 
56
 
•
 
VRC
-
RSVRGP084
-
00
-
VP
 
(DS
-
Cav1) 
drug
 
product is a sterile, aqueous, buffered 
solution filled
 
under aseptic conditions
 
into single dose vials
 
at a concentration of 500 
mcg/mL.  The formulation buffer is comprised of 20mM Histidine 
(buffer), 100mM 
Potassium Chloride (
isotonic acid
), 100mM Arginine HCl (stabilizer) and 2.5% 
w
eight per 
v
olume
 
Sucrose (
s
tabilizer) at pH 6.5.  The drug product is 
aseptically
 
filled at a volume of 1.2 ± 0.10 mL
 
in a 3 mL glass vial
.
 
 
Vials contain a clear
 
to 
slightly hazy sterile solution; some small white translucent particles may be visible.
 
•
 
A
lum
inum Hydroxide Suspension
,
 
alum
,
 
adjuvant
 
is composed of Alhydrogel
®
 
2% 
(Brenntag Biosector, Frederikssund Denmark) diluted with water for injection to a 
concent
ration of 5 mg/mL.  Adjuvant is 
aseptically 
filled at a volume of 0.7 ± 0.1 mL.
 
•
 
VRC
-
PBSPLA043
-
00
-
VP,
 
d
iluent
,
 
is comprised of Phosphate Buffered Saline 
(PBS) 
aseptically 
filled into single dose vials
 
at a volume of 1.2 ± 0.10 mL
.
 
7.2.
 
Study 
Product
 
Presentation
 
and Storage
 
7.2.1.
 
Labels
 
At the time of 
study 
product
 
delivery
 
to the pharmacy, study 
products
 
labels 
will 
have specific 
product information (e.g., lot number, fill volume, storage temperature).
 
 
L
abels will contain an 
Investigational Use Statement 
(“Limited by Federal Law to Investigational Use”) and 
manufacturer information.
 
7.2.2.
 
Storage
 
VRC
-
RSVRGP084
-
00
-
VP
:
 
 
DS
-
Cav1 vaccine vials will be shipped within the recommended 
temperature range using appropriate shipping configurations, to the study pharmacist
 
or 
designee
. 
 
Vials of vaccine should be stored until use at 
-
35°C to 
-
15
o
C in a qualified, 
continuously monitored, 
non
-
frost
-
free
 
freezer
 
until use
. 
 
As freezer temperatures may fluctuate, 
a temperature range of 
-
45°C to 
-
10°C is acceptable.
 
 
Storage belo
w 
-
45ºC is not permitted 
because of the stopper limitation.  
 
Vials, intended for single use only, do not contain preservative and should not be refrozen after 
thaw.  Vaccine vials are removed from the freezer and equilibrated to room temperature prior to 
product administration
. 
 
Aluminum Hydroxide Suspension
: 
 
Vials of 
alum
 
are stored until use at 2
o
C
 
to 
8
o
C in a 
qu
alified, 
continuously monitored
 
refrigerator. 
 
Do not freeze
.
  
Vials of adjuvant are intended for single use 
only.
 
 
VRC
-
PBSPLA043
-
00
-
VP
: 
 
Vials of 
PBS 
are
 
stored 
until use between
 
-
45°C to 
-
10°C
 
in a 
qualified, continuously monitored, 
non
-
frost
-
free
 
freezer
.
  
Vials of diluent are intended for single 
use only and should not be refrozen after thawing.
 
7.2.2.1.
 
Deviations in Temper
atures
  
 
Temperature excursions
 
that are outside of the specified ranges
 
will be reported per pharmacy 
guidelines.  
If deviations in storage temperature occur from the normal allowance, the site 
pharmacist
 
or designee
 
must report the storage temperature excursion promptly to the PI and 
IND 
S
ponsor
 
and product must be quarantined in a separate area
.  The excursion must be 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
31
 
of 
56
 
evaluated and investigated and action must be taken to restore
 
and maintain the desired 
temperature
 
limits.  Pending the outcome of the investigation, the IND 
Sponsor 
will notify the 
pharmacist 
or designee 
if continued clinical use of the product is acceptable
.
 
 
7.3.
 
Preparation of Study 
Product
s
 
for 
Administration
 
Refer to the group assignment for the study subject. 
 
The pharmacy will label the syringe 
before
 
delivery to the clinic with t
he subject identifier, 
the date
,
 
and t
he t
ime allowance for 
administration
.  
 
The following general instructions apply to all vacc
ine dose
 
preparations
 
(
alone and with 
adjuvant) for injection
.
 
•
 
Preparation will be done by a Pharmacist
 
or designee
 
in a clean preparation unit with 
limited access
;
 
 
•
 
Prepare all doses under sterile conditions
;
 
•
 
Thaw the vial(s) containing VRC
-
RSVRGP084
-
00
-
V
P and 
VRC
-
PBSPLA043
-
00
-
VP
 
at ambient temperature (15
ºC 
to 
25ºC
)
;
 
•
 
The vaccine (alone
 
and with
 
adjuvant) is stable in the vial and syringe for 8 hours 
refrigerated or at room temperature following removal from recommended storage 
conditions
;
 
•
 
Administer within 8 hours following removal of vaccine from freezer
;
 
•
 
Keep the prepared 
syringe at room temperature and
 
out of direct sunlight
;
 
•
 
Inversion of a prepared vial or syringe is defined as a gentle, complete 180 degree 
rotation of the container.
 
7.3.1.
 
Pr
eparation of 
VRC
-
RSVRGP084
-
00
-
VP
 
(non
-
adjuvanted)
 
•
 
For 500 mcg dose
: 
w
ithdraw 1.0
 
mL
 
(500
 
mcg) 
into a syringe
 
for administration
.
 
•
 
For 150 mcg dose
:
 
−
 
Transfer 0.45 mL (225 
mcg) of vaccine into a n
ew sterile vial using a syringe,
 
−
 
Transfer 1.05 mL
 
of PBS diluen
t into the same 
vial.  (Total preparation volume = 
1.5 mL),
 
−
 
Invert vial 5x to mix,
 
−
 
Withdraw 1.0 mL
 
(
1
50
 
mcg) into a 
new
 
syringe for administration
.
 
•
 
For 50 mcg dose:  
 
−
 
Transfer 0.
15 
mL 
(
75 
mcg) of vaccine into a new sterile vial using a syringe
,
 
−
 
Transfer 
1.35 
mL of PBS diluent into the same vial
 
(Total preparation volume = 
1.5 mL)
,
 
−
 
Invert vial 5x to mix
,
 
−
 
Withdraw 
1.0 
mL (50
 
mcg) into a 
new
 
syringe for administration.
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
32
 
of 
56
 
7.3.2.
 
Preparation of 
VRC
-
RSVRGP084
-
00
-
VP
 
with 
Adjuvant
 
Vials of a
lum 
and diluent 
will be
 
provided for field mixing. 
 
 
•
 
For 500 
mcg
 
dose
 
with adjuvant
:
 
−
 
Add 0.12 mL 
of 
adjuvant directly to a 
new 
vial of VRC
-
RSVRGP084
-
00
-
VP (1.2 
mL 
vaccine; 
total preparation volume = 1.32 mL
)
,
 
−
 
Invert 
vial 
5x to mix
, 
incubate at ambient temperature 
(15ºC 
to 
25ºC) 
for 15 
minutes
,
 
−
 
Withdraw 1.1 mL into a 
new 
syringe
 
for administration,
 
 
−
 
Invert 
syringe 
5x to mix
,
 
−
 
If not administered immediately, invert
 
syringe
 
5
x
 
to mix immediately prior to 
administration.
 
•
 
For 150 mcg dose
 
with adjuvant
:
 
−
 
Transfer
 
0.
4
5
 
mL 
(225 mcg) of vaccine into a new sterile vial using a syringe,
 
−
 
 
Transfer 0.15 mL of adjuvant into the same vial,
 
−
 
Invert 
vial 
5x to mix
, 
incubate at ambient temperature 
(15ºC 
 
-
 
25ºC) 
for 15 
minutes
,
 
−
 
Transfer 
0.9
 
mL of PBS diluent into the same vial, invert 5
x
 
to mix.
 
(Total 
preparation volume = 1.5 mL)
,
 
−
 
W
ithdraw 
1.0
 
mL 
(150 mcg) into a new syringe 
for administration
,
 
−
 
Invert 
syringe 
5x to mix
,
 
−
 
If not administered immediately, invert 
syringe 
5
x
 
to mix immediately p
rior to 
administration
.
 
•
 
For 50 mcg dose
 
with adjuvant
:
 
−
 
Transfer 0.
15
 
mL (
75 
mcg) of vaccine into a new sterile vial using a syringe
,
 
−
 
Transfer 0.
15
 
mL of 
a
djuvant 
into the same vial
,
 
−
 
Invert 
vial 
5x to mix, incubate at ambient temperature (15
ºC 
to 
25ºC) for 
15 
minutes
,
 
−
 
Transfer 
1.2
 
mL of PBS diluent into the same vial, invert 5X to mix
.
  
(Total 
preparation volume = 1.5 mL)
,
 
−
 
Withdraw 
1.0
 
mL (50 mcg) into a 
new
 
syringe for administration
,
 
−
 
Invert syringe 5x
 
to mix
,
 
−
 
If not administered immediately, invert 
5
x
 
to mix immediately prior to 
administration
.
 
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
33
 
of 
56
 
7.4.
 
Study Product
 
Administration
 
I
njection
s
 
must be administered within 
the time allowance on the syringe label
 
us
ing
 
standard 
needle and syringe injection 
technique.
 
 
The study product will be administered IM into the 
deltoid muscle by needle and syringe.
 
The plan for injection administration is to use standard injection techniques as follows:
 
•
 
Group
 
1:  Administer one injection of 1.0
 
mL of the 50 mcg/mL pre
paration for each 
50 mcg non
-
adjuvanted dose;
 
•
 
Group
 
2
:
 
 
Administer one injection of 
1.0
 
mL of the 50 mcg/mL field mixed with 
alum for each 50 mcg dose;
 
•
 
Group 3: 
 
Administer one injection of 1.0 mL of the 150
 
mcg/mL preparation for each 
15
0 mcg 
non
-
adjuvanted dose;
 
•
 
Group 4:
 
 
Administer one injection of 1.0 mL of the 150 mcg/mL field mixed with 
alum for each adjuvanted 150 mcg dose;
 
•
 
Group 5: 
 
Administer one injection of 1.0 mL of the 500 mcg/mL preparation for each 
non
-
adjuvanted
 
500 mcg dose;
 
 
 
•
 
G
roup
 
6: 
 
Administer one injection of 1.1 mL of the 500 mcg/mL field mixed with 
alum for each adjuvanted 500 mcg dose
.
 
 
7.5.
 
Study Produc
t Accountability
 
7.5.1.
 
Documentation
 
The study pharmacist 
or designee 
will be responsible for maintaining an accurate record of the
 
codes, inventory, and an accountability record of vaccine supplies for this study. Electronic 
documentation as well as paper copies will be used.
 
7.5.2.
 
Disposition
 
The empty vials and the unused portion of a vial will be discarded in a biohazard containment 
bag
 
and incinerated or autoclaved following the injection.  Any unopened vials that remain at the 
end of the study will be discarded at the discretion of the VRC in accordance with policies that 
apply to investigational products.  Partially used vials or expi
red prepared doses cannot be 
administered to other subjects nor used for 
in vitro
 
experimental studies and will be discarded as 
indicated above.
 
8.
 
HUMAN SUBJECTS PROTE
CTION
 
This research will be conducted in compliance with the protocol, Good Clinical Practi
ces (GCP) 
guidance, and all applicable regulatory requirements.
 
8.1.
 
Institutional Review Board
 
A copy of the protocol, proposed 
ICF
,
 
and any proposed advertising material will be submitted 
to the IRB for review and approval. 
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
34
 
of 
56
 
The PI
 
must
 
submit and
 
where neces
sary, obtain approval from the IRB fo
r all
 
subsequent 
protocol amendments and changes to the 
ICF
.
 
 
The PI will notify the IRB of deviations from the 
protocol and AEs.
 
The 
PI
 
will be responsible for obtaining annual IRB approval/renewal throughout the durat
ion of 
the 
study
. 
 
 
8.2.
 
Subject Recruitment and Enrollment
 
All study activities will be carried out at the NIH CC.  Study subjects will be recruited through 
on
-
site and off
-
site advertising done for the screening protocol, VRC 500 (11
-
I
-
0164).  Effort 
will be 
made to include women and minorities in proportions similar to that of the community 
from which they are recruited.
 
8.2.1.
 
Participation of Children
 
Children are not eligible to participate in this clinical trial because this study is designed for 
product 
evaluation in adults.  If the product is assessed as safe and immunogenic, other protocols 
designed for children may be conducted in the future
.
 
8.2.2.
 
Participation of 
Site
 
Employees
 
NIH employees and members of their immediate families may 
participate in this protocol.  VRC 
will follow the Guidelines for the Inclusion of Employees in NIH Research Studies and will give 
each employee a copy of the “NIH Information Sheet on Employee Research Participation”
 
and 
a copy of the “Leave Policy for NI
H Employees Participating in NIH Medical Research studies.”
 
Neither participation nor refusal to participate will have an effect, either beneficial or adverse, on 
the subject’s employment or work situation.  The NIH information sheet regarding NIH 
employee
 
research participation will be distributed to all potential subjects who are NIH 
employees.  The employee subject’s privacy and confidentiality will be preserved in accordance 
with NIH CC and NIAID policies.  For NIH employee subjects, consent will be obt
ained by an 
individual who is independent of the employee’s team.  If the individual obtaining consent is a 
co
-
worker to the subject, independent monitoring of the consent process will be included through 
the Bioethics Consultation Service.  Study staff wi
ll be trained on obtaining potentially sensitive 
and private information from co
-
workers or subordinates
.
 
8.3.
 
Informed Consent
 
The study ICF 
(
provided 
as a separate document) 
describes the investigational products, 
the 
purpose, methods, anticipated benefits, a
nd potential 
risks
 
of the 
study
.  
Before a
 
subject’s 
participation in the 
study
, it is the 
investigator
’
s
 
responsibility to ensure that written informed 
consent is obtained
 
from the subject
.
 
The acquisition of informed consent will be documented in the sub
ject’s medical records, as 
required by 21 CFR 312.62, and the ICF will be signed and personally dated by the subject and 
by the person who conducted the informed consent discussion.  The original signed ICF will be 
placed in the medical record and a copy w
ill be provided to the subject
. 
 
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
35
 
of 
56
 
8.4.
 
Subject Confidentiality
 
The
 
investigator 
must ensure that the subject’s anonymity is maintained
 
and will ensure that no 
information identifying the subject will be released to any unauthorized party
.  Subjects will not 
be identified in any reports of this study.  All records will be kept confidential to the extent 
provided by federal, state and local law.  Medical records will be made available for review 
when required by authorized agencies and regu
latory authorities only under the guidelines set by 
the 
U.S. 
Federal Privacy Act
 
and by relevant country
-
specific regulatory authorities
.  Direct 
access includes examining, analyzing, verifying, and reproducing any records and reports that 
are important to
 
the evaluation of the study.  
The investigator is obligated to inform the subjects 
that the above named representatives will review their study
-
related records without violating the 
confidentiality of the subjects.  Stored study research samples ar
e label
ed by a code 
that only the 
study team can link to the subject.  The requirement to maintain subject confidentiality is 
included in the ICF
.
 
8.5.
 
Risks and Benefits
 
8.5.1.
 
Risks
 
Risk 
of 
the DS
-
Cav1 
vaccine
:  
This is the first study in humans of the investigational DS
-
C
av1 
vaccine.  The risks noted are based on risks of vaccines in general.  
 
Potential side effects resulting from intramuscular injection include stinging, arm discomfort, 
redness of the skin, 
or 
mild bruising at vaccine injection sites.  
 
Subjects may exhi
bit general signs and symptoms associated with administration of a vaccine 
injection, including fever, chills, rash, aches and pains, nausea, headache, dizziness and fatigue. 
These side effects will be monitored, but are generally short term, mild to moder
ate severity and 
usually do not require treatment.
  
 
There may be side effects from the study 
products,
 
which may be
 
serious or life threatening, 
that 
we do not yet know about.
 
Risks of Aluminum Hydroxide Suspension
:  
Aluminum is the most common adjuvant u
sed in 
human vaccines licensed by the FDA 
[57]
 
used in 
billions of individuals over decades of clinical 
use 
[51]
.  Side effects are generally limited to minor local reactions at the injection site 
[51]
.  
Other more severe local reactions like erythema, subcutaneous nodules, contact hypersensitivity 
and granulomatous inflammation may occur 
[58]
.
  
 
Risks of Mucosa Sample Collection
: 
 
Coll
ection of samples by swabs and wicks rubbed over 
the mucosal surfaces may cause momentary discomfort and, in some cases, minor bleeding
.  
 
Risks
 
of Blood Drawing
:
  
Blood drawing may cause pain, bruising, fainting, and, rarely, 
infection at the site 
where t
he blood is taken.
 
Risks during Pregnancy
:
  
We do not know the possible effects of the study vaccine on the fetus 
or nursing infant. 
 
Therefore,
 
women
 
and adolescents
 
of reproductive potential will be tested for 
pregnancy prior to adminis
tration of each 
dose of study 
product
.  Women will be 
asked to notify 
the site immediately 
if they
 
suspect or learn they are 
pregnan
t
 
during this study.
 
 
In case of 
pregnancy, subjects
 
will continue to be followed for safety. 
 
The subject will be contacted about 
the outcome of a pregnancy that begins during the study.
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
36
 
of 
56
 
Other Risks
:  
It is possible that the standard medical tests performed as part of this research 
protocol will result in 
new diagnoses.  Depending on the medical findings and consequences of 
being provided with the new medical information about health status, the study subject may view 
this aspect of study participation as either a risk or a benefit. 
 
Any such information wi
ll be 
shared and discussed with the subject and, if requested by the subject, 
may 
be forwarded to the 
subject’s primary health care provider for further workup and management. 
 
Benefits
:  
Study subjects will not receive direct health benefit from study par
ticipation. 
 
This 
protocol is not designed to provide treatment for any condition.  Others may benefit from 
knowledge gained in this study that 
may aid in the development of an RSV 
vaccine.  
The
 
investigational vaccine 
is not expected to 
provide protection
 
from 
RSV
 
infection
. 
 
8.6.
 
Plan for Use and Storage of Biological Samples
 
To be eligible for this protocol, subjects must be willing to allow stored specimens to be used in 
the future for studying infectious diseases, immune function, vaccine response
s, and other 
medical conditions.  If tests 
show evidence of any acute or chronic condition, subjects will be 
informed of the results and advised to seek appropriate medical care for the condition. 
 
In 
general, testing performed at a research laboratory is 
not for diagnostic purposes and results will 
not be available to the study site or study subject.
 
8.6.1.
 
Use of 
S
amples
, S
pecimens
 
and D
ata
 
Samples
, specimens
,
 
and data collected under this protocol may be used to 
conduct protocol
-
related safety and immune respon
se evaluations, 
exploratory laboratory evaluations related to the 
type of infection the study 
product
 
was designed to prevent, exploratory laboratory evaluations 
related to vaccine or infectious disease research in general and for research assay validation
.
 
 
 
Genetic testing may be performed in accordance with the genetic testing information that was 
included in the study ICF. 
 
HLA testing may be done in association with identifying factors 
linked with the immune response development or progression of infec
tions.
 
8.6.2.
 
Storage and Tracking of Blood S
amples
 
and
 
Other S
pecimens
 
All of the stored research samples are labeled by a code that only the site can link to the subject.  
Samples are
 
stored at 
secure facilities with limited access including
 
VIP laboratory (formerly 
 
NVITAL, Gaithersburg, MD
,
)
 
and 
VRC Laboratories
,
 
(
Building 40
, Bethesda, MD
)
 
or other 
approved 
CRO 
facilities
.
 
 
Data will be kept in password
-
protected computers.  Only inve
stigators 
or designees
 
will have access to the samples an
d data.
 
 
Samples 
w
ill be tracked 
in the Laboratory 
Information Management System (LIMS) database or using another software designed for this 
purpose (e.g., Freezerworks).
 
8.6.3.
 
Disposition of S
amples
, S
pecimens
 
and D
ata at
 
C
ompletion of the 
P
rotocol
 
 
In the 
future, other investigators (both at NIH and outside) may wish to study these samples 
and/or data.  Regulatory approval through the proper human subjects protection agency will be 
sought prior to any sharing of samples that constitutes human subject
s
 
resea
rch. 
 
The research 
use of stored, unlinked or unidentified samples may be exempt from the need for IRB review and 
approval. 
 
When appropriate, exemption may be obtained through the proper regulatory 
procedures.
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
37
 
of 
56
 
At the 
time of protocol termination
, samples 
will remain in the 
VIP 
facility or VRC laboratories 
or,
 
after IRB approval, transferred t
o another
 
repository.
  
Regulatory oversight of the stored 
samples and data may be transferred to a stored samples protocol as part of the IRB
-
approved 
termination plan
. 
 
Data will be archived by the VRC in compliance with requirements for 
retention of research records, or after the IRB and the IND 
S
ponsor approval, it may be either 
destroyed or transferred to another repository.
 
8.6.4.
 
Loss or Destruction of Samples, Specimens
 
or Data
 
The NIH Intramural Protocol 
Deviation
 
definition related to loss of or destruction of samples 
or 
data 
will be followed
.  
Any loss or unanticipated destruction of samples (for example, due to 
freezer malfunction) or data (for example, misplacing a 
printout of data with identifiers) 
that 
compromises the scientific integrity of the study 
will be reported to the IRB
 
in accordance with 
institutional policies
.
 
 
The PI will also notify the IRB if the decision is made to destroy the 
remaining samples.
 
8.7.
 
Comp
ensation
 
Compensation for time and inconvenience of 
study 
participation
 
will be provided to s
ubjects in 
accordance 
with the standards for compensation of the Clinical Research Volunteer Program.  
The compensation per visit will be $275 for injection visits
 
and $175 for visits that include a 
blood draw only
. 
 
Any visit that includes mucosal sample collection will be 
compensated
 
an 
additional $50.
 
Compensation for any clinic visit that does not include a blood draw or 
mucosal 
sample collection
 
will be $75 and compensation for completion of electronic diary card will be 
$25.  The total compensation for the subject is based on the number of study cli
nic visits and 
injections completed.  The approximate total compensation is $
2600
, depending on the study 
visits and injections completed
.
 
Subjects will receive compensation
 
about 2 weeks a
fter each completed visit
 
by direct deposit.  
C
ompensation may need
 
to be reported to the Internal Revenue Service (IRS) as taxable income.  
 
8.8.
 
Safety Monitoring
 
8.8.1.
 
Protocol Safety Review Team
 
Close cooperation between the designated members of the Protocol Team will occur to evaluate 
and respond to individual AEs in a timely 
manner.  Study clinicians will conduct a daily safety 
review of any new clinical data.
 
 
The PSRT includes designated team members (PI, Associate 
Investigators, Study Coordinators, Protocol Specialist, and other study clinicians).  The PSRT 
will review the 
summary study safety data reports on a weekly basis through 4 weeks after the 
last subject receives the final study injection in order to be certain that the vaccine has an 
acceptable safety profile
,
 
and will continue to monitor the study safety data repor
ts on at least a 
monthly basis through completion of the study
.  
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
38
 
of 
56
 
9.
 
ADMINISTRATION AND L
EGAL OBLIGATIONS
 
9.1.
 
Protocol Amendments and Termination
 
Protocol amendments must be made only with the prior approval of the IND 
Sponsor
.  
Agreement from the investigator mu
st be obtained for all protocol 
and ICF amendments
. 
 
All 
amendments will also be submitted to the 
IRB 
for approval.  
 
The VRC, NIAID, NIH
, FDA and other regulatory authorities
 
reserve the right to terminate the 
study. 
 
The
 
PI
 
will notify the 
IRB of the stu
dy termination in writing and provide documentation 
to 
the IND Sponsor
.
 
9.2.
 
Study Documentation and Study Records Retention
 
The 
PI
 
will maintain a list of appropriately qualified persons to whom trial duties have been 
delegated. 
 
 
Source documents are original documents, data, and records from which the subject’s data are 
obtained. These include but are not limited to hospital record
s, clinical and office charts, 
laboratory and pharmacy records, radiographs, and correspondence. 
 
Long
-
term storage of source 
documents may be in the form of electronic files.  
 
The investigator and staff are responsible for maintaining a comprehensive and
 
centralized filing 
system of all essential study
-
related documentation, suitable for inspection at any time by 
representatives from the IND Sponsor, VRC, NIAID, NIH, IRB, FDA, and/or applicable 
regulatory authorities.
 
 
Elements include:
 
•
 
Subject files cont
aining completed 
ICF
 
and supporting copies of source documentation
, 
and,
 
 
•
 
Study files containing the protocol with all amendments
, the I
B,
 
and copies of all 
correspondence with the IRB
.
 
In addition, all original source documentation must be 
maintained and readily availab
le.
 
All essential documentation should be retained by the institution for the same period of time 
required for medical records retention. The FDA requires study records to be retained for two 
years after marketing approval or 
refusal (21 CFR 312.62). 
 
No study document should be 
destroyed without prior written agreement between the 
IND Sponsor 
and the 
PI
. Should the 
investigator wish to assign the study records to another party or move them to another location, 
VRC must be noti
fied in writing of the new responsible person and/or the new location.
 
9.3.
 
Data Collection
, Data Sharing,
 
and Protocol Monitoring
 
9.3.1.
 
Data C
ollection
 
Clinical research data will be collected in a secure electronic web
-
based clinical data 
management system.
 
 
Extrac
ted data without subject identifiers will be sent to the
 
protocol
 
statistician for statistical analysis as needed. 
 
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
39
 
of 
56
 
9.3.2.
 
Data Sharing Plan
 
D
ata generated in this 
study will be shared as d
e
-
identified d
ata in the government
-
funded
 
public 
repository
, 
www.ClinicalTrials.gov
.
 
 
D
ata 
may 
be shared
 
prior to publication at approved public 
presentations or for collaborative development and will be shared a
t the time of 
publication 
and
 
no later than
 
1 year 
after 
the primary completion date
.
 
9.3.3.
 
Source Documents 
 
The site will maintain appropriate medical and research records for this trial, in compliance with 
ICH
-
GCP, regulatory and institutional requirements for the protection of confidentiality of 
subjects.  
Source data are all information, or
iginal records of clinical findings, observations, or 
other activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  
Examples of these original documents and data records include, but are not limited to, medical 
records
, 
paper 
diary cards, 
laboratory reports, pharmacy records and other research records 
maintained for the clinical trial.
 
9.3.4.
 
Protocol Monitoring
 
T
he IND Sponsor 
or their authorized representatives are responsible for ensuring 
integrity 
of 
st
udy data and complia
nce with the protocol
. 
 
The 
PI will allow the study monitors, the IRB, and 
the FDA to inspect study documents (e.g., consent forms, drug distribution forms, and case 
report forms) and pertinent hospital or clinic records for confirmation of the study data.
  
Site 
visits by study monitors will be made to monitor the following: study operations, the quality of 
data collected in the research records, the accuracy and timeliness of data entered in the database, 
and to determine that all process and regulatory re
quirements are met.  Study monitoring visits 
will occur as defined by the IND Sponsor approved monitoring plan
.
 
9.4.
 
Language
 
All written information and other material to be used by subjects and investigative staff must use 
vocabulary and language that are readily understood. 
 
9.5.
 
Policy Regarding Research
-
Related Injuries
 
The
 
study site will provide immediate medical care for any i
njury resulting from
 
participation in 
this research.
 
 
In general, VRC, 
the 
NIH,
 
the NIH CC,
 
and
 
the 
U.S. 
Government will not provide 
long
-
term medical care or financial compensation for research
-
related injuries.
 
 
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
40
 
of 
56
 
10.
 
REFERENCES
 
1.
 
Collins, P.L. and B.S. Graham, 
Viral and host factors in human respiratory syncytial 
virus pathogenesis.
 
J Virol, 2008. 
82
(5): p. 2040
-
55.
 
2.
 
Chanock, R.M., et al., 
Serious respiratory tract disease caused by respiratory syncytial 
virus: prospects for improved therapy and effective immunization.
 
Pediatrics, 1992. 
90
(1 
Pt 2): p. 137
-
43.
 
3.
 
Graham, B.S., 
Pathogenesis of respiratory syncyti
al virus vaccine
-
augmented pathology.
 
Am J Respir Crit Care Med, 1995. 
152
(4 Pt 2): p. S63
-
6.
 
4.
 
Nair, H., et al., 
Global burden of acute lower respiratory infections due to respiratory 
syncytial virus in young children: a systematic review and meta
-
analys
is.
 
Lancet, 2010. 
375
(9725): p. 1545
-
55.
 
5.
 
CDC. 
Respiratory Syncytial Virus Infection (RSV); Trends and Surveillance
. 2015; 
Available from: 
http://www.cdc.gov/rsv/research/us
-
surveillance.html
.
 
6.
 
Hall, C.B., et al., 
The burden of respiratory syncytial virus infection in young children.
 
N 
Engl J Med, 2009. 
360
(6): p. 588
-
98.
 
7.
 
Hall, C.B., 
Respiratory syncytial virus in young children.
 
Lancet, 2010. 
375
(9725): p. 
1500
-
2.
 
8.
 
Miyairi, I. and J.P. D
eVincenzo, 
Human genetic factors and respiratory syncytial virus 
disease severity.
 
Clin Microbiol Rev, 2008. 
21
(4): p. 686
-
703.
 
9.
 
Falsey, A.R., et al., 
Respiratory syncytial virus infection in elderly and high
-
risk adults.
 
N Engl J Med, 2005. 
352
(17): p. 
1749
-
59.
 
10.
 
Duncan, C.B., et al., 
Risk factors for respiratory failure associated with respiratory 
syncytial virus infection in adults.
 
J Infect Dis, 2009. 
200
(8): p. 1242
-
6.
 
11.
 
Hall, C.B., et al., 
Immunity to and frequency of reinfection with respirator
y syncytial 
virus.
 
J Infect Dis, 1991. 
163
(4): p. 693
-
8.
 
12.
 
Papadopoulos, N.G., et al., 
Does respiratory syncytial virus subtype influences the 
severity of acute bronchiolitis in hospitalized infants?
 
Respir Med, 2004. 
98
(9): p. 879
-
82.
 
13.
 
Bourgeois, F.T
., et al., 
Relative impact of influenza and respiratory syncytial virus in 
young children.
 
Pediatrics, 2009. 
124
(6): p. e1072
-
80.
 
14.
 
Paramore, L.C., et al., 
Economic impact of respiratory syncytial virus
-
related illness in 
the US: an analysis of national 
databases.
 
Pharmacoeconomics, 2004. 
22
(5): p. 275
-
84.
 
15.
 
WHO. 
Immunization, Vaccines and Biologicals: RSV
. [webpage]  [cited 2015 October 
23]; Available from: 
http://www.who.int/immunization/research/meetings_workshops/WHO_PDVAC_RSV.p
df?ua=1
.
 
16.
 
Preventi
on of respiratory syncytial virus infections: indications for the use of 
palivizumab and update on the use of RSV
-
IGIV. American Academy of Pediatrics 
Committee on Infectious Diseases and Committee of Fetus and Newborn.
 
Pediatrics, 
1998. 
102
(5): p. 1211
-
6.
 
17.
 
Martorell, L., et al., 
Somatic instability of the myotonic dystrophy (CTG)n repeat during 
human fetal development.
 
Hum Mol Genet, 1997. 
6
(6): p. 877
-
80.
 
18.
 
Johnson, S., et al., 
A direct comparison of the activities of two humanized respiratory 
syncyt
ial virus monoclonal antibodies: MEDI
-
493 and RSHZl9.
 
J Infect Dis, 1999. 
180
(1): p. 35
-
40.
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
41
 
of 
56
 
19.
 
Subramanian, K.N., et al., 
Safety, tolerance and pharmacokinetics of a humanized 
monoclonal antibody to respiratory syncytial virus in premature infants and inf
ants with 
bronchopulmonary dysplasia. MEDI
-
493 Study Group.
 
Pediatr Infect Dis J, 1998. 
17
(2): 
p. 110
-
5.
 
20.
 
Meissner, H.C., et al., 
Immunoprophylaxis with palivizumab, a humanized respiratory 
syncytial virus monoclonal antibody, for prevention of respirat
ory syncytial virus 
infection in high risk infants: a consensus opinion.
 
Pediatr Infect Dis J, 1999. 
18
(3): p. 
223
-
31.
 
21.
 
Ruckwardt, T.J., K.M. Morabito, and B.S. Graham, 
Determinants of early life immune 
responses to RSV infection.
 
Curr Opin Virol, 2016.
 
16
: p. 151
-
7.
 
22.
 
Kim, H.W., et al., 
Respiratory syncytial virus disease in infants despite prior 
administration of antigenic inactivated vaccine.
 
Am J Epidemiol, 1969. 
89
(4): p. 422
-
34.
 
23.
 
Kapikian, A.Z., et al., 
An epidemiologic study of altered clinic
al reactivity to respiratory 
syncytial (RS) virus infection in children previously vaccinated with an inactivated RS 
virus vaccine.
 
Am J Epidemiol, 1969. 
89
(4): p. 405
-
21.
 
24.
 
Fulginiti, V.A., et al., 
Respiratory virus immunization. I. A field trial of two
 
inactivated 
respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an 
alum
-
precipitated respiratory syncytial virus vaccine.
 
Am J Epidemiol, 1969. 
89
(4): p. 
435
-
48.
 
25.
 
Chanock, R.M., et al., 
Influence of immunological factors in
 
respiratory syncytial virus 
disease.
 
Arch Environ Health, 1970. 
21
(3): p. 347
-
55.
 
26.
 
Levine, S., R. Klaiber
-
Franco, and P.R. Paradiso, 
Demonstration that glycoprotein G is 
the attachment protein of respiratory syncytial virus.
 
J Gen Virol, 1987. 
68 ( Pt 
9)
: p. 
2521
-
4.
 
27.
 
Bukreyev, A., L. Yang, and P.L. Collins, 
The secreted G protein of human respiratory 
syncytial virus antagonizes antibody
-
mediated restriction of replication involving 
macrophages and complement.
 
J Virol, 2012. 
86
(19): p. 10880
-
4.
 
28.
 
Lo
, M.S., R.M. Brazas, and M.J. Holtzman, 
Respiratory syncytial virus nonstructural 
proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon 
responsiveness.
 
J Virol, 2005. 
79
(14): p. 9315
-
9.
 
29.
 
Spann, K.M., K.C. Tran, and P.L. C
ollins, 
Effects of nonstructural proteins NS1 and NS2 
of human respiratory syncytial virus on interferon regulatory factor 3, NF
-
kappaB, and 
proinflammatory cytokines.
 
J Virol, 2005. 
79
(9): p. 5353
-
62.
 
30.
 
Wright, P.F., et al., 
Evaluation of a live, cold
-
p
assaged, temperature
-
sensitive, 
respiratory syncytial virus vaccine candidate in infancy.
 
J Infect Dis, 2000. 
182
(5): p. 
1331
-
42.
 
31.
 
Karron, R.A., et al., 
Identification of a recombinant live attenuated respiratory syncytial 
virus vaccine candidate that i
s highly attenuated in infants.
 
J Infect Dis, 2005. 
191
(7): p. 
1093
-
104.
 
32.
 
Bernstein, D.I., et al., 
Phase 1 study of the safety and immunogenicity of a live, 
attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in 
seronegative ch
ildren.
 
Pediatr Infect Dis J, 2012. 
31
(2): p. 109
-
14.
 
33.
 
Malkin, E., et al., 
Safety and immunogenicity of a live attenuated RSV vaccine in healthy 
RSV
-
seronegative children 5 to 24 months of age.
 
PLoS One, 2013. 
8
(10): p. e77104.
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
42
 
of 
56
 
34.
 
Gonzalez, I.M., et al., 
Evaluation of the live attenuated cpts 248/404 RSV vaccine in 
combination with a subunit RSV vaccine (PFP
-
2) in healthy young and older adults.
 
Vaccine, 2000. 
18
(17): p. 1763
-
72.
 
35.
 
Piedra, P.A., et al., 
Immunogenicity of a new
 
purified fusion protein vaccine to 
respiratory syncytial virus: a multi
-
center trial in children with cystic fibrosis.
 
Vaccine, 
2003. 
21
(19
-
20): p. 2448
-
60.
 
36.
 
Falsey, A.R., et al., 
Comparison of the safety and immunogenicity of 2 respiratory 
syncytial v
irus (rsv) vaccines
--
nonadjuvanted vaccine or vaccine adjuvanted with alum
--
given concomitantly with influenza vaccine to high
-
risk elderly individuals.
 
J Infect Dis, 
2008. 
198
(9): p. 1317
-
26.
 
37.
 
Munoz, F.M., P.A. Piedra, and W.P. Glezen, 
Safety and immun
ogenicity of respiratory 
syncytial virus purified fusion protein
-
2 vaccine in pregnant women.
 
Vaccine, 2003. 
21
(24): p. 3465
-
7.
 
38.
 
Swanson, K.A., et al., 
Structural basis for immunization with postfusion respiratory 
syncytial virus fusion F glycoprotein (
RSV F) to elicit high neutralizing antibody titers.
 
Proc Natl Acad Sci U S A, 2011. 
108
(23): p. 9619
-
24.
 
39.
 
Durbin, A.P. and R.A. Karron, 
Progress in the development of respiratory syncytial virus 
and parainfluenza virus vaccines.
 
Clin Infect Dis, 2003. 
3
7
(12): p. 1668
-
77.
 
40.
 
Hurwitz, J.L., 
Respiratory syncytial virus vaccine development.
 
Expert Rev Vaccines, 
2011. 
10
(10): p. 1415
-
33.
 
41.
 
Novavax. 
Novavax Announces Positive Top
-
Line Data from Phase 2 RSV F
-
Protein 
Vaccine Clinical Trial in Older Adults
. 2
015; Press Release]. Available from: 
http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol
-
newsArticle&ID=2078538
.
 
42.
 
Blanken, M.O., et al., 
Respiratory syncytial virus and recurrent wheeze in healthy 
preterm infants.
 
N Engl J Med, 2013. 
368
(19): p. 1791
-
9.
 
43.
 
Magro, M., et al., 
Neutralizing antibodies against the preactive form of respiratory 
syncytial virus fusion protein offer unique possibilities for clinical intervention.
 
Proc Natl 
Acad Sci U S A, 2012. 
109
(8): p. 3089
-
94.
 
44.
 
Ngwuta, J.O., et al., 
Pref
usion F
-
specific antibodies determine the magnitude of RSV 
neutralizing activity in human sera.
 
Sci Transl Med, 2015. 
7
(309): p. 309ra162.
 
45.
 
McLellan, J.S., et al., 
Structure
-
based design of a fusion glycoprotein vaccine for 
respiratory syncytial virus.
 
Science, 2013. 
342
(6158): p. 592
-
8.
 
46.
 
Graham, B.S., K. Modjarrad, and J.S. McLellan, 
Novel antigens for RSV vaccines.
 
Curr 
Opin Immunol, 2015. 
35
: p. 30
-
8.
 
47.
 
Brewer, J.M., 
(How) do aluminium adjuvants work?
 
Immunol Lett, 2006. 
102
(1): p. 10
-
5.
 
48.
 
Kuro
da, E., C. Coban, and K.J. Ishii, 
Particulate adjuvant and innate immunity: past 
achievements, present findings, and future prospects.
 
Int Rev Immunol, 2013. 
32
(2): p. 
209
-
20.
 
49.
 
FDA. 
Common Ingredients in U.S. Licensed Vaccines
. 2014; Available from: 
htt
p://www.fda.gov/biologicsbloodvaccines/safetyavailability/vaccinesafety/ucm187810.
htm
.
 
50.
 
He, P., Y. Zou, and Z. Hu, 
Advances in aluminum hydroxide
-
based adjuvant research 
and its mechanism.
 
Hum Vaccin Immunother, 2015. 
11
(2): p. 477
-
88.
 
51.
 
Brito, L.A., 
P. Malyala, and D.T. O'Hagan, 
Vaccine adjuvant formulations: a 
pharmaceutical perspective.
 
Semin Immunol, 2013. 
25
(2): p. 130
-
45.
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
43
 
of 
56
 
52.
 
Brito, L.A. and D.T. O'Hagan, 
Designing and building the next generation of improved 
vaccine adjuvants.
 
J Control Release,
 
2014. 
190
: p. 563
-
79.
 
53.
 
Schijns, V.E. and E.C. Lavelle, 
Trends in vaccine adjuvants.
 
Expert Rev Vaccines, 2011. 
10
(4): p. 539
-
50.
 
54.
 
Oleszycka, E. and E.C. Lavelle, 
Immunomodulatory properties of the vaccine adjuvant 
alum.
 
Curr Opin Immunol, 2014. 
28
: 
p. 1
-
5.
 
55.
 
Crank, M.C., et al., 
A proof of concept for structure
-
based vaccine design targeting RSV 
in humans.
 
Science, 2019. 
365
(6452): p. 505
-
509.
 
56.
 
Clements, C.J. and E. Griffiths, 
The global impact of vaccines containing aluminium 
adjuvants.
 
Vaccine
, 2002. 
20 Suppl 3
: p. S24
-
33.
 
57.
 
Petrovsky, N. and J.C. Aguilar, 
Vaccine adjuvants: current state and future trends.
 
Immunol Cell Biol, 2004. 
82
(5): p. 488
-
96.
 
58.
 
Baylor, N.W., W. Egan, and P. Richman, 
Aluminum salts in vaccines
--
US perspective.
 
Vaccine
, 2002. 
20 Suppl 3
: p. S18
-
23.
 
59.
 
Gupta, R.K., et al., 
Adjuvant properties of aluminum and calcium compounds.
 
Pharm 
Biotechnol, 1995. 
6
: p. 229
-
48.
 
60.
 
Roldao, A., et al., 
Virus
-
like particles in vaccine development.
 
Expert Rev Vaccines, 
2010. 
9
(10): p. 1
149
-
76.
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
44
 
of 
56
 
A
P
P
E
N
D
I
X
I
:
I
N
F
O
R
M
E
D
C
O
N
S
E
N
T
F
ORM
The
 
ICF
 
has been removed from the protocol and is
 
(instead)
 
provided as a separate document
.
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
45
 
of 
56
 
A
P
P
E
N
D
I
X
II
:
C
O
N
T
A
C
T
I
NFORMATION
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
48
 
of 
56
 
A
P
P
E
N
D
I
X
III
:
S
C
H
E
D
U
L
E
O
F
E
VALUATION
S
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
49
 
of 
56
 
SCHEDULE OF EVALUATIONS FOR VRC 317
 
Visit Number
 
 
01
 
02
 
02A
 
02B
 
02C
 
03
 
04
 
05
 
06
 
06A
 
06C
 
07
 
08
 
09
 
10
 
11
 
Week of Study
 
 
-
8 to 0
 
W0
 
W1
 
W1
 
W1
 
W2
 
W4
 
W8
 
W12
 
W13
 
W13
 
W14
 
W16
 
W24
 
W36
 
W44
 
Day of 
Study
 
 
-
56 to 0
 
D0
5
 
D1
 
D3
 
D7
 
D14
 
D28
 
D56
 
D84
 
D85
 
91
 
D98
 
D112
 
D168
 
D252
 
D308
 
Clinical Evaluations
 
Tube
 
 
Screen
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VRC 
500 Screening Consent
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VRC 317 AoU and Consent
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical History
 
 
X
 
X
 
 
X
 
X
 
X
 
X
 
X
 
X
 
 
X
 
X
 
X
 
X
 
X
 
X
 
1
Targeted Physical
 
 
 
X
 
X
 
 
X
 
X
 
X
 
X
 
X
 
X
 
 
X
 
X
 
X
 
X
 
X
 
X
 
2
Vital Signs
 
 
X
 
X
 
 
X
 
X
 
X
 
X
 
X
 
X
 
 
X
 
X
 
X
 
X
 
X
 
X
 
Preg
.
 
Prevention Counseling 
 
 
X
 
X
 
 
 
 
 
X
 
 
X
 
 
 
 
X
 
 
 
 
Pregnancy Test
 
 
X
 
X
 
 
 
 
 
X
 
 
X
 
 
 
 
X
 
 
 
 
3
Study Injection
 
 
 
X
 
 
 
 
 
 
 
X
 
 
 
 
 
 
 
 
Begin Diary Card
 
 
 
X
 
 
 
 
 
 
 
X
 
 
 
 
 
 
 
 
Phone Contact (or clinic visit)
 
 
 
 
X
 
 
 
 
 
 
 
X
 
 
 
 
 
 
 
4
HLA typ
ing
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20
 
 
 
CBC 
differential, platelets
 
EDTA
 
3
 
3
 
 
 
3
 
 
3
 
 
3
 
 
3
 
 
3
 
 
 
 
Creatinine and ALT
 
GLT
 
4
 
4
 
 
 
4
 
 
4
 
 
4
 
 
4
 
 
4
 
 
 
 
HIV a
ntibody
 
SST
 
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research Samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serum 
 
SS
T
 
16
 
6
4
 
 
 
16
 
40
 
40
 
16
 
40
 
 
16
 
40
 
40
 
40
 
40
 
40
 
PBMC and plasma 
 
EDTA
 
40
 
60
 
 
20
 
60
 
60
 
40
 
20
 
40
 
 
60
 
60
 
40
 
40
 
40
 
40
 
Oral secretions
 
 
 
X
 
 
 
 
 
 
 
 
 
 
X
 
 
 
 
 
Nasal secretions
 
 
 
X
 
 
 
 
 
 
 
 
 
 
X
 
 
 
 
 
Daily Volume (mL)
 
 
6
7
 
131
 
-
 
20
 
83
 
100
 
87
 
36
 
8
7
 
-
 
83
 
100
 
87
 
100
 
80
 
80
 
Cumulativ
e Volume (mL)
 
 
67
 
198
 
198
 
218
 
301
 
401
 
488
 
524
 
611
 
611
 
694
 
794
 
881
 
981
 
1061
 
1141
 
1
 
T
arge
ted physical exam is performed as needed, based on 
subject report or indications of illness
.
 
2
 
Complete post injection evaluations (temperature, BP, pulse, respiration) at least 60 minutes after each injection
 
3 
Th
e second 
injection 
is optional for the last 5 subjects enrolled in each group that receive the 
first 
injection
.
 
Subjects
 
who receive onl
y one injection will be expected to continue 
with follow
-
up through study Week 44.
 
4
 
HLA type blood sample is collected only once at any timepoint and is shown at Visit 0
9
 
for convenience. If HLA type is already in the medical record, 
do not
 
repeat. HLA type 
may also be obtained from a frozen sample
.
 
5
 
Day
 
0=day of enrollment and first injection. Day 0 evaluations and medical history prior to first injection are the baseline for 
subsequent safety assessments. If clinical 
assessment on Day 0 s
uggests changes since screening, then physical exam & laboratory 
tests
 
done on Day 0 are used for eligibility
 
and are baseline for safety 
assessments
.
 
Visit
 
windows
:
 
Visits 02A
, 06A
 
(+1 day);
 
Visit 02B (
±
1 day); 
Visit 02C, 06C (
-
2
 
days); Visit 
03
, 04, 05, 07, 08
 
(±
3
 
days);
 
Visit 0
6
 
(±7 days);
 
and Visit 
0
9
, 
1
0, 
11
 
(±
7
 
days)
.
  
Schedule 
V
isits 02A
-
06 relative to Visit 02, Visits 06A
-
11 relative to Visit 06.
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.
0
 
 
August 2
3
, 2019 
 
 
Page 
50
 
of 
56
 
A
P
P
E
N
D
I
X
IV
:
A
S
S
E
S
S
M
E
N
T
O
F
R
E
L
A
T
I
O
N
S
H
I
P
T
O
V
A
C
C
I
N
E
A
N
D
A
D
V
E
R
S
E
E
V
E
N
T
S
E
V
E
R
I
T
Y
G
RADING
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.0
 
 
August 2
3
, 2019
 
 
 
Page 
51
 
of 
56
 
Assessment of Causality Relationship of an Adverse Event to Study Vaccine: 
 
The relationship between an 
adverse event (
AE
)
 
and the vaccine will be assessed by the 
investigator on the basis of his or he
r clinical judgment and the definitions below.
 
•
 
Definitely Related
. 
The AE and administration of study 
product
 
are related in time, and a 
direct association can be demonstrated.
 
•
 
Probably Related
. 
The AE and administration of study 
product
 
are reasonably rel
ated in 
time, and the AE is more likely explained by study 
product
 
than other causes. 
 
•
 
Possibly Related
. The AE and administration of study 
product
 
are reasonably related in 
time, but the AE can be explained equally well by causes other than study 
product
.
 
•
 
Not Related
. There is not a reasonable possibility that the AE is related to the study 
product
. 
 
For purposes of preparing data reports in which AE attributions are limited to “
Related
” or “
Not 
Related
”, in this protocol, the “Definitely, Probably and Pos
sibly” attributions  will be  mapped 
to the “Related” category.  The definitions that apply when these two categories alone are used 
are as follows:
 
•
 
Related
 
–
 
There is a reasonable possibility that the AE may be related to the study 
product
.
 
•
 
Not Related
 
–
 
There is not a reasonable possibility that the AE is related to the study 
product
.
 
Grading the Severity of Adverse Events:
 
The FDA Guidance for Industry (September 2007): “Toxicity Grading Scale for Healthy Adult 
and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials” is the basis for the 
severity grading of 
AE
s in this protocol. Several modifications were ma
de to the table as follows:
 
•
 
“Emergency room visit” is not automatically considered a life
-
threatening event; these 
words have been removed from any “grade 4’ definition where they appear in the table 
copied from the guidance document.
 
•
 
Any laboratory value 
shown as a “graded” value in the table that is within the 
institutional normal range will not be severity graded or recorded as an 
AE
.
 
•
 
Severity grading for hemoglobin decrease on the basis of the magnitude of decrease from 
baseline is not applicable at the
 
grade 1 level; only absolute hemoglobin will be used to 
define grade 1 decrease.  Increases in hemoglobin are AEs only for values above the 
upper limit of normal and are graded by the systemic illness clinical criteria.
 
•
 
Severity grading definition for Gra
de 4 local reaction to injectabl
e product 
(Erythema/Redness and
 
Induration/Swelling) included added text “requiring medical 
attention”.
 
•
 
1 X ULN was removed from the definition for PT increase.
 
 
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.0
 
 
August 2
3
, 2019
 
 
 
Page 
52
 
of 
56
 
When not otherwise specified in the table, the 
following guidance will be used to assign a 
severity grade:
 
Grade 1 (Mild):  
No effect on activities of daily living
 
Grade 2 (Moderate):
 
Some interference with activity not requiring medical intervention 
 
Grade 3 (Severe):
 
Prevents daily activity and requi
res medical intervention 
 
Grade 4 (Life
-
threatening):
 
Hospitalization; immediate medical intervention or therapy
 
required to prevent death.
 
Grade 5 (Death):
  
Death is assigned a Grade 5 severity. 
 
Only the single 
AE
 
that is assessed as the primary cause of
 
death should be assigned “
G
rade 5” 
severity.
 
 
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.0
 
 
August 2
3
, 2019
 
 
 
Page 
53
 
of 
56
 
Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in 
Preventive Vaccine Clinical Trials
 
FDA Guidance
  
-
  
September 2007
 
A. Tables for Clinical Abnormalities 
 
Local Reaction to
 
Injectable Product
 
Mild
 
(Grade 1)
 
Moderate
 
(Grade 2)
 
Severe
 
(Grade 3)
 
Potentially Life
 
Threatening
 
(Grade 4)
 
Pain 
 
Does not interfere 
 
with activity 
 
Repeated use of non
-
narcotic pain reliever 
> 24 hours or 
interferes with 
activity 
 
Any use of narcotic 
pain reliever or 
prevents daily 
 
activity 
 
Hospitalization 
 
Tenderness 
 
Mild discomfort 
to touch 
 
Discomfort with 
movement 
 
Significant 
 
discomfort at rest 
 
Hospitalization 
 
1
Erythema/Redness  
 
2.5 
–
 
5 cm 
 
5.1 
–
 
10 cm 
 
> 10 cm 
 
Necrosis or 
 
exfoliative dermatitis 
requiring medical 
attention 
 
2 
Induration/Swelling  
 
2.5 
–
 
5 cm and 
does not interfere 
 
with activity 
 
5.1 
–
 
10 cm or 
 
interferes with 
 
activity 
 
> 10 cm or 
 
prevents daily 
 
activity 
 
Necrosis requiring 
medical attention 
 
 
3 
Vital Signs
 
Mild
 
(Grade 1)
 
Moderate
 
(Grade 2)
 
Severe
 
(Grade 3)
 
Potentially Life
 
Threatening
 
(Grade 4)
 
4 
Fever (°C) 
 
          
 
 
(°F) 
 
38.0 
–
 
38.4 
 
100.4 
–
 
101.1 
 
38.5 
–
 
38.9 
 
101.2 
–
 
102.0 
 
39.0 
–
 
40 
 
102.1 
–
 
104 
 
> 40 
 
> 104 
 
Tachycardia 
-
 
beats per 
 
minute 
 
101 
–
 
115 
 
116 
–
 
130 
 
> 130 
 
Hospitalization for 
 
arrhythmia 
 
5 
Bradycardia 
-
 
beats per 
 
Minute
 
50 
–
 
54 
 
45 
–
 
49 
 
< 45 
 
Hospitalization for 
 
arrhythmia 
 
Hypertension (systolic) 
-
 
 
mm Hg 
 
141 
–
 
150 
 
151 
–
 
155 
 
> 155 
 
Hospitalization for 
 
malignant 
 
hypertension 
 
Hypertension (diastolic) 
-
 
 
mm Hg 
 
91 
–
 
95 
 
96 
–
 
100 
 
> 100 
 
Hospitalization for 
 
malignant 
 
hypertension 
 
Hypotension (systolic) 
–
 
 
mm Hg 
 
85 
–
 
89 
 
80 
–
 
84 
 
< 80 
 
Hospitalization for 
 
hypotensive shock 
 
Respiratory Rate 
–
 
breaths 
 
per minute 
 
17 
–
 
20 
 
21 
–
 
25 
 
> 25 
 
Intubation 
 
 
1.
 
In addition to grading the measured local reaction at the greatest single diameter, the measurement should be recorded as 
a continuous variable. 
 
2.
 
Induration/Swelling should be evaluated and graded using the functional scale as well as the actual measuremen
t.
 
3.
 
Subject should be at rest for all vital sign measurements. 
 
4.
 
Oral temperature; no recent hot or cold beverages or smoking. 
 
5.
 
When resting heart rate is between 60 
–
 
100 beats per minute. Use clinical judgment when characterizing 
 
Bradycardia among some healthy subject populations, for example, conditioned athletes
.
 
 
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.0
 
 
August 2
3
, 2019
 
 
 
Page 
54
 
of 
56
 
Systemic (General)
 
Mild
 
(Grade 1)
 
Moderate
 
(Grade 2)
 
Severe
 
(Grade 3)
 
Potentially Life
 
Threatening
 
(Grade 4)
 
Nausea/vomiting 
 
No interference 
 
with activity or 1 
–
 
2
 
episodes/24 hours 
 
Some interference 
 
with activity or > 2 
 
episodes/24 hours 
 
Prevents daily 
 
activity, requires 
 
outpatient IV 
 
hydration 
 
Hospitalization for 
 
hypotensive shock 
 
Diarrhea 
 
2 
–
 
3 loose stools or
 
< 400 gms/24 hours
 
4 
–
 
5 stools or 
 
400 
–
 
800 gms/24 
 
hours 
 
6 or more watery 
 
stools or 
 
> 800gms/24 hours 
 
or requires 
 
outpatient IV 
 
hydration 
 
Hospitalization 
 
Headache 
 
No interference with
 
activity 
 
Repeated use of 
non
-
 
 
narcotic pain 
 
reliever > 24 hours 
or
 
some interference 
 
with activity 
 
Significant; any 
 
use of narcotic 
 
pain reliever or 
 
prevents daily 
 
activity 
 
Hospitalization 
 
Fatigue 
 
No interference with
 
activity 
 
Some interference 
 
with activity 
 
Significant; 
 
prevents daily 
 
activity 
 
Hospitalization 
 
Myalgia 
 
No interference with
 
activity 
 
Some interference 
 
with activity 
 
Significant; 
 
prevents daily 
 
activity 
 
Hospitalization 
 
 
Systemic Illness
 
Mild
 
(Grade 1)
 
Moderate
 
(Grade 2)
 
Severe
 
(Grade 3)
 
Potentially Life
 
Threatening
 
(Grade 4)
 
Illness or clinical 
adverse 
 
event (as defined 
 
according to applicable 
 
regulations) 
 
No 
interference with
 
activity 
 
Some interference 
 
with activity not 
 
requiring medical 
 
intervention 
 
Prevents daily 
 
activity and 
 
requires medical 
 
intervention 
 
Hospitalization 
 
 
B. Tables for Laboratory Abnormalities 
 
The laboratory values provided in the tables below serve as guidelines and are dependent upon 
institutional normal parameters.  Institutional normal reference ranges should be provided to 
demonstrate that they are 
appropriate.
 
 
Serum*
 
Mild
 
(Grade 1)
 
Moderate
 
(Grade 2)
 
Severe
 
(Grade 3)
 
Potentially Life
 
Threatening
 
(Grade 4)**
 
Sodium 
–
 
Hyponatremia 
mEq/L 
 
132 
–
 
134 
 
130 
–
 
131 
 
125 
–
 
129 
 
< 125 
 
Sodium 
–
 
Hypernatremia 
mEq/L 
 
144 
–
 
145 
 
146 
–
 
147 
 
148 
–
 
150 
 
> 150 
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.0
 
 
August 2
3
, 2019
 
 
 
Page 
55
 
of 
56
 
Serum*
 
Mild
 
(Grade 1)
 
Moderate
 
(Grade 2)
 
Severe
 
(Grade 3)
 
Potentially Life
 
Threatening
 
(Grade 4)**
 
Potassium 
–
 
Hyperkalemia mEq/L 
 
5.1 
–
 
5.2 
 
5.3 
–
 
5.4 
 
5.5 
–
 
5.6 
 
> 5.6 
 
Potassium 
–
 
Hypokalemia mEq/L 
 
3.5 
–
 
3.6 
 
3.3 
–
 
3.4 
 
3.1 
–
 
3.2 
 
< 3.1 
 
Glucose 
–
 
Hypoglycemia mg/dL 
 
65 
–
 
69 
 
55 
–
 
64 
 
45 
–
 
54 
 
< 45 
 
Glucose 
–
 
Hyperglycemia 
 
Fasting 
–
 
mg/dL 
 
Random 
–
 
mg/dL 
 
100 
–
 
110 
 
110 
–
 
125 
 
111 
–
 
125 
 
126 
–
 
200 
 
>125 
 
>200 
 
Insulin 
requirements or 
hyperosmolar coma 
 
Blood Urea Nitrogen 
 
BUN mg/dL 
 
23 
–
 
26 
 
27 
–
 
31 
 
> 31 
 
Requires dialysis 
 
Creatinine 
–
 
mg/dL 
 
1.5 
–
 
1.7 
 
1.8 
–
 
2.0 
 
2.1 
–
 
2.5 
 
> 2.5 or requires 
dialysis 
 
Calcium 
–
 
hypocalcemia 
mg/dL 
 
8.0 
–
 
8.4 
 
7.5 
–
 
7.9 
 
7.0 
–
 
7.4 
 
< 7.0 
 
Calcium 
–
 
hypercalcemia mg/dL 
 
10.5 
–
 
11.0 
 
11.1 
–
 
11.5 
 
11.6 
–
 
12.0 
 
> 12.0 
 
Magnesium 
–
 
hypomagnesemia mg/dL 
 
1.3 
–
 
1.5 
 
1.1 
–
 
1.2 
 
0.9 
–
 
1.0 
 
< 0.9 
 
Phosphorous 
–
 
hypophosphatemia 
mg/dL 
 
2.3 
–
 
2.5 
 
2.0 
–
 
2.2 
 
1.6 
–
 
1.9 
 
< 1.6 
 
CPK 
–
 
mg/dL 
 
1.25 
–
 
1.5 x ULN*** 
 
1.6 
–
 
3.0 x ULN 
 
3.1 
–
10 x ULN 
 
> 10 x ULN 
 
Albumin 
–
 
Hypoalbuminemia g/dL 
 
2.8 
–
 
3.1 
 
2.5 
–
 
2.7 
 
< 2.5 
 
--
 
 
Total Protein 
–
 
Hypoproteinemia g/dL 
 
5.5 
–
 
6.0 
 
5.0 
–
 
5.4 
 
< 5.0 
 
--
 
 
Alkaline phosphate 
–
 
 
increase by factor 
 
1.1 
–
 
2.0 x ULN 
 
2.1 
–
 
3.0 x ULN 
 
3.1 
–
 
10 x ULN 
 
> 10 x ULN 
 
Liver Function Tests 
–
ALT, AST 
 
increase by factor 
 
1.1 
–
 
2.5 x ULN 
 
2.6 
–
 
5.0 x ULN 
 
5.1 
–
 
10 x ULN 
 
> 10 x ULN 
 
Bilirubin 
–
 
when 
accompanied 
 
by any increase in Liver 
Function Test 
 
increase by factor 
 
1.1 
–
 
1.25 x ULN 
 
1.26 
–
 
1.5 x ULN 
 
1.51 
–
 
1.75 x U
LN 
 
> 1.75 x ULN 
 
Bilirubin 
–
 
when Liver 
Function Test is normal; 
increase by factor 
 
1.1 
–
 
1.5 x ULN 
 
1.6 
–
 
2.0 x ULN 
 
2.0 
–
 
3.0 x ULN 
 
> 3.0 x ULN 
 
Cholesterol 
 
201 
–
 
210 
 
211 
–
 
225 
 
> 226 
 
---
 
 
Pancreatic enzymes 
–
 
amylase, lipase 
 
1.1 
–
 
1.5 x ULN 
 
1.6 
–
 
2.0 x ULN 
 
2.1 
–
 
5.0 x ULN 
 
> 5.0 x ULN 
 
* The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal 
parameters. Institutional normal reference
 
ranges should be provided to demonstrate that they are appropriate. 
 
** The clinical signs or symptoms associated with laboratory abnormalities might result in characterization of 
the laboratory abnormalities as Potentially Life Threatening (Grade 4). For
 
example, a low sodium value that 
falls within a grade 3 parameter (125
-
129 mE/L) should be recorded as a grade 4 hyponatremia event if the 
subject had a new seizure associated with the low sodium value. 
 
***ULN” is the upper limit of the normal range.
 
Product: VRC
-
RSVRGP084
-
00
-
VP
 
 
Protocol VRC 31
7
, Version 
7.0
 
 
August 2
3
, 2019
 
 
 
Page 
56
 
of 
56
 
Hem
atology*
 
Mild
 
(Grade 1)
 
Moderate
 
(Grade 2)
 
Severe
 
(Grade 3)
 
Potentially Life
 
Threatening 
(Grade 4)
 
Hemoglobin (Female) 
-
 
gm/dL 
 
11.0 
–
 
12.0 
 
9.5 
–
 
10.9 
 
8.0 
–
 
9.4 
 
< 8.0 
 
Hemoglobin (Female) 
 
decrease from baseline 
value 
-
 
gm/dL 
 
not applicable
 
1.6 
–
 
2.0 
 
2.1 
–
 
5.0 
 
> 5.0 
 
Hemoglobin (Male) 
-
 
gm/dL 
 
12.5 
–
 
13.5 
 
10.5 
–
 
12.4 
 
8.5 
–
 
10.4 
 
< 8.5 
 
Hemoglobin (Male) 
 
decrease from baseline 
value 
–
 
gm/dL 
 
not applicable 
 
1.6 
–
 
2.0 
 
2.1 
–
 
5.0 
 
> 5.0 
 
WBC Increase 
-
 
cell/mm
3
 
10,800 
–
 
15,000 
 
15,001 
–
 
20,000 
 
20,001 
–
 
25, 000 
 
> 25,000 
 
WBC Decrease 
-
 
cell/mm
3
 
2,500 
–
 
3,500 
 
1,500 
–
 
2,499 
 
1,000 
–
 
1,499 
 
< 1,000 
 
Lymphocytes Decrease 
-
 
cell/mm
3
 
750 
–
 
1,000 
 
500 
–
 
749 
 
250 
–
 
499 
 
< 250 
 
Neutrophils Decrease 
-
 
cell/mm
3
 
1,500 
–
 
2,000 
 
1,000 
–
 
1,499 
 
500 
–
 
999 
 
< 500 
 
Eosinophils 
-
 
cell/mm
3
 
650 
–
 
1500 
 
1501 
-
 
5000 
 
> 5000 
 
Hypereosinophilic 
 
Platelets Decreased 
-
 
cell/mm
3
 
125,000 
–
 
140,000 
 
100,000 
–
 
124,000 
 
25,000 
–
 
99,000 
 
< 25,000 
 
PT 
–
 
increase by factor 
 
(prothrombin time) 
 
1.10 x ULN** 
 
1.11 
–
 
1.20 x ULN 
 
1.21 
–
 
1.25 x ULN 
 
> 1.25 ULN 
 
PTT 
–
 
increase by factor 
 
(partial thromboplastin 
time) 
 
1.10 
–
 
1.20 x ULN 
 
1.21 
–
 
1.4 x ULN 
 
1.41 
–
 
1.5 x ULN 
 
> 1.5 x ULN 
 
Fibrinogen increase 
-
 
mg/dL 
 
400 
–
 
500 
 
501 
–
 
600 
 
> 600 
 
--
 
 
Fibrinogen decrease 
-
 
mg/dL 
 
150 
–
 
200 
 
125 
–
 
149 
 
100 
–
 
124 
 
< 100 or associated 
 
with gross bleeding 
 
or disseminated 
intravascular 
coagulation (DIC) 
 
* The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal 
parameters. Institutional normal reference ranges should be provided to demonstrate that 
they are appropriate.
 
 
 
 21 (1   2 3 5 , ,3  ( ,1     ,1,    5( ( 5     8  
 
   
0( ,    5( 25 
 
 
              
  $G OW 3DWLHQW RU       3DUHQW  IRU 0LQRU 3DWLHQW
 
 
 
,167,787( 
 
1DWLRQDO ,QVWLW WH RI $OOHU   DQG ,QIHFWLR V  LVHDVHV
 
 
 
678   180 (5 
 
  
 
,
 
    
 
 
35,1 ,3$/ ,19(67, $725   
 UDFH  KHQ  0   03+
 
 
 
678   7,7/( 
 
95  
   
  
$ 3KDVH , 5DQGRPL]HG  2SHQ
 
/DEHO  OLQLFDO 7ULDO WR (YDO DWH  RVH  6DIHW   7ROHUDELOLW  DQG 
,PP QR HQLFLW  RI D 6WDELOL]HG 3UHI VLRQ 569 ) 6 E QLW 3URWHLQ 9DFFLQH  95 
 
5695 3   
 
  
 
93   6
 
 DY    $ORQH RU  LWK $O P $GM YDQW  LQ +HDOWK  $G OWV
 
 
 
 
 RQWLQ LQ 
 
5HYLH  $SSURYHG E  WKH ,5  RQ
 
      
 
$PHQGPHQW $SSURYHG E  WKH ,5  RQ 
         .
 
 
 
 
 DWH 3RVWHG WR :HE  
    
   
 
6W G   RQVHQW  9HUVLRQ 
 
  
 
 
 
3  ,(1  , (1 ,),   ,21
 
 21 (1   2 
3 5 , ,3  ( ,1     ,1,   
 
 
5( ( 5     8  
 
 
    $G OW 3DWLHQW RU        3DUHQW  IRU 0LQRU 3DWLHQW
 
 
1,+
 
    
 
   
  
 
  
 
 
 
3 $     
 
  
 
    
 
 
)LOH LQ 6HFWLRQ     3UR
WRFRO  RQVHQW   
 
 
 
 
,1 52 8  ,21
 
:H LQYLWH  R  WR WDNH SDUW LQ D UHVHDUFK VW G  DW WKH 1DWLRQDO ,QVWLW WHV RI +HDOWK  1,+  
 
 
)LUVW   H  DQW  R  WR NQR  WKDW WDNLQ  SDUW LQ 1,+ UHVHDUFK LV HQWLUHO  YRO QWDU  
 
•
 
 R  PD  GHFLGH QRW WR WDNH SDUW  RU  R  PD  
 LWKGUD  IURP WKH VW G  DW DQ  WLPH   7KHUH LV QR SHQDOW  RU ORVV RI 
EHQHILWV IRU FKRRVLQ  QRW WR WDNH SDUW LQ WKLV VW G  RU WR  LWKGUD    +R HYHU  WR  HW FDUH DW WKH 1,+   R  P VW EH 
WDNLQ  SDUW LQ D VW G  RU EH  QGHU HYDO DWLRQ IRU VW G  SDUWLFLSDWLRQ 
 
•
 
 
R  PD   HW QR EHQHILW IURP WDNLQ  SDUW   7KH UHVHDUFK PD   LYH  V NQR OHG H WKDW PD  KHOS SHRSOH LQ WKH 
I W UH 
 
6HFRQG  VRPH SHRSOH KDYH SHUVRQDO  UHOL LR V RU HWKLFDO EHOLHIV WKDW PD  OLPLW WKH NLQGV RI PHGLFDO RU UHVHDUFK WUHDWPHQWV 
WKH   R OG  DQW WR  H
W  OLNH EORRG WUDQVI VLRQV    ,I  R  KDYH WKHVH EHOLHIV  SOHDVH GLVF VV WKHP  LWK  R U 1,+ GRFWRUV RU 
UHVHDUFK WHDP EHIRUH  R  D UHH WR WKH VW G  
 
1R   H  LOO GHVFULEH WKLV UHVHDUFK VW G     HIRUH  R  GHFLGH WR WDNH SDUW  SOHDVH WDNH DV P FK WLPH DV  R  QH
HG WR DVN 
DQ  T HVWLRQV DQG GLVF VV WKLV VW G   LWK DQ RQH DW 1,+  RU  LWK IDPLO   IULHQGV RU  R U SHUVRQDO SK VLFLDQ RU RWKHU 
KHDOWK SURIHVVLRQDO 
 
38532 ( 2)   
, 
 
  8  
 
7KLV LV D UHVHDUFK VW G  RI DQ H[SHULPHQWDO YDFFLQH D DLQVW UHVSLUDWRU  V QF WLDO YLU 
V  569    ([SHULPHQWDO  PHDQV WKDW 
WKH VW G  YDFFLQH KDV QRW EHHQ DSSURYHG E  WKH 8 6  )RRG DQG  U   $GPLQLVWUDWLRQ  ) $    7KH ) $ DOOR V WKLV YDFFLQH 
WR EH  VHG IRU UHVHDUFK S USRVHV RQO    7KLV YDFFLQH KDV QHYHU EHHQ  LYHQ WR K PDQV EHIRUH WKLV VW G    
:H GR QRW NQR  
LI WKH YDFFLQH  RUNV   7KH PDLQ S USRVH RI WKLV VW G  LV WR VHH LI WKH H[SHULPHQWDO YDFFLQH LV VDIH DQG LI WKHUH DUH DQ  VLGH
 
HIIHFWV   :H DOVR  DQW WR VW G  LPP QH UHVSRQVHV WR WKH YDFFLQH LQFO GLQ  FHOOV WKDW PD  UHFR QL]H DQG IL KW 569   
 
   .
 
5281  21 5 9
 
569 LV D UHVSLUDWRU  YLU V WKDW LQIHFWV WKH O Q V DQG EUHDWKLQ 
 
SDVVD HV   +HDOWK  SHRSOH  KR  HW 569  V DOO  H[SHULHQFH 
PLOG FROG V PSWRPV WKDW ODVW IRU RQH RU W R  HHNV   569 LQIHFWLRQ FDQ DOVR EH VHULR V  HVSHFLDOO  IRU LQIDQWV DQG ROGHU 
DG OWV   569 LV WKH PRVW FRPPRQ FD VH RI EURQFKLROLWLV  LQIODPPDWLRQ RI WKH VP
DOO DLU D V LQ WKH O Q   DQG SQH PRQLD LQ 
 
 
 
 21 ,18  ,21   ((  IRU 
HLWKHU 
 
  
0( ,    5( 25 
 
1,      
 
    RQVHQW WR 3DUWLFLSDWH LQ 
D
 
 OLQLFDO 5HVHDUFK  W G 
 
 
1,      
 
   0LQRU 3DWLHQW V  VVHQW WR 3DUWLFLSDWH 
L
Q 
D
 
 OLQLFDO 5HVHDUFK  W G 
 
 
6
78   180 (5 
 
  
 
,
 
    
 
 
 
 217,18$7,21  
3D H 
 
 
RI 
 
 
 
 
 
 
 
 
3  ,(1  , (1 ,),   ,21
 
 21 ,18  ,21   ((  IRU HLWKHU 
 
 
1,+
 
    
 
     
 
   
 
 
1,+
 
    
 
     
 
   
 
 
3 $     
 
  
 
    
 
 
FKLOGUHQ  R Q HU WKDQ    HDU RI D H LQ WKH 8 6   $OPRVW DOO FKLOGUHQ  LOO EH LQIHFWHG  LWK 569 E  WKHLU VHFRQG ELUWKGD    
569 LV DOVR D VL QLILFDQW FD VH RI UHVSLUDWRU  LOOQHVV LQ ROGHU DG OWV  
 
569 FDQ EH VSUHDG 
 KHQ DQ LQIHFWHG SHUVRQ FR  KV RU VQHH]HV  FUHDWLQ  GURSOHWV WKDW FDUU  WKH YLU V LQ WKH DLU   2WKHUV 
FDQ  HW LQIHFWHG LI WKH GURSOHWV  HW LQ WKHLU QRVH  PR WK  RU H H 
 
 
 
,QIHFWLRQ FDQ DOVR KDSSHQ IURP GLUHFW DQG LQGLUHFW FRQWDFW  LWK QRVH RU RUDO IO LGV I
URP LQIHFWHG SHRSOH    LUHFW FRQWDFW 
 LWK WKH YLU V FDQ KDSSHQ  IRU H[DPSOH  E  NLVVLQ  WKH IDFH RI D FKLOG  LWK 569   ,QGLUHFW FRQWDFW FDQ KDSSHQ LI WKH YLU V 
 HWV RQ DQ HQYLURQPHQWDO V UIDFH  OLNH D GRRUNQRE  WKDW LV WKHQ WR FKHG E  RWKHU SHRSOH   
 
7KHUH
 
LV F UUHQWO  QR YDFFLQH WR SUHYHQW 569 LQIHFWLRQ DQG QR F UH IRU 569 LQIHFWLRQ   
 
2QH H[SHULPHQWDO 569 YDFFLQH  ),
 
569   DV WHVWHG LQ WKH     V LQ EDELHV   ),
 
569  DV PDGH
 
 VLQ   KROH YLU V WKDW  DV 
NLOOHG E  D FKHPLFDO WUHDWPHQW   ,W GLG QRW SUHYHQW 569 LQIHFWLRQ LQ EDELHV DQG LW PDGH WKHLU 569 LOOQHVV  RUVH 
 
 
7KH EDELHV 
WKDW  RW ),
 
569 KDG QHYHU KDG DQ 569 LQIHFWLRQ EHIRUH   7KLV PD  KDYH SOD HG D SDUW LQ WKHLU  HDN LPP Q
H UHVSRQVH   
) 
 
569  DV YHU  GLIIHUHQW IURP WKH YDFFLQH LQ WKLV VW G  
 
 
2 U YDFFLQH KDV RQO  RQH YLUDO SURWHLQ   7KLV SURWHLQ FD VHG D 
VWURQ  LPP QH UHVSRQVH LQ DQLPDO VW GLHV   $OVR  DOO DG OWV KDYH KDG 569 LQIHFWLRQ DW OHDVW RQFH  DQG PD EH PDQ  WLPHV  
V
R  H H[SHFW D EHWWHU DQG VWURQ HU LPP QH UHVSRQVH LQ DG OWV 
 
 
7KHUH LV RQH PHGLFLQH  SDOLYL] PDE  WKDW KHOSV SUHYHQW VHYHUH 569 LOOQHVV LQ VRPH LQIDQWV DQG FKLOGUHQ     W WKH PHGLFLQH 
FDQQRW KHOS F UH RU WUHDW FKLOGUHQ  KR DOUHDG  KDYH VHULR V 569 GLVHDVH 
DQG LW FDQQRW SUHYHQW LQIHFWLRQ  LWK 569 
 
:H  LOO WHOO  R  LI  H OHDUQ DQ WKLQ  QH  G ULQ  WKLV VW G  WKDW PL KW FD VH  R  WR FKDQ H  R U PLQG DER W VWD LQ  LQ WKH 
VW G    $W WKH HQG RI WKH VW G    H  LOO WHOO  R   KHQ VW G  UHV OWV PD  EH DYDLODEOH DQG KR
  WR OHDUQ DER W WKHP  
 
  8   
352 8  
 
 
9DFFLQHV DUH V EVWDQFHV WKDW DUH  LYHQ
 
WR KHOS WKH ERG  IL KW RII DQ LQIHFWLRQ   :KHQ  R   HW D GRVH RI WKLV YDFFLQH  LW  LOO 
ORRN OLNH D SURWHLQ WKDW LV RQ WKH R WVLGH V UIDFH RI 569    R U ERG  PD  PDNH DQ LPP QH UHVSRQVH EDVHG RQ WKLV 
SURWHLQ   
 
,Q WKLV VW G   WKH YDFFLQH LV FDOOHG  95 
 
569
5 3   
 
  
 
93  RU   6
 
 DY   RU VLPSO   569 YDFFLQH    7KH YDFFLQH  DV 
GHYHORSHG E  WKH 9DFFLQH 5HVHDUFK  HQWHU  95   DW WKH 1,+   ,W  DV PDGH DW WKH 95  3LORW 3ODQW LQ )UHGHULFN  0    7KLV 
YDFFLQH GRHV QRW KDYH DQ  OLYH RU NLOOHG 569 LQ LW   ,W LV LPSRVVLEO
H IRU  R  WR  HW 569 IURP WKLV YDFFLQH   7KLV LV WKH ILUVW 
VW G  WR  LYH WKLV 569 YDFFLQH WR K PDQV    R  VKR OG QRW H[SHFW WKLV H[SHULPHQWDO YDFFLQH WR SURWHFW  R  IURP 569 
LQIHFWLRQ   
 
6RPH 
SHRSOH
 
LQ WKLV VW G   LOO  HW WKH 569 YDFFLQH PL[HG  LWK DQRWKHU
 
VW G  SURG FW FDOOHG DQ DGM YDQW   $GM YDQWV DUH 
V EVWDQFHV WKDW PD  PDNH  R U ERG  V UHVSRQVH WR WKH YDFFLQH EHWWHU   7KH DGM YDQW LQ WKLV VW G   LOO EH DO PLQ P 
K GUR[LGH  DO P    $O P KDV EHHQ  VHG IRU RYHU  
 
 
 HDUV 
LQ ELOOLRQV RI YDFFLQDWLRQV  LWK OLF
HQVHG YDFFLQHV DQG KDV EHHQ 
IR QG WR EH VDIH   7KH  VH RI WKH DO P DV DQ DGM YDQW LQ WKLV VW G  KDV EHHQ UHYLH HG DQG DSSURYHG E  WKH ) $ 
 
( , , , ,  
 
 R  PD  T DOLI  WR WDNH SDUW LQ WKLV VW G  LI 
 
•
 
 R  DUH EHW HHQ    DQG     HDUV RI D H  
 
•
 
 R  D UHH QRW WR 
EHFRPH SUH QDQW IRU DW OHDVW    HHNV DIWHU  R   HW WKH ODVW LQMHFWLRQ   KLFK LV DER W   PRQWKV 
DIWHU WKH VW G  EH LQV
 
•
 
 R  KDYH SK VLFDO H[DP DQG EORRG WHVW UHV OWV WKDW PHHW VW G  UHT LUHPHQWV  DQG 
 
•
 
 R  GR QRW KDYH DQ  VHULR V PHGLFDO SUREOHPV DV GHWHUPLQH
G E   R U VFUHHQLQ   
 
 
 
 21 ,18  ,21   ((  IRU 
HLWKHU 
 
  
0( ,    5( 25 
 
1,      
 
    RQVHQW WR 3DUWLFLSDWH LQ 
D
 
 OLQLFDO 5HVHDUFK  W G 
 
 
1,      
 
   0LQRU 3DWLHQW V  VVHQW WR 3DUWLFLSDWH 
L
Q 
D
 
 OLQLFDO 5HVHDUFK  W G 
 
 
6
78   180 (5 
 
  
 
,
 
    
 
 
 
 217,18$7,21  
3D H 
 
 
RI 
 
 
 
 
 
 
 
 
3  ,(1  , (1 ,),   ,21
 
 21 ,18  ,21   ((  IRU HLWKHU 
 
 
1,+
 
    
 
     
 
   
 
 
1,+
 
    
 
     
 
   
 
 
3 $     
 
  
 
    
 
 
 
  8   3
  1
 
7KH VW G  SODQ LQFO GHV DER W    SHRSOH   6W G  SDUWLFLSDWLRQ  LOO ODVW IRU DER W    HDU  LWK DW OHDVW    FOLQLF YLVLWV G ULQ
  
WKDW WLPH   
 
7KH VW G   LOO KDYH   GLIIHUHQW  UR SV  LWK DER W    SHRSOH LQ HDFK   
:H  LOO VWDU
W E  HQUROOLQ  SHRSOH WR  HW WKH OR HVW 
GRVH RI    PF    :H  LOO UHYLH  WKH GDWD 
IURP DER W    SHRSOH 
DIWHU    HHNV WR PDNH V UH WKH YDFFLQH LV VDIH EHIRUH  H 
VWDUW HQUROOLQ  SHRSOH WR  HW WKH QH[W GRVH RI     PF    :H  LOO UHYLH  WKH GDWD
 
IURP DER W    SHRSOH
 
IRU WKLV GRVH DIWHU 
   HHNV WR PDNH V UH WKH YDFFLQH LV VDIH EHIRUH  H VWDUW HQUROOLQ  WKH KL KHVW GRVH RI     PF  
 
:H  LOO FRQWLQ H 
WR 
HQUROO 
         
 QWLO WKHUH DUH DER W    SHRSOH LQ HDFK WUHDWPHQW  UR S
 
 
)RU HDFK GRVH  S
HRSOH  LO
O EH UDQGRPO  DVVL QHG  OLNH S OOLQ  D Q PEHU IURP D KDW  WR  HW HLWKHU YDFFLQH RU YDFFLQH   
DO P   2QFH HQUROOHG   R   LOO NQR   KLFK  UR S  R  DUH LQ   7KH   SRVVLEOH  UR SV DUH VKR Q EHOR  
 
 UR S
 
  EMHFWV
 
 RVH
 
 D   
 
:HHN   
   
 
 
 
  
 
   PF 
 
  
YDFFLQH
 
  
YDFFLQH
 
 
 
  
 
  
YDFFLQH   DO P
 
  
YDFFLQH   DO P
 
 
 
  
 
    PF 
 
  
YDFFLQH
 
  
YDFFLQH
 
 
 
  
 
  
YDFFLQH   DO P
 
  
YDFFLQH   DO P
 
 
 
  
 
    PF 
 
  
YDFFLQH
 
  
YDFFLQH
 
 
 
  
 
  
YDFFLQH   DO P
 
  
YDFFLQH   DO P
 
7RWDO
 
  
   
 
   
 
7KH ODVW   V EMHFWV LQ HDFK  UR S WKDW  HW WKH ILUVW LQMHFWLRQ  LOO 
EH DOOR HG WR FKRRVH  KHWKHU RU QRW WR 
 HW 
WKH VHFRQG LQMHFWLRQ 
DW :HHN    
 
 
 
 
 
(
[WUD V EMHFWV
 
  S WR    LQ 
WRWDO
 
 
PD  EH DGGHG WR DQ   UR S WR 
ORRN DW 
WKH ERG  V UHVSRQVH WR 
WKH YDFFLQH
 
GRVH 
 LYHQ
 
 
7KH   LOO 
DOVR KDYH WKH FKRLFH WR  HW WKH VHFRQG LQMHFWLRQ DW :HHN    RU 
QRW  
 
 
  8   352 ( 85( 
 
,I  R  D UHH WR WDNH SDUW LQ WKLV VW G    R   LOO 
 HW 
QR PRUH WKDQ W R LQMHFWLRQV  WKH ILUVW RQ 
 D    DQG 
WKH VHFRQG 
DW 
:HHN      
$OO LQMHFWLRQV  LOO EH  LYHQ LQ WKH  SSHU DUP P VFOH  VLQ  D QHHGOH DQG V ULQ H   
 R   LOO  HW WKH VDPH SURG FW 
IRU ERWK LQMHFWLRQV
  
HLWKHU WKH 5
69 YDFFLQH
 
DORQH
 
RU WKH 569 YDFFLQH PL[HG
 
 LWK DO P
 
GHSHQGLQ  RQ 
WKH
 
 UR S  R  DUH LQ  
7KH ODVW   V EMHFWV HQUROOHG LQWR HDFK  UR S WKDW  HW WKH ILUVW LQMHFWLRQ  LOO KDYH WKH FKRLFH WR 
QRW 
 HW WKH VHFRQG LQMHFWLRQ 
DW :HHN     7KH VW G  FOLQLFLDQV  LOO WHOO  R  LI  R  DUH 
RQH RI WKHVH   V EMHFWV  KR  LOO EH DOOR HG WR PDNH WKLV FKRLFH 
 
 
,I  R  DUH D  RPDQ  KR LV DEOH WR  HW SUH QDQW   H  LOO GR D SUH QDQF  WHVW EHIRUH  R   HW HDFK LQMHFWLRQ   7KH WHVW 
P VW VKR  WKDW  R  DUH QRW SUH QDQW WR  HW WKH LQMHFWLRQ 
 
:H  LOO  DWFK  
R  IRU DW OHDVW    PLQ WHV DIWHU  R   HW HDFK LQMHFWLRQ   :H  LOO DVN  R  WR FRPSOHWH D GLDU  FDUG IRU   
GD V DIWHU HDFK GRVH    R   LOO  HW D SDVV RUG WR D VHF UH  HEVLWH WR HQWHU WKLV GDWD RQOLQH  ,I  R  SUHIHU   R  FDQ  VH D 
SDSHU GLDU  FDUG LQVWHDG    
R   LOO QHHG WR UHFRUG  R U WHPSHUDW UH DQG DQ  VLGH HIIHFWV WKDW  R  IHHO RQ WKH GLDU  FDUG   
:H  LOO  LYH  R  D WKHUPRPHWHU WR PHDV UH  R U WHPSHUDW UH    R   LOO DOVR QHHG WR ORRN DW WKH LQMHFWLRQ VLWH RQ  R U 
DUP HDFK GD  DQG UHFRUG KR  LW ORRNV   :H  
LOO DOVR  LYH  R  D PHDV ULQ  GHYLFH  U OHU  WR PHDV UH DQ  VNLQ FKDQ HV DW 
 
 
 21 ,18  ,21   ((  IRU 
HLWKHU 
 
  
0( ,    5( 25 
 
1,      
 
    RQVHQW WR 3DUWLFLSDWH LQ 
D
 
 OLQLFDO 5HVHDUFK  W G 
 
 
1,      
 
   0LQRU 3DWLHQW V  VVHQW WR 3DUWLFLSDWH 
L
Q 
D
 
 OLQLFDO 5HVHDUFK  W G 
 
 
6
78   180 (5 
 
  
 
,
 
    
 
 
 
 217,18$7,21  
3D H 
 
 
RI 
 
 
 
 
 
 
 
 
3  ,(1  , (1 ,),   ,21
 
 21 ,18  ,21   ((  IRU HLWKHU 
 
 
1,+
 
    
 
     
 
   
 
 
1,+
 
    
 
     
 
   
 
 
3 $     
 
  
 
    
 
 
WKH LQMHFWLRQ VLWH   7KH FOLQLF VWDII  LOO FDOO  R  WKH QH[W GD  DIWHU HDFK LQMHFWLRQ YLVLW DQG DUH DYDLODEOH WR  R  E  SKRQH
 
   
KR UV D GD  IRU  R  WR UHSRUW DQ  FRQFHUQLQ  VLGH H
IIHFWV   :H  LOO DVN  R  WR UHYLH   R U GLDU  FDUG  LWK  V   
 
,I  R  IHHO VLFN
 
DW DQ  WLPH G ULQ  WKH VW G 
   R  VKR OG 
FRQWDFW
 
WKH FOLQLF UL KW D D    :H PD  DVN  R  WR FRPH WR WKH 
FOLQLF IRU DQ H[DPLQDWLRQ EHIRUH  R U QH[W SODQQHG YLVLW   ,W LV YHU  LPSR
UWDQW WKDW  R  IROOR  WKH LQVWU FWLRQV  H  LYH  R   
 
(DFK YDFFLQDWLRQ YLVLW  LOO ODVW DER W   WR   KR UV   2WKHU YLVLWV  LOO ODVW DER W   WR   KR UV   
 
$W HDFK YLVLW   H  LOO FKHFN  R  IRU DQ  KHDOWK FKDQ HV RU SUREOHPV   :H  LOO FKHFN  R  IRU SRVVLEOH VLG
H HIIHFWV IURP WKH 
YDFFLQH   :H  LOO DVN KR   R  DUH IHHOLQ  DQG LI  R  KDYH WDNHQ DQ  PHGLFDWLRQV   $W VFKHG OHG VW G  YLVLWV   H  LOO GUD  
DER W   
WR 
   W EHV RI EORRG IURP  R   GHSHQGLQ  RQ WKH YLVLW   ,I DQ  RI  R U WHVW UHV OWV VKR  D KHDOWK SUREOHP  
 H  LOO 
WHOO  R  DER W LW DV VRRQ DV SRVVLEOH    R  PL KW QHHG WR KDYH H[WUD FOLQLF YLVLWV DQG ODERUDWRU  WHVWV LI  R  KDYH KHDOWK 
FKDQ HV WKDW  H QHHG WR FKHFN 
 
,I  R   HW VLFN  LWK DQ  SSHU UHVSLUDWRU  LQIHFWLRQ  85,    H PD  WDNH VDPSOHV IURP  R U QRVH 
WR WHVW IRU SRVVLEOH FD VHV 
RI WKH LOOQHVV  OLNH WKH IO  RU 569   :H  LOO  VH D VPDOO GLVSRVDEOH VSRQ H WKDW ORRNV OLNH D  4
 
WLS  WR FROOHFW WKHVH VDPSOHV   
(DFK VSRQ H LV QH  DQG VWHULOH  DQG LV VDIH IRU  VH LQ VHQVLWLYH SDUWV RI WKH ERG     R  PD  QHHG W
R VHH  R U SULPDU  FDUH 
SURYLGHU LI  R  QHHG WUHDWPHQW RU IROOR 
 
 S FDUH IRU  R U 85, 
 
:H  LOO 
DOVR 
FROOHFW VDPSOHV 
IURP  R U
 
PR WK DQG QRVH IRU UHVHDUFK 
S USRVHV 
DW 
 
 
VFKHG OHG 
VW G  YLVLWV  
:H
 
 LOO 
 VH WKH 
VDPH RU D VLPLODU
 
VPDOO GLVSRVDEOH VSRQ H WR 
FROOHFW WKHVH VDPSOHV
   7KHVH VDPSOHV DUH QRW 
 VHG WR
 
FKHFN  R U KHDOWK DQG 
GR QRW UHSODFH UR WLQH KHDOWK FDUH  
 
([SHULPHQWDO YDFFLQH VW GLHV IROOR  D VHW VFKHG OH   7KH VW G  VFKHG OH IRU  R U YLVLWV DOOR V VRPH IOH[LELOLW   E 
W LW LV 
LPSRUWDQW WKDW  R   RUN  LWK WKH VWDII WR IROOR  WKH VFKHG OH    R  VKR OG WU  WR QRW PLVV DQ  YLVLWV   
 
021, 25,1  2)   (   
8  
 
7KLV VW G   LOO EH PRQLWRUHG E  D  UR S RI SK VLFLDQV DQG VFLHQWLVWV DVVRFLDWHG  LWK WKH 1,+   7KLV  UR S  LOO UHYLH  W
KH 
VW G  LQIRUPDWLRQ DQG  LOO SD  FORVH DWWHQWLRQ WR DQ  UHDFWLRQV   ,I WKHUH DUH VHULR V VLGH HIIHFWV  LQMHFWLRQV PD  EH 
GHOD HG RU FDQFHOHG 
 
 (1( ,   (  ,1 
 
6RPH RI WKH EORRG GUD Q IURP  R  DV SDUW RI WKLV VW G   LOO EH  VHG IRU  HQHWLF WHVWV  6RPH  HQHWLF WHVWV DUH GRQH LQ 
UHVHDUFK VW GLHV WR VHH LI  HQHWLF GLIIHUHQFHV LQ SHRSOH FD VH GLIIHUHQW W SHV RI LPP QH UHVSRQVHV    R U EORRG VDPSOH 
 VHG LQ WKHVH  HQHW
LF WHVWV  LOO QRW KDYH  R U QDPH RQ LW DQG WKH UHV OWV  LOO QRW EH LQ  R U PHGLFDO UHFRUG   7KHVH WHVWV 
DUH QRW  VHG WR FKHFN  R U KHDOWK DQG  H  LOO QRW WHOO  R  WKH UHV OWV  
 
$ VSHFLDO  HQHWLF WHVW  FDOOHG +/$ W SLQ   PD  EH GRQH E  WKH 1,+  
OLQLFDO 
 
HQW
HU
 
PHGLFDO ODERUDWRU   7KHVH UHV OWV  LOO EH 
LQ  R U PHGLFDO UHFRUG E W WKH   LOO QRW EH  VHG WR FKHFN  R U KHDOWK  $Q   HQHWLF WHVWLQ   LQFO GLQ  +/$ W SLQ   LV IRU 
UHVHDUFK S USRVHV RQO   $Q   HQHWLF LQIRUPDWLRQ FROOHFWHG RU OHDUQHG DER W  R   LOO EH NHS
W FRQILGHQWLDO  0HGLFDO UHFRUGV  
LQFO GLQ  +/$ WHVW UHV OWV  DUH NHSW VHF UHO    :H  LOO QRW  LYH DQ   HQHWLF LQIRUPDWLRQ WKDW LV LQ  R U PHGLFDO UHFRUG WR 
DQ RQH  LWKR W  R U SHUPLVVLRQ 
  
,I +/$ W SLQ  LV GRQH LQ D UHVHDUFK ODERUDWRU   WKH UHV OW  LOO QRW
 
EH LQ  R U PHGLFDO 
UHFRUG 
 
 
 
 
 
 21 ,18  ,21   ((  IRU 
HLWKHU 
 
  
0( ,    5( 25 
 
1,      
 
    RQVHQW WR 3DUWLFLSDWH LQ 
D
 
 OLQLFDO 5HVHDUFK  W G 
 
 
1,      
 
   0LQRU 3DWLHQW V  VVHQW WR 3DUWLFLSDWH 
L
Q 
D
 
 OLQLFDO 5HVHDUFK  W G 
 
 
6
78   180 (5 
 
  
 
,
 
    
 
 
 
 217,18$7,21  
3D H 
 
 
RI 
 
 
 
 
 
 
 
 
3  ,(1  , (1 ,),   ,21
 
 21 ,18  ,21   ((  IRU HLWKHU 
 
 
1,+
 
    
 
     
 
   
 
 
1,+
 
    
 
     
 
   
 
 
3 $     
 
  
 
    
 
 
  25(    03 ( 
 
:H  LOO FROOHFW EORRG DQG RWKHU ERGLO  IO LGV LQFO GLQ  QDVDO DQG RUDO VHFUHWLRQV IURP  R  G ULQ  WKLV VW G    :H  LOO NHHS 
WKHVH VDPSOHV WR VW G   R U LPP QH UHVSRQVH WR WKH YDFFLQH DQG IRU I W UH UHVHDUFK WR O
HDUQ PRUH DER W 569  YDFFLQHV  
WKH LPP QH V VWHP  RU RWKHU PHGLFDO FRQGLWLRQV   5HV OWV IURP WKH UHVHDUFK GRQH IURP  R U VWRUHG VDPSOHV DUH QRW IRU 
PHGLFDO FDUH DQG  LOO QRW EH LQ  R U PHGLFDO UHFRUG  
 
 DEHOLQJ RI  WRUHG  DPSOHV   
 R U VWRUHG VDPSOHV  LOO 
EH ODEHOHG E  D VSHFLDO FRGH RU Q PEHU WKDW RQO  WKH VW G  
WHDP FDQ OLQN WR  R    $Q  LQIRUPDWLRQ WKDW FR OG LGHQWLI   R   OLNH  R U QDPH RU GDWH RI ELUWK   LOO EH NHSW DV FRQILGHQWLDO
 
DV DOOR DEOH E  OD    (YHQ  LWK WKHVH SURWHFWLRQV  WKHUH LV D VPDOO FKD
QFH WKDW LQIRUPDWLRQ LGHQWLI LQ   R   LOO EH 
DFFLGHQWDOO   LYHQ WR VRPHRQH  KR VKR OG QRW  HW LW 
 
) W UH  W GLHV   
,Q WKH I W UH  RWKHU UHVHDUFKHUV DW 1,+ RU R WVLGH RI 1,+ PD   LVK WR VW G   R U VWRUHG VDPSOHV   
:KHQ  R U VDPSOHV DUH VKDUHG  WKH   LOO EH 
PDUNHG  LWK D FRGH    R U VDPSOHV  LOO QRW KDYH DQ  LQIRUPDWLRQ RQ WKHP 
WKDW FR OG LGHQWLI   R    6RPH RWKHU LQIRUPDWLRQ DER W  R   V FK DV  R U  HQGHU  D H  KHDOWK KLVWRU   RU HWKQLFLW  PD  EH 
VKDUHG   $Q  I W UH UHVHDUFK GRQH  LWK  R U VDPSOHV  LOO EH GR
QH LQ D  D  WKDW SURWHFWV  R U UL KWV DQG SULYDF  
 
 R U VWRUHG VDPSOHV  LOO EH  VHG RQO  IRU UHVHDUFK DQG  LOO QRW EH VROG   7KH UHVHDUFK GRQH  LWK  R U VDPSOHV PD  EH 
 VHG WR GHYHORS QH  SURG FWV LQ WKH I W UH E W  R   LOO QRW  HW SD PHQW IRU WKHVH SURG F
WV 
 
 80 1         5,1 
 
7R DGYDQFH VFLHQFH  LW LV KHOSI O IRU UHVHDUFKHUV WR VKDUH LQIRUPDWLRQ WKH   HW IURP VW G LQ  K PDQV E  S WWLQ  LW LQWR 
VKDUHG VFLHQWLILF GDWDEDVHV   5HVHDUFKHUV FDQ WKHQ VW G  WKH LQIRUPDWLRQ FRPELQHG IURP PDQ  VW GLHV WR OHDUQ HYHQ PRUH 
DER W KHDOWK DQG 
GLVHDVHV  
 
,I  R  D UHH WR WDNH SDUW LQ WKLV VW G   VRPH RI  R U GDWD  LOO EH SODFHG LQWR RQH RU PRUH VFLHQWLILF GDWDEDVHV   :H  LOO 
UHPRYH LGHQWLI LQ  LQIRUPDWLRQ OLNH  R U QDPH  DGGUHVV  DQG ELUWK GDWH   7KH GDWD PD  WKHQ EH  VHG IRU I W UH UHVHDUFK 
DQG 
VKDUHG EURDGO  IRU UHVHDUFK S USRVHV  2QO  UHVHDUFKHUV  KR DUH DSSURYHG WR DFFHVV WKH GDWDEDVH PD  EH DEOH WR VHH 
DQG  VH  R U LQIRUPDWLRQ    R   LOO QRW  HW DQ  GLUHFW EHQHILWV IURP I W UH UHVHDUFK WKDW  VHV  R U GDWD DQG LQIRUPDWLRQ   
 
 R  PD  VWRS SDUWL
FLSDWLQ  LQ WKLV VW G  DW DQ  WLPH DQG  LWKGUD  SHUPLVVLRQ IRU  R U LQGLYLG DO GDWD  VSHFLPHQV  DQG 
KHDOWK LQIRUPDWLRQ WR EH  VHG IRU DGGLWLRQDO RU I W UH UHVHDUFK 
 
 
 R  PD  DVN WR KDYH  R U UHVHDUFK GDWD 
GHVWUR HG 
  
+R HYHU  LW PD  QRW EH SRVVLEOH WR  LWK
GUD  RU GHOHWH GDWD RQFH WKH  KDYH EHHQ VKDUHG  LWK RWKHU 
UHVHDUFKHUV 
 
32  ,  (   8   5, . 
 
ULVNV 
RI
 
LQMHFWLRQV   
7HPSRUDU  VWLQ LQ   SDLQ  UHGQHVV  VRUHQHVV  LWFKLQHVV  V HOOLQ   RU EU LVLQ    7KHUH LV D 
YHU  VPDOO FKDQFH RI LQIHFWLRQ 
 
U
LVNV RI EORRG GUD LQJ   
3DLQ  EOHHGLQ   EU LVLQ   IHHOLQ  OL KWKHDGHG  RU IDLQWLQ   DQG UDUHO   LQIHFWLRQ DW WKH 
VLWH  KHUH WKH EORRG LV WDNHQ 
 
ULVNV RI 
P
 FRVD 
V
DPSOH 
F
ROOHFWLRQ
 
  
6DPSOHV FROOHFWHG E  U EELQ  V DEV RYHU P FRVDO V UIDFHV LQ WKH 
PR WK RU LQ WKH QRVH FDQ FD VH EULHI GLVFRPIRUW
 
 
RU
 
D OLWWOH EOHHGLQ   
 
ULVNV 
RI
 
DQ  YDFFLQH   
)HYHU  FKLOOV  UDVK  DFKHV DQG SDLQV  QD VHD  KHDGDFKH  GL]]LQHVV  DQG IHHOLQ  WLUHG R
U 
 Q HOO   6RPH SHRSOH KDYH DOOHU LF UHDFWLRQV WR YDFFLQHV   7KHVH W SHV RI UHDFWLRQV DUH  V DOO   UHDWHVW  LWKLQ WKH ILUVW    
 
 
 21 ,18  ,21   ((  IRU 
HLWKHU 
 
  
0( ,    5( 25 
 
1,      
 
    RQVHQW WR 3DUWLFLSDWH LQ 
D
 
 OLQLFDO 5HVHDUFK  W G 
 
 
1,      
 
   0LQRU 3DWLHQW V  VVHQW WR 3DUWLFLSDWH 
L
Q 
D
 
 OLQLFDO 5HVHDUFK  W G 
 
 
6
78   180 (5 
 
  
 
,
 
    
 
 
 
 217,18$7,21  
3D H 
 
 
RI 
 
 
 
 
 
 
 
 
3  ,(1  , (1 ,),   ,21
 
 21 ,18  ,21   ((  IRU HLWKHU 
 
 
1,+
 
    
 
     
 
   
 
 
1,+
 
    
 
     
 
   
 
 
3 $     
 
  
 
    
 
 
KR UV DIWHU DQ LQMHFWLRQ DQG W SLFDOO  ODVW   WR   GD V   2YHU
 
WKH
 
FR QWHU PHGLFLQH  V FK DV DFHWDPLQRSKHQ  PD  EH  VHG 
WR KHOS U
HOLHYH WKHVH V PSWRPV 
 
9HU  UDUHO   D VHULR V DOOHU LF UHDFWLRQ  LWK V PSWRPV 
OLNH
 
KLYHV  WUR EOH EUHDWKLQ   RU V GGHQ  HDNQHVV PD  KDSSHQ 
VKRUWO  DIWHU DQ  YDFFLQDWLRQ   7KLV LV FDOOHG  DQDSK OD[LV  DQG PD  EH OLIH
 
WKUHDWHQLQ    :KLOH  R  DUH  DLWLQ  LQ W
KH FOLQLF 
DIWHU WKH LQMHFWLRQV   H  LOO PRQLWRU  R  IRU DQDSK OD[LV   7UHDWPHQW IRU DQDSK OD[LV  LOO EH  LYHQ UL KW D D  LI LW KDSSHQV 
  
 
ULVNV 
RI
 
WKH 5 9 YDFFLQH   
7KLV LV WKH ILUVW VW G  WR  LYH WKH 569 YDFFLQH WR K PDQV   7KHUH PD  EH VLGH 
HIIH
FWV  HYHQ VHULR V RU OLIH WKUHDWHQLQ  RQHV   KLFK  H GR QRW NQR  DER W  HW   
$V RI 6HSWHPEHU 
  
        
  
 
V EMHFWV 
KDYH UHFHLYHG 
WKH 569 YDFFLQH 
DQG QR VDIHW  FRQFHUQV 
KDYH EHHQ IR QG
  
:H  LOO WHOO  R  LI  H OHDUQ DER W DQ  LPSRUWDQW 
QH  ILQGLQ V RU 
VHULR V VLGH HIIHFWV G ULQ  WKH VW G  WKDW PD  FKDQ H  R U PLQG DER W  R U GHVLUH WR FRQWLQ H LQ WKH 
VW G  
 
ULVNV 
RI
 
DO P   
$O P LV WKH PRVW FRPPRQ DGM YDQW  VHG LQ K PDQ YDFFLQHV OLFHQVHG E  WKH ) $   ,Q KHDOWK  
V EMHFWV  VLGH HIIHFWV DUH  HQHUDO
O  PLOG ORFDO UHDFWLRQV DW WKH LQMHFWLRQ VLWH WKDW PD  LQFO GH WHQGHUQHVV  UHGQHVV  DQG RU 
V HOOLQ    $QRWKHU PRUH VHYHUH ORFDO UHDFWLRQ DW WKH LQMHFWLRQ VLWH PD  LQFO GH O PSV  QGHU WKH VNLQ 
 
 
ULVNV G ULQJ 3UHJQDQF    
:H GR QRW NQR  LI  HWWLQ  WKH
 
VW G  SURG FWV  LOO DIIHFW D IHW V   7KHUHIRUH  
 RPHQ  KR FDQ  HW SUH QDQW P VW D UHH WR  VH DQ HIIHFWLYH PHWKRG RI ELUWK FRQWURO VWDUWLQ  DW OHDVW    GD V EHIRUH 
 HWWLQ  WKH ILUVW LQMHFWLRQ  QWLO    HHNV DIWHU WKH ODVW LQMHFWLRQ   :H  LOO GLVF VV HIIHFWL
YH ELUWK FRQWURO PHWKRGV  LWK  R    
,I  R  DUH SUH QDQW RU  DQW WR EHFRPH SUH QDQW LQ WKH QH[W     HHNV   R  FDQQRW SDUWLFLSDWH   
 
  ULQ  WKH VW G   LI  R  WKLQN  R  PL KW EH SUH QDQW   R  P VW WHOO WKH FOLQLF VWDII UL KW D D    ,I  R  DUH SUH QDQW   R  
 L
OO QRW  HW DQ  PRUH GRVHV RI VW G  SURG FW    R   LOO EH DVNHG WR FRQWLQ H  LWK VRPH IROOR 
 
 S YLVLWV VR WKDW  H FDQ 
FKHFN RQ  R U KHDOWK   :H  LOO DVN  R  DER W WKH R WFRPH RI WKH SUH QDQF  
 
 
ULVNV 
RI
 
JHQHWLF WHVWLQJ   
8QSODQQHG UHOHDVH RI LQIRUPDWLRQ WKDW FR OG EH  VHG E  LQV UHUV RU HPSOR HUV
 
WR 
GLVFULPLQDWH D DLQVW  R  RU  R U IDPLO 
  GLVFRYHULQ  D  HQH WKDW V   HVWV ULVN RI GLVHDVH IRU  R  RU  R U IDPLO   
GLVFRYHULQ   QNQR Q IDPLO  UHODWLRQVKLSV 
 
 
ULVNV 
RI
 
GD
WD VKDULQJ
  
 
,QIRUPDWLRQ LQ WKH VKDUHG GDWDEDVHV FR OG EH OLQNHG EDFN WR  R  DQG  VHG WR 
GLVFULPLQDWH D DLQVW  R  RU  R U IDPLO    6WDWH DQG IHGHUDO OD V SURYLGH VRPH SURWHFWLRQV D DLQVW  HQHWLF DQG SUH
 
H[LVWLQ  
FRQGLWLRQV GLVFULPLQDWLRQ 
 
 
ULVNV   
:
H GR QRW NQR  LI WKH VW G  SURG FW  LOO DIIHFW KR   R  UHVSRQG WR DQ  569 LQIHFWLRQ RU 569 YDFFLQH 
WKDW  R  PD   HW LQ WKH I W UH   
 
 R  PD  QRW GRQDWH EORRG  KLOH WDNLQ  SDUW LQ WKLV VW G  DQG  R  PD  QRW GRQDWH EORRG IRU RQH  HDU DIWHU WKH GDWH RI 
 R U O
DVW VW G  LQMHFWLRQ 
 
32  ,  (  (1(),  
 
7KLV VW G  LV QRW GHVL QHG
 
WR EHQHILW  R  RU WR SURWHFW  R  IURP 569 LQIHFWLRQ    R  DQG RWKHUV PD  EHQHILW LQ WKH I W UH 
IURP WKH LQIRUPDWLRQ WKDW  H OHDUQ IURP WKH VW G  
 
 2    
2) 
3 5 , ,3  ,21
 
7KHUH DUH QR FRVWV WR  R  IRU WDNLQ  SDUW LQ WKLV VW G     R  RU  R U KHDOWK LQV UDQFH
 
 LOO KDYH WR SD  IRU DOO PHGLFDO FRVWV 
IRU PHGLFDO FDUH WKDW  R   HW R WVLGH RI WKLV VW G    ,W LV SRVVLEOH WKDW  R  PD  KDYH VRPH FRVWV WKDW DUH QRW FRYHUHG E  
WKH VW G  FRPSHQVDWLRQ  H  LYH  R  
 
 
 
 21 ,18  ,21   ((  IRU 
HLWKHU 
 
  
0( ,    5( 25 
 
1,      
 
    RQVHQW WR 3DUWLFLSDWH LQ 
D
 
 OLQLFDO 5HVHDUFK  W G 
 
 
1,      
 
   0LQRU 3DWLHQW V  VVHQW WR 3DUWLFLSDWH 
L
Q 
D
 
 OLQLFDO 5HVHDUFK  W G 
 
 
6
78   180 (5 
 
  
 
,
 
    
 
 
 
 217,18$7,21  
3D H 
 
 
RI 
 
 
 
 
 
 
 
 
3  ,(1  , (1 ,),   ,21
 
 21 ,18  ,21   ((  IRU HLWKHU 
 
 
1,+
 
    
 
     
 
   
 
 
1,+
 
    
 
     
 
   
 
 
3 $     
 
  
 
    
 
 
 203(1   ,21  2  28 )25   .,1  3 5  ,1   (   8  
 
 R   LOO 
 HW FRPSHQVDWLRQ FRQVLVWHQW  LWK WKH 1,+ SROLF  WR KHOS  LWK WUDQVSRUWDWLRQ FRVWV DQG RWKHU H[SHQVHV WKDW PD  
RFF U EHFD VH RI VW G  SDUWLFLSDWLRQ    R  PD  KDYH VRPH H[SHQVHV WKDW DUH QRW FRYHUHG E  WKH FRPSHQVDWLRQ SURYLGHG 
 
7KH FRPSHQVDWLRQ LV       IRU
 
VFKHG OHG YLVLWV WKDW LQFO GH EORRG GUD LQ  
RQO   
     IRU YDFFLQDWLRQ YLVLWV 
 
DQ DGGLWLRQDO 
    IRU DQ  YLVLW WKDW LQFO GHV P FRVDO VDPSOH FROOHFWLRQ  
    IRU ILQLVKLQ  DOO   GD V RI DQ HOHFWURQLF GLDU   DQG     IRU 
FOLQLF YLVLWV WKDW GR QRW LQFO GH EORR
G GUD LQ  RU P FRVDO V DEV   7RWDO FRPSHQVDWLRQ IRU FRPSOHWLRQ RI WKH VW G 
 
DQG DOO 
LQMHFWLRQV
 
LV HVWLPDWHG WR EH  
    
   $FW DO FRPSHQVDWLRQ LV EDVHG RQ WKH Q PEHU DQG W SH RI YLVLWV  R  FRPSOHWH  
 
 R   LOO  HW  R U FRPSHQVDWLRQ DER W    HHNV DIWHU HDFK F
RPSOHWHG YLVLW E  GLUHFW GHSRVLW LQWR D EDQN DFFR QW WKDW  R  
VSHFLI  WR WKH YRO QWHHU SD PHQW RIILFH    RPSHQVDWLRQ PD  QHHG WR EH UHSRUWHG WR WKH ,QWHUQDO 5HYHQ H 6HUYLFH  ,56  DV 
WD[DEOH LQFRPH
 
  
 
5(  21  )25   233,1   285   8   ,1-(  ,21 
 
 R  PD  
QRW  HW DOO RI  R U SODQQHG VW G  YDFFLQDWLRQV   5HDVRQV IRU WKLV PD  LQFO GH 
 
•
 
 R  GHFLGH QRW WR  HW WKH VHFRQG LQMHFWLRQ LI WKLV RSWLRQ LV RIIHUHG WR  R  
 
•
 
 R  GR
 
Q
R
W NHHS DSSRLQWPHQWV RU IROOR  SURFHG UHV 
 
•
 
 R   HW D VHULR V LOOQHVV WKDW QHHGV RQ RLQ  PHGL
FDO FDUH 
 
•
 
 R  KDYH D VHULR V VLGH HIIHFW WKR  KW WR EH G H WR WKH VW G  YDFFLQH 
 
•
 
 R  EHFRPH SUH QDQW 
 
•
 
 R  QHHG WR  HW WUHDWPHQW  LWK D PHGLFDWLRQ WKDW DIIHFWV  R U LPP QH V VWHP  V FK DV D VWHURLG OLNH SUHGQLVRQH  
 
•
 
WKH VW G  LV VWRSSHG E  UH  ODWRU  D HQFL
HV  WKH VW G  VSRQVRU RU VW G  LQYHVWL DWRUV   ,I WKLV KDSSHQV  
 H
 
 LOO 
WHOO 
 R 
 
 K  
 
5(  21  )25 5(029,1   28 )520   (   8   
 
 R  PD  EH WDNHQ
 
R W RI WKH VW G   LWKR W  R U FRQVHQW   5HDVRQV IRU WKLV PD  LQFO GH 
 
•
 
FRQWLQ LQ  LQ WKH VW G  FR OG K UW  R   
 
•
 
 R  GRQ W IROOR  LQVWU FWLRQV RU NHHS  R U DSSRLQWPHQWV  RU 
 
•
 
WKH VW G  LV VWRSSHG E  WKH 1,+  WKH ) $ RU RWKHU UH  ODWRU  D WKRULWLHV 
 
,I  R  D 
UHH WR WDNH SDUW LQ WKLV VW G   LW LV LPSRUWDQW IRU  R  WR NHHS DOO RI  R U DSSRLQWPHQWV   R U SDUWLFLSDWLRQ LQ WKLV 
VW G  LV FRPSOHWHO  YRO QWDU     R  FDQ FKRRVH WR VWRS WDNLQ  SDUW LQ WKH VW G  DW DQ  WLPH   7KHUH LV QR SHQDOW  RU ORVV RI 
EHQHILWV IRU F
KRRVLQ  WR OHDYH WKH VW G   
 
,I  R   HW WKH ILUVW LQMHFWLRQ E W QRW WKH VHFRQG   H  LOO
 
VWLOO  DQW 
 R  WR FRQWLQ H 
 LWK 
DOO 
SODQQHG IROOR 
 
 S YLVLWV  QWLO WKH 
HQG RI WKH VW G    ,W LV LPSRUWDQW WKDW  H FRQWLQ H WR FKHFN  R U KHDOWK HYHQ LI  R  GR QRW  HW W
KH VHFRQG GRVH 
 
 
 
 
 21 ,18  ,21   ((  IRU 
HLWKHU 
 
  
0( ,    5( 25 
 
1,      
 
    RQVHQW WR 3DUWLFLSDWH LQ 
D
 
 OLQLFDO 5HVHDUFK  W G 
 
 
1,      
 
   0LQRU 3DWLHQW V  VVHQW WR 3DUWLFLSDWH 
L
Q 
D
 
 OLQLFDO 5HVHDUFK  W G 
 
 
6
78   180 (5 
 
  
 
,
 
    
 
 
 
 217,18$7,21  
3D H 
 
 
RI 
 
 
 
 
 
 
 
 
3  ,(1  , (1 ,),   ,21
 
 21 ,18  ,21   ((  IRU HLWKHU 
 
 
1,+
 
    
 
     
 
   
 
 
1,+
 
    
 
     
 
   
 
 
3 $     
 
  
 
    
 
 
 
   (51  ,9( 
 
7KLV VW G  LV QRW GHVL QHG WR WUHDW RU SUHYHQW DQ  GLVHDVH    R  PD  FKRRVH QRW WR WDNH SDUW LQ WKLV VW G  
 
 21) ,   2) ,1 (5(   
 
7KH 1,+ UHVHDUFK VWDII LV FKHFNHG  HDUO  IRU FRQIOLFWV RI LQWHUHVW   R  PD  DVN WKH UHVHDUFK WH
DP IRU PRUH LQIRUPDWLRQ   
7KLV VW G  PD  KDYH LQYHVWL DWRUV  KR DUH QRW 1,+ HPSOR HHV   1RQ
 
1,+ LQYHVWL DWRUV DUH H[SHFWHG WR IROOR  WKH 
SULQFLSOHV RI WKH 3URWRFRO 5HYLH    LGH 
 
7KH 1,+  LQFO GLQ  VRPH PHPEHUV RI WKH 95  VFLHQWLILF VWDII  GHYHORSHG WKH LQY
HVWL DWLRQDO YDFFLQH EHLQ   VHG LQ WKLV 
UHVHDUFK VW G    7KH UHV OWV RI WKLV VW G  FR OG SOD  D UROH LQ  KHWKHU WKH ) $  LOO DSSURYH WKH YDFFLQH IRU VDOH DW VRPH 
WLPH LQ WKH I W UH   ,I DSSURYHG  WKH I W UH VDOH RI WKH YDFFLQH FR OG OHDG WR SD PHQWV WR 1,+
 
DQG VRPH 1,+ VFLHQWLVWV     
8 6  OD    RYHUQPHQW VFLHQWLVWV DUH UHT LUHG WR UHFHLYH V FK SD PHQWV IRU WKHLU LQYHQWLRQV   R   LOO QRW UHFHLYH DQ  
PRQH  IURP WKH GHYHORSPHQW RU VDOH RI WKH SURG FW  
 
  ,1,    5,     29
 
$ GHVFULSWLRQ RI WKLV 
FOLQLFDO WULDO  LOO EH DYDLODEOH RQ
 
     OLQLFDO7ULDOV  RY
 
  
7KLV  HEVLWH  LOO QRW LQFO GH LQIRUPDWLRQ WKDW 
FDQ LGHQWLI   R    $W PRVW  WKH  HEVLWH  LOO LQFO GH D V PPDU  RI WKH VW G  UHV OWV    R
  FDQ VHDUFK WKLV  HEVLWH DW DQ  
WLPH 
 
 
 
 
 21 (1   2 3 5 , ,3  ( ,1     ,1,    5( ( 5     8  
 
   
0( ,    5( 25 
 
 
  
$G OW 3DWLHQW RU    
 
  
3DUHQW  IRU 0LQRU 3DWLHQW
 
 
678   180 (5  
 
  
 
,
 
    
 
 
 
 217,18$7,21  
3D H 
 
 
RI 
 
 
 
 
 
 
 
3  ,(1  , (1 ,),   ,21
 
 21 (1   2 3 5 , ,3  ( ,1     ,1,   
 
 
5( ( 5     8     RQWLQ DWLRQ  KHHW 
 
 
   $G OW 3DWLHQW RU      3DUHQW  IRU 0LQRU 3DWLHQW
 
 
1,+
 
    
 
   
  
 
  
 
 
 
3 $     
 
  
 
    
 
 
)LOH LQ 6HFWLRQ     3
URWRFRO  RQVHQW
 
 
 
2  (5 3(5 ,1(1  ,1)250  ,21
 
 
  
 
 RQILGHQWLDOLW 
   
:KHQ UHV OWV RI DQ 1,+ UHVHDUFK VW G  DUH UHSRUWHG
 
LQ PHGLFDO MR UQDOV RU DW VFLHQWLILF PHHWLQ V  WKH SHRSOH  KR 
WDNH SDUW DUH QRW QDPHG DQG LGHQWLILHG   ,Q PRVW FDVHV  WKH 1,+  LOO QRW UHOHDVH DQ  LQIRUPDWLRQ DER W  R U UHVHDUFK LQYROYHP
HQW  LWKR W 
 R U  ULWWHQ SHUPLVVLRQ   +R HYHU  LI  R  VL Q D UHOHDVH
 
RI LQIRUPDWLRQ IRUP  IRU H[DPSOH  IRU DQ LQV UDQFH FRPSDQ   WKH 1,+  LOO  LYH 
WKH LQV UDQFH FRPSDQ  LQIRUPDWLRQ IURP  R U PHGLFDO UHFRUG   7KLV LQIRUPDWLRQ PL KW DIIHFW  HLWKHU IDYRUDEO  RU  QIDYRUDEO   
WKH 
 LOOLQ QHVV RI WKH LQV UDQFH FRPSDQ  WR VHOO  R 
 
LQV UDQFH 
 
7KH )HGHUDO 3ULYDF  $FW SURWHFWV WKH FRQILGHQWLDOLW  RI  R U 1,+ PHGLFDO UHFRUGV   +R HYHU   R  VKR OG NQR  WKDW WKH $FW DOOR
 V UHOHDVH 
RI VRPH LQIRUPDWLRQ IURP  R U PHGLFDO UHFRUG  LWKR W  R U SHUPLVVLRQ  IRU H[DPSOH  LI LW LV UHT LUHG E  WKH 
) $  PHPEHUV RI  RQ UHVV  
OD  HQIRUFHPHQW RIILFLDOV  RU D WKRUL]HG KRVSLWDO DFFUHGLWDWLRQ RU DQL]DWLRQV 
 
 
  
 
3ROLF  5HJDUGLQJ 5HVHDUFK
 
5HODWHG ,QM ULHV
   7KH 
1,+ 
 OLQLFDO  HQWHU  LOO SURYLGH VKRUW
 
WHUP PHGLFDO FDUH IRU DQ  LQM U  
UHV OWLQ  IURP  R U SDUWLF
LSDWLRQ LQ UHVHDUFK KHUH   
,Q  HQHUDO  QR ORQ 
 
WHUP PHGLFDO FDUH RU ILQDQFLDO FRPSHQVDWLRQ IRU UHVHDUFK
 
UHODWHG 
LQM ULHV  LOO EH SURYLGHG E  WKH 1,+  WKH 1,+  
OLQLFDO 
 
HQWHU
  RU WKH )HGHUDO  RYHUQPHQW   +R HYHU   R  KDYH WKH UL KW WR S UV H OH DO 
UHPHG  LI
 
 R  EHOLHYH WKDW  R U LQM U  M VWLILHV V FK DFWLRQ 
 
 
  
 
3D PHQWV 
  
7KH DPR QW RI SD PHQW WR UHVHDUFK YRO QWHHUV LV   LGHG E  WKH 
1,+
 
SROLFLHV   ,Q  HQHUDO  SDWLHQWV DUH QRW SDLG IRU 
WDNLQ  SDUW LQ UHVHDUFK VW GLHV DW WKH 
1,+
 
 
 
5HLPE UVHPHQW RI WUDYHO DQG V EVLVWHQFH  LOO EH RIIHUHG FRQVLVWHQW  LWK 1,+   LGHOLQHV 
 
 
  
 
3UREOHPV RU 4 HVWLRQV
   
,I  R  KDYH DQ  SUREOHPV RU T HVWLRQV DER W WKLV VW G   
RU DER W  R U UL KWV DV D UHVHDUFK SDUWLFLSDQW  
RU DER W DQ  UHVHDUFK
 
UHODWHG LQM U 
  FRQWDFW WKH 3ULQFLSDO ,QYHVWL DWRU  
 RU WKH 6W G   RRUGLQDWRU  
 
  
 
 
 
R  PD  DOVR FDOO WKH 1,+  
OLQLFDO 
 
HQWHU
 
3DWLHQW 5HSUHVHQWDWLYH DW 
 
 
  
 
 RQVHQW  RF PHQW
   3OHDVH NHHS D FRS  
RI WKLV GRF PHQW LQ FDVH  R   DQW WR UHDG LW D DLQ 
 
 
 
 203 ( (  335235,  ( , (0     ( 2: 
 
 
 G OW  W G  3DUWLFLSDQW V  RQVHQW
 
, KDYH UHDG WKH H[SODQDWLRQ DER W WKLV VW G  DQG KDYH EHHQ  LYHQ
 
WKH RSSRUW QLW  WR GLVF VV LW DQG WR DVN T HVWLRQV  , 
KHUHE  FRQVHQW WR WDNH SDUW LQ WKLV VW G  
 
 
 
 
         
 
           
 
 
 
 
                                                    
7LPH
 
 
B
 
B
 
     
 
 
         
 
6L QDW UH RI $G OW 3DUWLFLSDQW 
                                 
 DWH
 
 
 
   
BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
 
3ULQW 1DPH
 
  ,   21 (1   2 80(1  
     ((1  33529(  )25 8 ( 
 
)520 
 (3 (0 (5         
  528  
 
 (3 (0 (5   
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6L QDW UH RI 
,QYHVWL DWRU 
                              
 DWH
 
3HUVRQ 2EWDLQLQ   RQVHQW
 
 
 
   
BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
 
3ULQW 1DPH
 
6L QDW UH RI :LWQHVV
                                      
 DWH
 
 
 
 
   
BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
 
3ULQW 1DPH
 
 